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Abstract 
Myeloperoxidase (MPO) is a peroxidase enzyme generated by activated leukocytes at sites 
of inflammation. MPO plays a key role in generating biological oxidants that contributes to 
the bacterial cell killing of invading pathogens, which is a crucial mechanism in the innate 
immune system. However, misplaced and excessive generation of these oxidants is also 
linked to the exacerbation of inflammatory disease states, including atherosclerosis. 
Atherosclerosis is a disease characterised by the build up of lipid laden macrophages within 
walls of large arteries. Accumulation of lipid laden macrophages, also referred to as foam 
cells, represents the initial stage of atherosclerotic plaque development. The oxidative 
modification of low-density lipoprotein (LDL) is reported to be a possible pathway that 
contributes to the formation of foam cells. In this case, changes in the LDL molecule allows 
for increased recognition and uptake of this molecule by macrophages. There are many 
studies that have defined different sources of oxidation that occur in vivo, which may cause 
modifications on LDL, including transition metal ions (Cu2+ and Fe2+), lipoxygenase, glucose, 
superoxide, thiols, nitric oxide/peroxynitrous acid and the MPO-derived oxidant, 
hypochlorous acid (HOCl). 
Although there is extensive evidence showing the contribution of HOCl to the modification 
of LDL, the involvement of the other major MPO oxidant, hypothiocyanous acid (HOSCN) in 
LDL modification has not been comprehensively assessed. HOSCN is generated 
enzymatically by MPO from the reaction of hydrogen peroxide (H2O2) with thiocyanate 
(SCN-) ions. Formation of HOSCN has high biological importance in smokers, who have 
increased plasma concentrations of SCN-, which results in the formation of HOSCN in these 
individuals. Tobacco smoking is known to be a risk factor in the development of 
cardiovascular disease, though the mechanisms involved in this process have not been well 
elucidated. HOSCN has also been reported to decompose to other potentially damaging 
species, including cyanate (OCN-), which has been linked with the onset of premature 
atherosclerosis, particularly in patients with renal disease. 
In this study, the contribution of HOSCN to LDL modification was comprehensively assessed 
and compared to that observed with HOCl and OCN- under similar conditions. HOCl and 
HOSCN were shown to modify both the protein and lipid component of LDL. HOSCN 
modifies the apoB100 in a more specific manner compared to HOCl, with oxidation of only 
Cys and Trp observed. In contrast, HOCl was shown to extensively modify the apoB100, 
x 
 
resulting in the loss of several amino acid residues in agreement with previous data. OCN- 
was shown to cause protein carbamylation with the formation of homocitrulline (HCit), 
which is derived from the modification of Lys residues. The extent of lipid modification 
observed on LDL induced by HOSCN and HOCl were also shown to differ, with HOSCN 
showing the capacity to induce more extensive lipid peroxidation, and formation of lipid 
hydroperoxides, 9-hydroxyoctadecaenoic acid (9-HODE) and F2-isoprostanes. 
The contribution of HOSCN, HOCl and OCN--modified LDL to macrophage dysfunction was 
also studied, which may exacerbate the progression of atherosclerosis. HOSCN-, HOCl- and 
OCN--modified LDL did not contribute to the onset of cell lysis after exposure of 
macrophages to the modified LDL for 24 h. However, there was increased uptake of 
cholesterol and cholesteryl esters detected after exposure of macrophage cells to each 
modified LDL, which may trigger the formation of foam cells. In this case, the effect of 
HOSCN- and OCN--modified LDL was not as significant at inducing cholesterol and 
cholesteryl ester accumulation in macrophages compared to HOCl-modified LDL. The 
outcomes observed in this study were reflective of the extent of LDL modifications 
observed, with HOSCN and OCN- inducing more specific and less extensive modifications, 
particularly on the apoB100 moiety of the LDL. 
Furthermore, the inactivation of lysosomal enzymes was also detected after exposure of 
macrophages to HOSCN-, HOCl- and OCN- -modified LDL. These enzymes play a key role in 
the hydrolysis and detoxification of internalised proteins and lipids. Thus, the inactivation 
of these enzymes may contribute to the observed accumulation of cholesterol and 
cholesteryl esters. In this case, HOSCN-modified LDL induced a greater loss of activity on 
intact macrophages, particularly the thiol-dependent cathepsin enzymes B and L, compared 
to HOCl-modified LDL. 
The outcomes observed in this study contribute to the knowledge regarding the role of 
MPO and SCN-‘–derived oxidants in the development of cardiovascular disease. MPO is an 
independent risk factor and a prognostic predictor of cardiovascular events, and it is well 
established that smokers are at a higher risk of atherosclerosis, with SCN- levels known to 
correlate with foam cell formation. However, the data found in the present study is 
consistent with SCN- having a protective effect, which resulted in preventing foam cell 
formation and modulating the extent of LDL modification induced by MPO.  
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Chapter 1: Introduction 
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1.1   Inflammation and Myeloperoxidase 
Inflammation is the response by the body after the onset of injury. The initial process of 
inflammation involves the recruitment and infiltration of leukocytes into the affected sites 
[1-3]. Polymorphonuclear neutrophils (PMN) constitute the majority of these cells, 
resulting in the release of oxidants and effector proteins that serve an antimicrobial 
function [1-3]. A major protein released by neutrophils is myeloperoxidase (MPO). MPO is a 
heme peroxidase that is responsible for the catalytic generation of biological oxidants [1, 
2]. Other heme peroxidase enzymes also exist including eosinophil peroxidase (EPO) and 
lactoperoxidase (LPO) [4, 5]. Neutrophils promote the engulfment of pathogens and foreign 
particles, thought to be pathogenic to host tissues. These internalised particles are 
localised to compartments called the phagosomes, where synthesised oxidants are 
released to aid further degradation of the pathogen [1-3].  
Neutrophils contain up to 3 different types of intracellular granules within their cytoplasm. 
These granules are the site where synthesised substances are stored [3]. MPO is stored 
mainly within the primary granules, also referred to as azurophils. In addition to MPO, 
serine proteases and lysosomal hydrolases are also stored within azurophils [3].  The 
synthesis of these granules is associated with promyelocytes that reside within the bone 
marrow during cell development. During neutrophil activation, azurophil granules fuse with 
the phagosomes, resulting in most secreted MPO being contained within the phagosomal 
compartment [3]. However, MPO can also be released extracellularly with superoxide 
radical ions (O2
.-) generated by NADPH oxidases, the latter dismutate resulting in the 
generation of hydrogen peroxide (H2O2) [1-3]. The reaction of MPO with H2O2, in the 
presence of halide/pseudohalide ions, gives rise to the production of other biological 
oxidants, primarily hypohalous acids, which will be further discussed in section 1.2 [6-8]. 
Although MPO plays an important protective role in the immune system, misplaced 
generation of oxidants by MPO can occur, which may damage host tissues [2]. 
Mononuclear cells also generate MPO in vivo during the development and maturation 
stage. This ability to synthesise MPO is diminished however, during the transformation of 
these cells to monocytes [2]. Hence circulating monocytes generally contain lower levels of 
MPO than neutrophils. The diapedesis of monocytes within peripheral tissues and 
transformation to macrophages has also been shown to diminish production of MPO [9]. 
However, in certain disease states, the ability of macrophage cells to generate MPO 
appears to be retained. In particular, significant levels of MPO activity have been detected 
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within cerebral plaques in Alzheimer’s disease [10] and also lesion-associated macrophages 
in atherosclerosis [11]. The presence of MPO is thought to be associated with dysfunction 
in cellular signalling and processing [12]. Whether this phenomenon may also hold true in 
other disease states, has still to be determined. 
1.2   Formation of MPO-derived Oxidants 
The mechanism of MPO’s catalytic activity is complex and is divided into multiple stages, 
including the halogenation and peroxidase cycles (Figure 1.1) [13]. The halogenation cycle 
involves the initial reaction of native ferric MPO with H2O2 to generate an intermediate, 
called Compound I [14, 15]. Formation of Compound I is reversible and it can be reduced 
back to native ferric MPO by a two-electron transfer reaction mediated by halides or 
pseudo halide ions, including chloride (Cl-) and thiocyanate (SCN-). This step results in the 
formation of hypohalous acids [9, 16, 17]. An alternative pathway that regenerates native 
MPO is the peroxidase cycle. This process involves two separate single electron transfer 
reactions that allows for the regeneration of native ferric MPO via Compound II formation 
[13]. Other redox states of MPO also exist, including ferrous MPO and Compound III. 
Ferrous MPO is generated when ferric MPO reacts with reducing radicals formed during 
MPO’s catalytic activity, resulting in formation of the Fe(II) state. Compound III can be 
generated from reaction of ferric MPO with H2O2, ferrous MPO with two oxygen molecules, 
and Compound II with H2O2 [18-20]. 
 
Figure 1.1 – Diagram of MPO’s catalytic activities [21].    X- = Cl-, Br-, SCN- 
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MPO catalyses the formation of several biological oxidants through the halogenation cycle 
depending on the halide or pseudo-halide substrate oxidised (Reaction 1). Hypochlorous 
(HOCl) and hypobromous acid (HOBr) generated from reaction of H2O2 with Cl
- and Br- are 
the most well characterised of the hypohalous acids [9, 17]. However, the pseudo halide 
thiocyanate (SCN-) is the favoured substrate for both MPO and EPO, which under 
physiological conditions can result in the consumption of significant amounts of H2O2 to 
form hypothiocyanous acid (HOSCN) [17]. Furthermore, this oxidant species can be further 
formed from the reaction of both HOCl and HOBr with SCN- [22, 23]. It has been postulated 
that most of the HOBr formed under physiological conditions may be converted to HOSCN, 
owing to a fast rate constant [23]. This may be an important in the context of 
cardiovascular disease, as smokers who are at high risk of developing cardiovascular 
disease, have higher levels of SCN- in their plasma [24]. 
 
H2O2  + Cl
- , SCN- or Br-    HOCl, HOSCN, HOBr (1) 
 
1.2.1   Beneficial Effects of MPO-derived Oxidants 
The generation of biological oxidants by MPO and their beneficial effects have been well 
documented in the literature [1-3]. Several in vitro studies showed that these oxidants play 
a key role in the killing of several strains of infectious bacteria [7, 25]. For example, 
Escherichia coli were inactivated after exposure to a mixture of MPO, H2O2 and Cl
-, which 
yields HOCl [7]. HOCl was shown to have multiple chemical targets in bacteria, including 
sulfhydryl, iron-sulfur, sulfur-ether, heme groups, and unsaturated fatty acids [26]. 
Modification of these targets results in a loss of microbial membrane transport [27], 
disruption in the electron transport chain [28], consumption of adenylate energy reserves 
[29] and diminished DNA synthesis [29]. 
Peroxidase inhibitors have been used to establish the ability of MPO-derived oxidants to kill 
infectious bacteria. The use of azide [8, 30], cyanide [8, 30], sulfonamides [31] and 4-
aminobenzoic acid hydrazide resulted in the reduction of bacterial killing rates mediated by 
MPO release. However, use of these inhibitors in MPO-deficient neutrophils resulted in no 
change in the bactericidal activity of these cells. Thus, the ability of neutrophils to remove 
infectious bacteria is most commonly attributed to the presence of MPO and formation of 
MPO, EPO, LPO 
Hydrogen Peroxide          Halide/pseudo-halide ions               Hypohalous acids 
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oxidants [2]. In contrast to HOCl, HOSCN is reported to be a bacteriostatic agent, which can 
limit bacterial cell growth [32, 33]. HOSCN production by the LPO/H2O2/SCN
- system 
appears to play a key role in the antimicrobial defence in the oral cavity, airway and also 
milk preservation [32, 33]. 
Besides bacterial cell killing, biological oxidants generated from MPO also have other 
beneficial effects, including a viricidal effect on HIV-1 [34], neutralising microbial toxins 
from diphtheria or tetanus [35, 36], inducing platelets [37, 38] and mast cell secretion [39-
41], and the ability to activate proteases in vitro [42]. 
1.2.2   Detrimental Effects of MPO-derived Oxidants 
Despite the profound contribution of MPO and its oxidants to the immune system, 
excessive or misplaced generation of these oxidants is believed to be damaging to host 
tissues, particularly as MPO is released extracellularly and may target surrounding tissues 
[11]. The detrimental effects of MPO-derived oxidants are elaborated below, highlighting 
the reactivity of MPO-derived oxidants with biomolecules (proteins, lipids, carbohydrates 
and DNA damage), their cellular effects and contribution to different disease states. 
1.3   Reactivity of the Hypohalous Acids with Biomolecules 
1.3.1 Protein Modification 
Considerable evidence exists in the literature for the reactivity of MPO-derived oxidants 
with proteins [16, 43-63]. Several kinetic studies have revealed that proteins are a 
preferred target of MPO-derived oxidants [52]. However, the selectivity and specificity of 
these oxidants vary from one another [54]. HOCl reacts with individual amino acids in the 
following order: cysteine (Cys) > methionine (Met) >> cystine ~ histidine (His) ~ α-amino > 
tryptophan (Trp) > lysine (Lys) >> tyrosine (Tyr) >> arginine (Arg) > glutamine (Gln) ~ 
asparagine (Asn) [56]. While HOBr reacts in the following order: Cys > Trp ~ Met ~ His ~ α-
amino > cystine > Lys ~ Tyr >> Arg > backbone amides > Gln / Asn [64]. HOSCN reactivity is 
more specific compared to HOCl and HOBr. In particular, HOSCN is highly specific for Cys 
and seleno (Sel) residues, with some reactivity documented with Trp residues [65, 66]. 
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1.3.1.1 HOCl and HOBr 
HOCl and HOBr react readily with Cys, Met and other residues with nitrogen-containing 
functional groups such as His, Lys and Trp. Cys oxidation results in the formation of sulfenic, 
sulfinic and sulfonic acids (RSOH, RSO2H, RSO3H) and disulfide formation, and methionine 
oxidation leads to the formation of methionine sulfoxide (MetSO) [46, 56]. These 
modifications to Cys and Met residues, especially within the active site of enzymes, can 
lead to inactivation [46, 47, 67-70]. For example, the exposure of lysozyme and trypsin 
inhibitor (a1-trypsin and soy trypsin inhibitor) to HOCl and HOBr resulted in the inhibition of 
their activity [46, 47]. 
The reaction of amines and amides with HOCl and HOBr results in the formation of 
halamines (chloramines, bromamines) and halamides (chloramides, bromamides) at both 
the backbone and side chain sites [61, 63]. When individual amino acids are incorporated 
into proteins, resulting in the derivatisation of the α-amino group, the formation of 
halamines is restricted to His, Lys and Arg side chain sites [61, 63]. Formation of halamides 
in proteins at backbone sites only occurs with high molar excess of oxidants. Gln and Asn 
residues also react with HOCl and HOBr to yield halamides, though this reaction is slow 
[49]. 
Halamines and halamides generated from HOCl and HOBr retain the oxidising ability of 
their parent oxidant, contributing to secondary reactions mediated by these oxidants [71, 
72]. Some of these reactions involve the regeneration of the parent amine while others 
contribute to modification of the amine group [44, 46-48, 53, 55-59, 73-77]. In particular, 
the hydrolysis of the amine group leads to the formation of reactive aldehydes species, 
which occurs more readily with bromamines [61]. The formation of aldehydes results in 
further reactions to yield Schiff bases (imines) and thus, the formation of advanced 
glycation end products (AGEs). This secondary reaction pathway has been suggested to be 
important in the development of vascular disease (reviewed in [78, 79]). 
Aromatic rings and double bonds present in amino acids (Tyr and Trp) are also targeted by 
HOCl, HOBr and reactive halamines (reviewed in [49, 55]). Although these reactions occur 
in each case, reaction of halamines with these targets in proteins were found to be slower 
than the parent oxidant [44]. Modification of Tyr results in the formation of 3-
chlorotyrosine (3-chloro Tyr) and 3-bromotyrosine (3-bromo Tyr) and further modification 
of these products with excess oxidant can lead to the formation of 3,5-dichloroTyr and 3,5-
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dibromoTyr [49, 50, 80, 81]. Although these products can arise from direct oxidation of Tyr 
residues, formation of halamines can also be important in generating these oxidation 
products [60]. Furthermore, Tyr can also react with HOCl and HOBr to form low yields of 
Tyr dimers called o-o’ diTyr [46]. Trp modification by HOCl and chloramines initially leads to 
the formation of 3-chloroindole. Further hydrolysis of this adduct can lead to the formation 
of 2-oxindole [16, 43, 49]. More recent studies, however, have indicated that the product 
formed from Trp modification is dependent upon neighbouring amino acid sequences. 3-
chloroindole and 2-oxindole are formed when neighbouring sequences involve glycine and 
alanine. In the presence of other amino acid side chains, formation of mono- and 
deoxygenated forms of Trp was detected [43]. Similar reactions are likely to occur with 
HOBr [16]. 
1.3.1.2 HOSCN 
The reactivity of HOSCN has been debated in the literature [4, 17, 51, 82-87]. Unlike HOCl 
and HOBr, HOSCN may not be the only species produced on oxidation of SCN- by MPO in 
the presence of H2O2. It has been suggested that thiocyanogen (SCN)2 [83, 85], 
cyanosulfurous acid (HO2SCN), cyanosulfuric acid (HO3SCN), and cyanide (CN
-) are formed 
via the decomposition of HOSCN, which may contribute to the biological effects of this 
oxidant [87]. Furthermore, (SCN)2 can be further converted trithiocyanate (SCN
-)3 [88]. 
Further studies have demonstrated that cyanate (OCN-) is formed on decomposition of 
HO2SCN and HO3SCN in the EPO/H2O2/SCN
- system [4]. It has been reported that the 
enzymatic MPO/H2O2/SCN
- system can generate a 10% yield of OCN- [24]. Moreover, 
oxidation of SCN- has also been suggested to lead to the formation of radicals such as SCN., 
OSCN ., and (SCN)2
- .[51, 82, 89]. 
HOSCN can react with proteins, owing to its selectivity and specificity for reaction with Cys 
residues [4, 65, 90]. The reaction of HOSCN with Cys primarily forms sulfenyl thiocyanate 
(RS-SCN) species and disulfides [65, 91]. The formation of these products can be reversed 
on addition of reductants [65, 91]. However, further reactions of RS-SCN and disulfides can 
yield other products, including sulfenic acids [4, 65] (see also section 1.3.2). 
There is limited evidence for the reactivity of HOSCN with other amino acid residues. With 
the enzymatic LPO/H2O2/SCN
- system, modification of aromatic amino acid residues Tyr, His 
and Trp is reported [65]. However, the oxidative process that occurs in this case was 
attributed to the presence of (SCN)2, with addition of SCN
+ into the aromatic ring [65]. 
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Furthermore, amino thiocyanate (RN-SCN) were detected on the imidazole groups of His, 
though these products are reported to be unstable on Lys residues [92]. Hawkins et al. have 
shown that HOSCN can directly modify Trp residues in the absence of LPO with some 
evidence also provided for the formation of RN-SCN products on Lys residues [66, 93]. 
Products resulting from the HOSCN decomposition have also been shown to modify Lys 
residues, resulting in the formation of stable carbamylated derivatives [24]. This reaction 
process is mediated by the formation of OCN- on decomposition of HOSCN [24]. 
1.3.2 Thiol Modification 
Thiols are important targets for all hypohalous acids [94-96]. These compounds exist as 
either low-molecular mass thiols (e.g. reduced glutathione; GSH) or protein-bound thiols 
(free Cys residues) [65, 66, 91, 92, 97]. GSH is an important cellular antioxidant, protecting 
cells from excessive levels of free radicals and other reactive species [26]. Modification of 
Cys by HOCl residues results in the formation of sulfenyl chloride (RS-Cl), which can further 
react with thiols to form disulfides [94]. When water is present, the formation of sulfenic 
(R-SOH), sulfinic (R-SO2H) and sulfonic (R-SO3H) acids have also been reported [95, 98]. In 
particular, cysteic acid is observed upon reaction of disulfides with HOCl [49]. 
HOSCN oxidises thiols to form thiosulfenyl thiocyanates (RS-SCN) [65, 66, 91], which 
hydrolyse to sulfenic acid intermediates. Thiosulfenyl thiocyanates can also react with 
other thiol compounds to form disulfides [65, 66, 87]. Exposure of isolated GSH to HOSCN 
gives rise to oxidised glutathione [99, 100]. Under acidic conditions, formation of Cys 
dimers was also observed with low-molecular weight thiols [101].    
1.3.3 Lipid Modification 
Lipids have been shown to react with MPO-derived oxidants. In particular, HOCl and HOBr 
react readily with the amine head groups that are present in phospholipids. 
Phosphatidylethanolamine and phosphatidylserine are the most reactive, giving rise to 
chloramines and bromamines [102-104]. A similar pattern of reactivity is observed on 
exposure of these targets to MPO/EPO in the presence of H2O2 and halide ions [105]. 
Furthermore, HOCl and HOBr also contribute to the modification of mono- and poly-
unsaturated fatty acids. These oxidants target double bonds present within these lipids, 
giving rise to halohydrins. Subsequent reactions of these reactive products can yield the 
formation of epoxides [104, 106-112]. 
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There is limited evidence for the reaction of SCN- derived oxidants with lipids. A study by 
Exner et al. showed that SCN- derived oxidants generated by MPO contributed to lipid 
modification in lipoproteins [82]. In this study, formation of conjugated dienes and lipid 
hydroperoxides was observed, which was prevented on inclusion of a heme poison (azide, 
cyanide) that inhibits peroxidase activity, or addition of ascorbate to scavenge radicals [82]. 
OCN- is postulated to react with amines present within the phospholipids head groups. This 
was detected with reagent OCN- and isocyanates, but not the MPO/H2O2/SCN
- enzymatic 
system [113, 114]. Several studies have shown that (SCN)2 can react with the double bonds 
present in fatty acids, giving rise to products that are similar to the halohydrins generated 
by HOCl and HOBr exposure [115, 116]. However, again, this reaction has not yet been 
proven to be possible in a peroxidase-mediated system.   
1.3.4 DNA Modification 
DNA is targeted by HOCl and HOBr with these reactions giving rise to the formation of 
halamines and stable chlorinated or brominated products [73, 117, 118]. Both free and 
incorporated (in DNA and RNA) forms of nucleosides and nucleotides are targeted by the 
oxidants [73, 117, 118]. HOCl and HOBr react with the nitrogen centres present in purine 
and pyrimidine bases, giving rise to the formation of chloramines and bromamines [105]. 
Stable downstream products formed from these reactions include 5-chlorocytosine, 5-
chloro(2’-deoxy)cytidine, 5-chlorouracil, 8-chloroadenine, 8-chloro(2’-deoxy)guanosine, 
and the corresponding brominated forms of these products [105]. Furthermore, 
hydroxylated and ring open nucleobase-derived products have been detected after 
exposure of DNA and RNA to these oxidants [119, 120]. DNA modifications mediated by 
HOCl and HOBr have been postulated to be mutagenic [121, 122], and have been detected 
in vivo at inflammatory sites [123]. In contrast, no evidence of reactivity of HOSCN with 
DNA/RNA or related species has been reported. 
1.3.5 Carbohydrate Modification 
Carbohydrates mainly exist in tissues as glycoaminoglycans (GAG), which are long 
polysaccharide chains [124]. Carbohydrate modification occurs on HOCl and HOBr exposure 
[75, 76, 125]. The main target of these oxidants is the amine group present in 
glycosaminoglycans (GAG). GAG are mainly composed of repeating disaccharide units, in 
which each unit contains an amino sugar and a uronic acid sugar [126]. Both free and 
glycosaminoglycans attached to proteins (proteoglycans) were demonstrated to be 
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modified in previous studies, with formation of mono- and dihalamines, halamides, and N-
halosulfonamides [75, 76, 125]. Modifications of these carbohydrate-containing molecules 
are biologically important as they are major components of the extracellular matrix [75, 76, 
127, 128]. MPO-induced damage to the extracellular matrix and the vessel walls have been 
correlated with inflammatory disease states [129, 130]. 
1.4   Cellular Effects of Oxidants 
Modification of different biomolecules by reactive oxidants has implications for their 
effects on different cell types. These effects may contribute to the role of these oxidants in 
the progression of disease. While there are fewer studies that investigate the role of HOBr 
in cells [103, 131], there are numerous studies that highlight the important contribution of 
HOCl on cellular dysfunction of different cell types [94, 131-134], leading to cell death. 
Furthermore, there is growing evidence for the role of HOSCN in cellular dysfunction, 
particularly in macrophages and endothelial cells [135, 136]. 
1.4.1 HOCl Exposure 
Detrimental cellular effects upon treatment with HOCl is well documented in the literature 
with reports of disturbances of the redox balance [94, 133, 137], metabolic processes [134, 
138, 139], modulation of cell signalling [140-143], inhibition of DNA synthesis [144] and 
induction of apoptosis and necrosis [136]. 
The redox balance in cells is mediated by the presence of low-molecular weight thiols 
(reduced glutathione; GSH) that plays an important role in the cell’s antioxidant defence 
and detoxification pathways [26]. HOCl is highly reactive with GSH [94] and readily depletes 
GSH in many different types of cells [94, 133]. These findings demonstrate that generation 
of these oxidants and exposure to cells can contribute to compromising redox balance in 
cells [26, 94, 133, 137].  
HOCl also contributes to disturbance of the metabolic processes in cells. Nicotinamide 
adenine dinucleotide (NADH) contributes to the production of adenosine triphosphate 
(ATP), which is the energy source of cells during metabolism [77, 145]. HOCl readily reacts 
with NADH [139], causing a reduction in ATP being produced in cells. Consequently, these 
cells have an altered and defective metabolism that will ultimately contribute to cell death 
[134, 138, 139, 146].  
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Altered modulation of signalling pathways in cells has also been detected upon treatment 
with HOCl and chloramines. Mitogen-activating protein (MAP) kinases MAP kinases exist in 
three different forms, including extracellular signal-regulated kinase (ERK1/2), p38 and c-
Jun N-terminal kinase (JNK) [147]. These signalling molecules play a crucial role in the 
embryogenesis, cell differentiation, proliferation, and cell death [140-142]. MAP kinases 
were upregulated on exposure of cells to HOCl [143]. With the exposure of fibroblasts and 
HUVEC to HOCl, there was activation of both ERK1/2 and p38 at sublethal concentrations 
(10 – 50 μM) [143]. Furthermore, a recent study also showed that the exposure of J774A.1 
cells to HOCl results in the inhibition of protein tyrosine phosphatases (PTP), which may be 
associated with the hyperphosphorylation of MAP kinase ERK2 and p38 [148]. 
Exposure of cells to HOCl and chloramines led to the induction of apoptosis and necrosis, 
which has been reported in different cell types. Apoptosis was induced after treatment of 
different cells to low doses of HOCl (≤ 40 nmol) and chloramines [120], including liver, 
endothelial [149-151], gastric epithelial [152], leukemia [153], lymphoma [154] and 
cartilage cells [155]. Most of these cells display activated caspase-dependent apoptotic 
mechanisms after treatment by HOCl (e.g. [151, 156]). However, it was also reported that 
HOCl and chloramines can contribute to an alternative pathway of apoptosis by the release 
of cytochrome c, apoptosis inducing factor (AIF) and endonuclease G [157]. While low 
doses of HOCl lead to apoptosis, it has been shown that high doses of HOCl can lead to 
necrosis of cells. Necrosis was detected in several cell types including red blood cells, 
monocytes, macrophages, and endothelial cells [151, 158]. In a similar study, it was shown 
that generation of chloramines at the same dose does not elicit necrosis in lymphoma cells, 
implying that only HOCl induces necrosis, while chloramine treatment does not under the 
conditions used [154]. 
1.4.2 HOBr Exposure 
There are fewer studies that have examined the effect of HOBr on cells. Exposure of red 
blood cells, THP-1 monocytes and J77A.1 macrophage-like cells to HOBr resulted in cell 
death [103, 131]. Time course studies showed that cell death in red blood cells induced by 
HOBr was faster compared to HOCl exposure. This difference was attributed to the faster 
reaction of HOBr with membrane lipids and proteins [103]. The rates of cell death induced 
by HOCl and HOBr, however, were not different in monocytes and macrophage cells  [131].  
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The exposure of red blood cells to HOBr also resulted to the consumption of cellular GSH, 
which compromises the redox balance mediated by cells during antioxidant defence and 
detoxification pathways [103]. The associations of cellular GSH depletion and the induction 
of cell death in these cells were not clear, since the rate of GSH consumption did not match 
with the rate of cell death mediated by HOBr [103]. 
Studies investigating the induction of cell apoptosis by HOBr are quite limited. Exposure of 
leukemia cells to HOBr or the MPO/H2O2/Br
- system resulted in the induction of apoptosis 
[159]. In this case however, apoptosis was induced due to the presence of bromamines 
that formed after the reaction of HOBr with amines present in the media [159]. Subsequent 
studies using amine-free cell media did not lead to the apoptosis of these cells [159]. 
Necrosis can be induced by HOBr exposure in several cell types including red blood cells, 
monocytes, macrophages, endothelial cells and fibroblasts [131, 160].   
1.4.3 HOSCN Exposure 
Although HOSCN is not as reactive as HOCl and HOBr, its specificity for cellular thiols may 
be more damaging to cells [136]. HOSCN was shown to enter red blood cells, leading to the 
consumption of oxyhaemoglobin and cellular GSH, resulting in cell death [90]. Further 
studies demonstrated that cell death occurred prior to the depletion of GSH and 
intracellular enzymes [4]. A more recent study showed that HOSCN reacts readily with 
creatine kinase (CK) and glyceraldehyde-3-phosphate dehydrogenase (GADPH), which have 
a thiol-containing active site that is sensitive to oxidation [161]. 
Exposure of HUVECs to HOSCN contributed to the modulation of cellular function in 
inflammatory states [162]. Treatment of cells with HOSCN led to the expression of tissue 
factor (TF) gene and upregulation of proinflammatory p65/p50 NF-κB transcription factors 
[162]. These inflammatory mediators contribute to thrombogenesis, and expression of 
several adhesion molecules and proinflammatory cytokines. In particular, endothelial cell 
adhesion molecules (E-selectin, ICAM-1 and VCAM-1) were upregulated upon treatment of 
HUVECs with HOSCN [163]. 
A recent study highlighted the role of HOSCN in macrophage apoptosis and necrosis. The 
effect of HOSCN was compared with HOCl and HOBr [136]. HOSCN was more effective in 
inducing apoptosis and necrosis compared to HOCl and HOBr. The mechanism of apoptosis 
was associated with a cytosolic increase in cytochrome c levels. This effect was attributed 
to the ability of HOSCN to react with membrane thiol proteins in mitochondria, resulting in 
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an increased permeability and leakage of cytochrome c into the cytosol [136]. This 
mechanism of apoptosis was demonstrated to be caspase-independent with no decrease in 
apoptosis associated with treatment with caspase inhibitors [136]. Similar results have 
been reported for human coronary artery endothelial cells (HCAEC) [135], but not with 
HUVEC [164], though cellular dysfunction was evident in this case. 
1.5   Myeloperoxidase in Inflammatory Disease 
The role of MPO and its biological oxidants in different disease states relating to 
inflammation have been studied extensively, particularly in relation to cardiovascular 
disease, neurodegenerative disease, cancer, renal disease and respiratory diseases 
(reviewed in [105]). 
1.5.1 Neurological Disease 
The role of MPO is also linked with the development of neurological disorders, with 
evidence supporting a role for this peroxidase in Alzheimer’s disease [10, 165], Parkinson’s 
disease [166] and Multiple sclerosis [167]. 
Direct evidence for a correlation between elevated levels of MPO and Alzheimer’s disease 
has been obtained. It was previously suggested that MPO contributes to the pathology of 
the disease, demonstrated by its high expression in brain tissues of patients suffering from 
Alzheimer’s disease [10]. Furthermore, catalytically active MPO colocalises with β-amyloid 
peptide and there is evidence for the formation of 3-chloro Tyr in brain tissues [165]. These 
data suggest a potential contribution of HOCl to the development and progression of 
Alzheimer’s disease. 
The relationship between the onset of Parkinson’s disease and MPO is based on indirect 
evidence [168]. Parkinson’s disease is characterised by the destruction of dopaminergic 
neurons in the substantia nigra pars compacta area of the brain [169]. MPO is present in 
this region in patients suffering from Parkinson’s disease and in mice with induced loss of 
dopaminergic neurons [166]. Furthermore, formation of 3-chloro Tyr and other chlorinated 
proteins was detected in mouse models of Parkinson’s disease, implicating a role for HOCl 
in disease development and progression [166]. 
MPO has also been linked with the development of multiple sclerosis. Multiple sclerosis is a 
disease marked by demyelination and damage of neuronal axons, leading to the formation 
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of lesions scattered throughout the central nervous system. Macrophages and microglial 
cells from patients with this disease were shown to express MPO [167]. It was suggested 
that myelin from axons are removed through damage mediated by MPO-derived oxidants. 
However, there is no direct evidence for a contribution of HOCl, with no 3-chloro Tyr 
detected [167]. Positive correlations were demonstrated using epidemiologic studies that 
early onset of disease in females and severe tissue damage was associated with enhanced 
expression of MPO [167, 170]. Other studies in this area, however, demonstrated the 
converse effect. In particular, the activity of leukocyte expressed-MPO was lower in 
multiple sclerosis patients [171, 172]. 
1.5.2 Cancer 
The involvement of MPO in carcinogenesis has been proposed on the basis that oxidants 
may damage DNA contained within cells. Chronic inflammation mediated by infections, 
non-infectious irritants or allergens is associated with increased risk of developing cancer 
(reviewed in [173]). In this case, heightened generation of oxidants important in the 
inflammatory response may modify DNA in cells after co-localisation, leading to 
mutagenesis and the development of cancer [174]. Studies in vitro showed genotoxicity in 
cultured cells that were co-incubated with activated neutrophils. This effect was inhibited 
when neutrophils were replaced with ones that lack the ability to generate oxidants [175, 
176]. Supplementation with protective enzymes (SOD and catalase) and antioxidants (low-
molecular weight thiols) inhibited modification of cellular DNA [175]. There are also in vivo 
studies that support the role of MPO in cancer. In particular, elevated levels of MPO were 
detected in colonic tumours, which were not detected in normal tissues [177]. Collectively, 
these studies implicate MPO-derived oxidants in genotoxicity that may be associated with 
carcinogenesis [177].   
Chlorination and bromination of DNA bases has been detected in biological tissues during 
human inflammatory states, showing the significance of MPO oxidants in pathological 
conditions [178]. These reactions can result in products that can mediate multiple cellular 
effects including cytotoxicity and mutagenesis (reviewed in [179]). In particular, chlorinated 
pyrimidine bases were shown to modulate these effects on conversion to 
deoxyribonucleotides. Gene silencing, a process that contributes to carcinogenesis, can also 
occur on incorporation of 5-chloro/bromo cytosine in place of 5-methyl cytosine [180].  
Development of lung cancer has also been linked with the presence of MPO. Exposure of 
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cigarette smoke and asbestos were shown to elevate MPO levels in broncoalveolar fluids 
compared to individuals not exposed to these particulate irritants [181]. 
A correlation between the development of cancer and MPO has also been demonstrated in 
several epidemiologic studies. It was demonstrated that there has been a reduced risk in 
developing lung cancer when there is modification of the gene that encodes for MPO (G-
463A), leading to decreased expression of the enzyme (reviewed in [182, 183]). In addition, 
modification of the same gene that leads to an increased expression of MPO showed 
increased risk in developing carcinogenesis with the onset of leukemia [184].  
1.5.3 Renal Disease 
MPO has been proposed to contribute to the development of renal disease (reviewed in [2, 
185]). There is evidence showing the contribution of MPO in the development of 
neutrophil-mediated glomerulonephritis. Infusion of MPO into the renal artery of rats with 
H2O2 and Cl
- ions led to damage in the glomerulus and onset of proteinuria [186]. As the 
levels of H2O2 and Cl
- ions introduced into the artery were non-toxic, this damage was 
attributed to the contribution of the chlorinating activity of HOCl [186]. Patients with 
Wegener granulomatosis and renal dysfunction in rats also display elevated expressaion of 
MPO in renal biopsies [187, 188]. 
Direct evidence also exists for the detection of HOCl in renal disease. Immunohistochemical 
studies in patients affected with renal disease showed detection of chlorinated proteins. In 
some cases, these products were observed to be colocalised with MPO protein [189]. 
Chronic hemodialysis patients with kidney failure also have chlorinated plasma proteins. 
These data support a role for HOCl-mediated damage in renal disease [190]. 
1.5.4 Respiratory Disease 
The involvement of MPO in respiratory disease has been exemplified in cystic fibrosis. The 
role of MPO in promoting chronic inflammation and progressive lung dysfunction in cystic 
fibrosis is well characterised (eg [191, 192]). In particular, sputum samples from cystic 
fibrosis patients showed higher peroxidase activity compared to control samples. Also, the 
activity detected correlates with the severity of disease, highlighting a critical role of MPO 
[193]. Furthermore, it was demonstrated that the activity of MPO from circulating 
neutrophils was associated with the development of airway obstruction and production of 
sputum in cystic fibrosis patients [194]. 
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Evidence of chlorination, mediated by HOCl, has been well documented, with 3-chloro Tyr 
detected on proteins that accumulate in sputum and bronchoalveolar lavage fluid in 
affected patients [195, 196]. Moreover, chlorinated products have even been detected in 
young children affected by this disease, thus contributing to the notion that MPO and its 
oxidants may play a crucial role in the development of cystic fibrosis [195]. Exposure of 
airway epithelium to oxidants was associated with increased membrane permeability, 
which may contribute to the leakage of plasma proteins into the airways of patients [193, 
197]. 
HOCl can mediate indirect damage that contributes to the onset of cystic fibrosis. It was 
demonstrated that α1-antitrypsin was readily modified by oxidants after isolation from 
patients. This contributes to the notion that HOCl can inactivate protease inhibitors that 
protect the host from enzymatic damage [198]. Furthermore, HOCl can also activate and 
exaggerate the effects of proteases, including latent collagenase and metalloproteinases 
(e.g. gelatinase), suggesting that the activation of these enzymes may contribute to 
damage to the airway epithelium of patients affected by cystic fibrosis [199]. 
The contribution of HOSCN to the exacerbation of respiratory disorders is very different to 
HOCl. In this case, formation of HOSCN is generally reported to be a detoxification process 
that removes H2O2 and HOCl [23, 200-204]. Furthermore, it was also demonstrated that 
cells derived from the respiratory tract were not damaged by HOSCN, which may 
contribute to the notion that HOSCN production may limit respiratory disease [201-204]. 
1.5.5 Cardiovascular Disease 
Cardiovascular disease (CVD) is a major cause of death and disability worldwide. In 
developed countries like Australia, one of the most common forms of CVD is 
atherosclerosis [205]. Atherosclerosis is a condition characterised by the build-up of 
triglycerides, cholesterol and cholesteryl esters within the walls of large arteries. This 
disease can manifest itself clinically in different ways. For example, atherosclerosis that 
affects the cerebral circulation or the coronary circulation can result in the development of 
a cerebral angina (stroke) or a myocardial infarction (heart attack), respectively [205]. 
There are different controllable risk factors that are associated with the development of 
atherosclerosis. These factors include tobacco smoking, elevated blood pressure, reduced 
physical activity, elevated blood cholesterol and triglyceride levels, poor diet/nutrition and 
diabetes. It is known that atherosclerosis risk is strongly increased with age [206]. Previous 
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surveys have shown that CVD accounted for 35% of deaths in Australia during the year 
2005 and the prevalence was higher in males than in females (55% to 45% respectively). 
There was a high disability rate attributed to CVD, with 1.4 million Australians estimated to 
be affected. CVD is a major financial burden costing $5.9 billion in terms of health care 
expenditure. As a result research into the causes and treatment of CVD remains a critical 
component of health policies and strategies [206]. 
1.5.5.1 The Role of Myeloperoxidase 
Compelling evidence suggests that MPO is involved in the development of CVD [21, 207-
211]. It was postulated that altered trafficking of cells and processing can lead to the 
excessive presence of MPO within lesions [12]. Several studies in biochemical, 
epidemiologic and clinical studies support a role for MPO (reviewed in [21, 105]). 
1.5.5.1a Early Atherosclerosis 
The early stages of atherosclerosis are characterised by the accumulation of lipoprotein-
derived lipids and leukocytes within the artery wall. The interaction between lipids and 
leukocytes results in the formation of “foam cells”, an early hallmark of atherosclerosis 
[212]. These foam cells can accumulate to form fatty streaks within the walls of the 
arteries. This build up of lipid deposits is known as early atheroma (Figure 1.2). Early 
atherosclerotic lesions can either cease to develop by the stabilisation of plaque, or can 
progress into more complex and advanced lesions [213]. 
Biochemical studies show strong evidence supporting a role of MPO in cardiovascular 
disease. Immunostaining studies using an anti-human MPO antibody demonstrated the 
presence of active MPO in all atherosclerotic lesions [11]. In addition, the role of MPO was 
associated with the generation of HOCl formation and thus, elevated levels of chlorinated 
products were observed in atherosclerotic lesions, including 3-chloro Tyr [50] and 5-
chlorouracil [214, 215]. Other markers of oxidative damage including α-chloro fatty 
aldehydes have also been detected in lesions [216], supporting the role of chlorinating 
oxidants in atherosclerosis [210, 217, 218]. 
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Figure 1.2 – The development of atherosclerosis [219] (Extracted from Libby, 2002, 
Inflammation in Atherosclerosis, Nature, 420, 868-874) 
 
One of the major effector cells within the early stages of atherosclerosis are macrophages 
[220]. Macrophages are scavenger cells that play a pivotal role in inflammation. These cells 
recognise and remove foreign particles that are thought to be pathogenic to host tissues. 
However, macrophages can also play a detrimental and damaging role in diseases that 
involve an inflammatory mechanism, including atherosclerosis [221, 222].  In fact, 
compelling evidence using a rabbit animal model revealed that the initiation of an 
atherogenic diet allows the attachment and recruitment of circulating monocytes to  
endothelial cells [223]. Under normal physiological conditions, endothelial cells do not 
allow the prolonged attachment of leukocytes unless they are activated by an 
inflammatory stimulus [219]. This observation adds more evidence to the notion that 
inflammatory mechanisms play a crucial role in the initiation and the development of 
atherosclerosis, owing to the recruitment of leukocytes within the arterial wall.  Studies 
involving the use of animal (mice) models showed reduction of atherosclerotic lesion 
development in situations where macrophage numbers were depleted or their activation 
was impaired [224]. For example, impairing the migration of macrophages into the lesion 
site can prevent the onset of atherosclerosis in LDL receptor deficient mice [225]. 
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Multiple clinical studies have examined the importance and correlation of MPO in the 
development of cardiovascular disease (e.g. [207-209]). One study showed increases in 
leukocyte numbers and blood MPO levels in patients with coronary artery disease [226]. 
This study concluded that MPO may provide a role as a marker in the development of this 
disease [226]. Furthermore, assessment of MPO serum levels in patients with acute 
coronary syndromes and endothelial cell dysfunction also showed a correlation between 
elevated MPO and the development of cardiovascular disease [208, 227], with serum MPO 
levels being a strong risk factor for cardiovascular events [208, 227]. The ability of MPO to 
predict the onset of cardiovascular events was also assessed in patients with chest pain, 
with MPO levels shown to be a strong predictor of cardiovascular events, including 
myocardial infarction and the need for revascularisation [228].  
Development of heart failure in patients after the onset of myocardial infarction was also 
associated with elevated levels of MPO compared to healthy controls [229, 230]. The 
strong association between MPO and the onset of heart failure was still apparent even with 
adjustment according to age and levels of brain natriuretic peptide (BNP) [230]. Plasma 
levels of MPO were also elevated in patients with stable and severe systolic heart failure 
[230, 231]. In stable heart failure patients, MPO levels were correlated with impaired 
diastole, indicating its predictive role in assessing impaired ventricular relaxation of the 
failing heart [231]. Increased levels of MPO in plasma were associated with heart failure 
irrespective of the etiology of the disease [232] and was demonstrated to be predictive of 
1-year mortality in patients with heart failure [233]. 
Genetic studies also support a correlation between MPO and cardiovascular disease. High 
expression of MPO was associated with the G-463A polymorphism in the promoter region 
of the MPO gene [234]. Increased cardiovascular events were observed in individuals who 
express high levels of MPO with this polymorphism [234]. Conversely, individuals who 
express low levels of MPO did not have a high risk of developing cardiovascular disease 
[207, 235].  
1.5.5.1b Advanced Atherosclerosis 
Advanced lesions are characterised by the deposition and accumulation of cholesterol and 
the formation of vulnerable plaques within the extracellular matrix of the intima. 
Vulnerable plaques are a stage of plaque development that are prone to disruption and 
rupture, causing  damage and disorganisation to the walls within affected arteries [219, 
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236]. Lesion development can cease at this point, through plaque stabilisation and the 
formation of a fibrous cap that acts as a barrier between the atheromatous plaque and the 
circulating blood stream. However, physical disruptions within the lesion can occur that 
lead to thrombosis. There are at least three different physical factors/disruptions that 
influence plaque disruption and cause arterial thrombosis [237]. These disruptions include 
superficial erosion or desquamination of endothelial cells, microvessel haemorrhage of 
new microvascular channels within atherosclerotic lesions, and the fracture of the fibrous 
cap. These processes are strongly associated with inflammatory pathways [219]. 
The most common and well understood scenario that accounts for ~ 75% of developing 
myocardial infarctions is rupture of the fibrous cap [238]. The formation of a fibrous cap 
allows the sequestration of tissue factor within the developing lesion from the circulating 
blood stream. Tissue factor is a pro-coagulant stimulus that plays a role in the activation of 
the coagulation cascade, resulting in thrombosis. Again, this particular scenario also 
involves an inflammatory mechanism [219]. A rupture in the developing fibrous cap allows 
the exposure of the blood stream to the tissue factor within the atherosclerotic lesions and 
the subsequent activation of coagulation factors [239]. The coagulation factors undergo a 
cascade of activation that is involved in the wound healing response, which repairs 
ruptured and damaged tissues. In addition, activated platelets release PDGF and TGF-beta, 
both of which play a crucial role in the formation of a tensile fibrous tissue compensating 
for the damage in the artery wall [239]. Ultimately, if the activity of the fibrinolysis 
overcomes the pro-coagulant mechanism associated in thrombosis, the resulting thrombus 
would not be occlusive to the arteries. However in some cases of heightened inflammatory 
response, the resulting thrombus can occlude the blood flow of affected arteries, which 
results in a myocardial infarction [219]. 
MPO has been shown to disrupt endothelial cell-derived matrix [240, 241], which 
contributes to the assembly of the basement membrane and arterial function [242]. A 
major component of this matrix is the heparan sulfate proteoglycan perlecan [243]. 
Exposure of endothelial cell-derived matrix to the enzymatic MPO/H2O2/Cl
- system results 
in the oxidation of this component and release of perlecan-derived fragments [244].  
Similar findings were reported when smooth muscle cell-derived matrix was exposed to 
HOCl, HOBr and the enzymatic MPO/H2O2/Cl
- system [76, 245, 246]. These data support the 
notion of the damage mediated by the hypohalous acids when generated in the 
subendothelial compartment [76, 245, 246]. Studies using isolated heparan sulfate 
21 
 
demonstrated that HOCl and HOBr can react rapidly with amino acids present within the 
backbone of sugars in glycosaminoglycan chains [74, 76, 125]. The exposure of HOCl and 
HOBr to heparan sulfate-bound perlecan did not contribute to the oxidative modification of 
this component, however, the protein core of the perlecan molecule was extensively 
modified [128]. This effect mediated by MPO-derived oxidants may contribute to altered 
structure and function of the extracellular matrix, which may exacerbate the development 
and progression of atherosclerosis [128]. 
The presence of MPO and generation of hypohalous acids has been linked to plaque 
rupture. In patients that had experienced sudden cardiac death, elevated levels of 
macrophage-derived MPO and the presence of HOCl-modified proteins were detected 
within atherosclerotic lesions [247]. Furthermore, HOCl was also shown to induce 
endothelial cell apoptosis and elevate tissue factor activity, which may contribute to the 
onset of plaque erosion and thrombogenesis [149]. Moreover, it was also suggested that 
matrix metalloproteinase (MMP) are also activated after the degranulation phase of 
phagocytes, including the release of MPO [248]. 
1.6   Atherosclerosis and LDL Modification 
The pathogenesis of atherosclerosis involves the accumulation of lipid plaques in the walls 
of large arteries [212, 249]. The source of these lipids is derived from low-density 
lipoprotein (LDL) [212, 249]. 
1.6.1 Low-density Lipoprotein 
LDL is a particle generated in vivo that is responsible for the transport of cholesterol within 
the blood stream. The presence of these lipoproteins allows for the supply of cholesterol to 
both tissues and cells [250, 251]. The importance of lipoproteins is highlighted by the fact 
that cultured mammalian cells cannot survive unless they are provided with a source of 
cholesterol [250, 251]. 
1.6.1.1 Structure 
LDL is composed of lipids, antioxidants and a single large protein, with the lipids 
constituting 75% of the total mass [252, 253]. The lipid portion of LDL consists of two 
compartments, the non-polar core and the polar surface [254]. The non-polar, hydrophobic 
core of the particle (Figure 1.3) is predominantly composed of cholesteryl esters, 
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cholesterol and triglycerides [252, 253]. The polar surface of the LDL consists of a 
phospholipid monolayer, where the polar heads of these molecules are facing the outside 
of the particle and the non-polar tails are sequestered to the inside of the particle (Figure 
1.3). Free (unesterified) cholesterols are present within this phospholipid monolayer 
structure. The polar component of the phospholipids allows the transportation of 
cholesterol incorporated into the LDL particle, since it can interact with the aqueous 
environment in the blood stream [254].  
ApoB100 is the major protein on LDL and constitutes the remainder (~25%) of the whole 
LDL molecule [253]. This protein serves as both recognition sites for receptor-mediated 
uptake of LDL into cells and enzyme interaction, responsible for lipid metabolism [255]. 
Studies have demonstrated that apoB100 has a functional site in the C-terminal region that 
allows recognition by LDL receptors [255, 256]. There has been a major focus on the role of 
LDL and apoB100 in disease development, particularly in cardiovascular diseases including 
atherosclerosis [257]. 
 
 
Figure 1.3 – A schematic diagram representing the structure of low-density lipoprotein 
(LDL) (modified from [258]) 
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1.6.2 Theories of Atherogenesis 
The complex mechanisms that outline the initiation of atherosclerosis have been 
thoroughly debated after years of investigation. Several theories or hypotheses have been 
developed to explain the events that occur during the initiation of this disease [259]. In 
particular, three theories have emerged that are still under investigation, which include 
“The Response to Injury Hypothesis”, “The Reponse to Retention Hypothesis”, and the 
“Oxidative Modification of LDL Hypothesis”.  These theories are not exclusive to one 
another, but each highlights the critical initiating concept necessary for the development of 
the disease [259]. 
1.6.2.1 Response to Injury 
The response to injury hypothesis proposes the notion that injury and the denudation of 
endothelial cells are initiating event in the disease. This theory originates from the early 
proposal by Rokitansky suggesting that the intimal thickening of the arterial walls is due to 
fibrin deposition [260]. This builds on an idea proposed by Virchow, who suggested lipid 
complexes with mucopolysaccharides can cause the development of atherosclerosis [261]. 
This led to Ross and Glomset proposing that the damage to endothelial cells can induce 
certain responses that results in the upregulation of leukocyte and platelet adhesion, and 
establishment of a procoagulant milieu [262]. It is widely established that leukocytes and 
platelets contribute a critical role in the induction of an inflammatory response through the 
release of cytokines, growth factors and vasoactive agents [262]. These processes influence 
the smooth muscle cells located in the media, which are stimulated to migrate towards the 
intima and exert pro-atherogenic effects [262]. 
However, further investigations show that endothelial cell denudation and desquamination 
is not a requirement for the development of atherosclerosis [222]. It has been reported 
that an intact endothelium can cover and give rise to the progression of atherosclerosis, 
which further weakens the proposal of injury as the initiating factor of the disease [222].  
Furthermore, a refinement of the hypothesis led to the notion that the denudation of 
endothelial cells was sufficient to promote the disease due to an increased permeability to 
LDL [263]. More problems have been shown with this proposal however, with studies 
showing the accumulation of LDL within undamaged arteries that were predisposed to 
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develop into future lesions [264]. This study suggests that LDL accumulation may not rely 
on damage to and desquamination of arterial walls, which gave rise to other theories that 
explain the development of atherosclerosis. 
 
1.6.3.2 Response to Retention 
The response to retention hypothesis stresses the notion that the accumulation of LDL is 
the critical factor in the initiation of atherosclerosis. This theory was established after the 
injection of experimental rabbits with LDL caused its accumulation within arteries,  and the 
formation of microaggregates [265]. It has been shown that 85% of the accumulated LDL in 
arteries occurred due to transcytosis [266]. Moreover, the retention of lipoproteins 
involves the association of these particles with components of the extracellular matrix. In 
particular, the apoB100 component of LDL associates with proteoglycans present within 
the arterial walls [124, 267]. This association was postulated to be mediated by specific 
residues within the apoB100 structure [268]. In support of this, experimental data has 
shown that mutation of these residues between 3359 and 3369 in the apoB100 protein can 
protect experimental mice against the development of atherosclerosis [268, 269]. This 
mutation results in a loss of the positive charge of Lys residues on replacement with neutral 
amino acids [268, 269]. The apoB component in mice, namely apoB48, which has been 
shown to be comparably atherogenic to apoB100 from humans, was also determined to 
associate and bind strongly with proteoglycans [270, 271]. This interaction occurred at 
residues 84-94 of apoB48. This site contains 3 Lys residues that gave an overall positive 
charge to this sequence. As with human apoB100, mutation of these charged residues to 
neutral amino acids, removed its interaction with proteoglycans [270, 271]. These data 
support a role of proteoglycans in the initiation of atherosclerosis through the retention of 
LDL. 
Another factor that contributes to this theory is the role of lipolytic and lysosomal enzymes 
present within the extracellular matrix. In particular, in vitro studies have shown elevated 
and enhanced binding of LDL to endothelial cells, which was strongly dependent on the 
enzymatic activity of lipoprotein lipase [272]. Microaggregates were also observed after the 
retention of LDL within arterial walls [265, 273], due to the involvement and action of 
sphingomyelinase [274]. This enzyme also generates ceramides that can influence cellular 
apoptosis and mitogenesis [275, 276]. Moreover, microaggregate formation is also 
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influenced by other lysosomal enzymes including cathepsin D and lysosomal acid lipase 
[277].  
The “response to retention” hypothesis also explains the formation of foam cells within the 
arterial walls [278]. Previous studies show that aggregation of LDL in response to 
monoclonal antibody and the formation of proteoglycan-lipoprotein aggregates influences 
the ability of  macrophages and smooth muscle cells to take up this particle [279]. Due to 
this supporting evidence, investigators have suggested that retention of LDL may be the 
contributing factor in the initiation of atherosclerosis. 
1.6.2.3 Oxidative Modification of Atherosclerosis 
The most well-known theory of atherogenesis is the oxidative modification of LDL, shown in 
Figure 1.4. The theory originally proposed by Steinberg et al, stated that native and 
unmodified LDL does not elicit any atherogenic effects, but oxidative modification results in 
pro-atherogenic events  [280]. In this theory, oxidation of LDL can lead to several responses 
involved in the initiation of atherosclerosis. These effects include the recruitment of 
circulating monocytes, decreased macrophage efflux from the site of lesion formation, and 
the subsequent recognition and uncontrolled uptake of LDL by macrophages [281]. 
Together, the effects contribute to the formation of foam cells. 
The oxidative modification theory is based on evidence indicating that normal and 
unmodified LDL do not provide any atherogenic effects [280]. Moreover, Goldstein et al 
determined that production of LDL modified through acetylation allowed for the 
recognition of LDL by scavenger receptors expressed by macrophages [282]. Acetylation of 
LDL resulted in a loss of endothelial cell integrity, which correlated with ‘the response to 
injury hypothesis’, allowing the progression of an early and simple lesion to a more 
advanced and complex lesion [280]. Although this finding was a major development in 
atherosclerosis research, it was also determined that the acetylation of LDL is unlikely to 
occur in vivo. However, Brown and Goldstein postulated that oxidative modification could 
mimic the effects of acetylation of LDL [283]. Henriksen et al showed that oxidative 
modification of LDL occurs on incubation of this particle with endothelial cells [284]. In this 
case, the oxidation was attributed to the release of Fe2+ and Cu2+ ions by endothelial cells 
[284]. Since this work, many studies have examined the potential mechanisms and 
products formed on LDL, which may be responsible for inducing uptake by macrophages, 
and endothelial dysfunction, which will be discussed in more detail below. 
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Figure 1.4 – The process of the oxidative modification of low-density lipoprotein (LDL) and 
it’s pro-atherogenic effects [259]. Native LDL is initially retained in the intima within walls 
of large arteries. Accumulation of native LDL allows for their oxidation, which transforms 
LDL into a pro-atherogenic form. There are several pro-atherogenic effects observed when 
native LDL is transformed to oxidised LDL, including:  (A) the enhancement of chemotactic 
signals that increases the recruitment of macrophages within sites of lesions, (B) the 
prevention of resident macrophages to leave the site of lesions, (C) the transformation of 
macrophages into foam cells and (D) the induction of endothelial cell dysfunction, which 
results in the decreased integrity of the vasculature. (Extracted from Stocker & Keaney, 
2004, Role of Oxidative Modifications in Atherosclerosis, Physiol. Rev. 84, 1381-1478) 
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1.6.2.3a Uptake, Intracellular LDL Metabolism and Foam Cell 
Formation 
Within the vessel wall, macrophages recognise and scavenge cholesterol and triglycerides 
from modified lipoproteins. Under normal physiological conditions, LDL is taken up by cells 
after recognition by the LDL receptor [285]. However, in the case of modified LDL, there is a 
lack of recognition by the LDL receptor. Rather, modified LDL is recognised by specialised 
structures, called scavenger receptors that are expressed on the surface of cells, including 
macrophages that allow the recognition and removal of foreign particles. Scavenger 
receptors identified in macrophages include; scavenger receptor A (SRA), CD36, and SRBI 
[286]. Under normal physiological conditions, macrophages have a protective mechanism 
that prevents the accumulation of free cholesterol, which involve sequestration of 
cholesterol through esterification; control of lipoprotein uptake; and cholesterol efflux 
from the cell [287]. Macrophages possess several lysosomal enzymes that are important for 
the metabolism and breakdown of foreign (non-self) particles (Figure 1.5) [288, 289]. These 
enzymes include a family of proteases, called cathepsins, that contribute to the hydrolysis 
of apoB100 [288, 290]. Moreover, lipases are also present within the lysosomes, which play 
a role in the breakdown of cholesterol and cholesteryl esters present within LDL [291, 292]. 
However, in the case of foam cell development, these tightly controlled protective 
mechanisms may be disrupted. Specifically, modifications to lipoprotein structure can 
result in an unregulated cellular uptake of lipids, causing an uncontrolled accumulation of 
lipids within cytoplasmic droplets that appear foamy in appearance when viewed under the 
microscope. Hence, these lipid-laden macrophages are often referred to as foam cells [293, 
294]. In the case of acetylated LDL accumulation induced by SRA recognition, cholesteryl 
esters accumulate within the cytoplasm, which suggests that lysosomal hydrolysis is 
functioning normally [283]. However, the accumulation of Cu2+-oxidised LDL results in the 
accumulation of lipid droplets within the lysosomal compartment, which suggests the 
impaired degradation of these particles by lysosomal hydrolysis [284]. 
Foam cells can also contribute to the amplification of local inflammatory processes, via the 
secretion of inflammatory mediators and MMP [295-297]. MMP is a family of proteinases 
that degrade the extracellular matrix within the intima. This degradation may result in 
alteration and remodelling of the artery wall, and a thinning and weakening of the fibrous 
plaque, which makes it prone to thrombosis [219]. Foam cells release a number of potent 
pro-inflammatory cytokines, including interferon-γ (IFN-γ). IFN-γ inhibits the synthesis of 
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collagen, which is crucial in providing tensile strength to the developing fibrous cap [219, 
298]. The combined effect of MMPs and IFN-γ may contribute to the subsequent thinning 
of the fibrous cap, rupture and thrombosis [219]. Foam cells can also promote the release 
of reactive oxygen species (ROS) within atherosclerotic lesions, which may further 
propagate cellular damage and oxidative stress [219]. 
 
 
Figure 1.5 – Schematic diagram showing the turnover of native LDL (A) vs modified LDL 
(B). (A) Native LDL is recognised by the LDL receptor, which is endocytosed into an 
endosome together with the LDL receptor. Lysosomes containing enzymes are mobilised 
and fused with the endosome to hydrolyse internalised LDL. The resulting amino acids and 
cholesterol fatty acids are released into the cytoplasm for metabolism. (B) Modified LDL is 
recognised by the scavenger receptor, which is endocytosed into an endosome together 
with the scavenger receptor. Lysosomes containing enzymes are mobilised and fused with 
the endosome to hydrolyse internalised modified LDL. Lysosomes are inactivated with the 
presence of modified LDL, which prevents the hydrolysis of LDL. Lysosomes containing 
modified LDL accumulate within the cytoplasm, resulting in the formation of foam cells.  
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1.6.3 Role of MPO in LDL Modification 
Given the potential importance of MPO in atherosclerosis, the ability of MPO-derived 
oxidants to modify LDL and the consequences of these reactions have been extensively 
studied. Almost all studies involving LDL and MPO-derived oxidants have focused on the 
reactivity of HOCl, which is the major MPO oxidant formed under physiological conditions 
[299]. The oxidation of LDL has been typically investigated after exposure to relatively large 
molar excesses of HOCl (typically 100 – 1000 fold; reviewed in [217]). 
1.6.3.1 Low-density Lipoprotein and HOCl 
1.6.3.1a ApoB100 Modification 
The oxidation of LDL by HOCl has been demonstrated using both reagent HOCl and a 
system containing MPO/H2O2/Cl
-, which yield a similar extent of oxidation of parent 
residues and the formation of oxidation products [300, 301]. Several studies have shown 
that treatment of LDL with increasing concentrations of HOCl, resulted in the rapid loss of 
certain side chains from amino acids in the apoB100 molecule, in a dose-dependent 
manner, with Cys, Trp, Met and Lys residues shown to be important targets [302]. It was 
observed that Met and Cys residues were more rapidly oxidised compared to the Trp 
residues, with Lys modification also detected at higher oxidant concentrations (> 100 fold). 
Oxidation of both Met and Cys residues occurred before the oxidation of other residues 
[299]. It was shown that Lys, Trp, and Cys modification accounted for ca. 78% of the HOCl 
added, while < 1 % and 1.2 % of HOCl consumed was attributed to the loss of lipids and 
antioxidants, respectively, after treatment with a 300-fold molar excess of HOCl [102, 302]. 
Loss of both Lys and His resulted in the generation of chloramines after HOCl mediated 
oxidation of these side chains [52, 53, 302, 303]. 
Evidence has also been obtained for the reaction of HOCl with apoB100 Tyr residues, 
resulting in the formation of 3-chloro Tyr. In experiments with 100-fold molar excess HOCl, 
0.05% of parent Tyr residues were converted to 3-chloro Tyr, a product that has been 
shown to be important marker of HOCl-induced damage within atherosclerotic lesions [50]. 
However, the results obtained in this study were inconsistent with other studies, only 
showing the same extent of Tyr oxidation at 200-fold molar excess HOCl. This variation may 
arise from the generation of chloramines, which can induce secondary reactions that 
modify specific residues within apoB100 [81, 303]. 
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Studies have also been carried out using agarose and SDS-PAGE gels to investigate the 
modification of apoB100 within the LDL particle, in terms of both the particle charge and its 
subsequent fragmentation and aggregation after exposure to HOCl [302, 304]. Agarose gel 
studies have demonstrated that there is an enhanced dose-dependent mobility of the LDL 
after exposure of the native LDL to varying concentrations of the oxidant [302, 305, 306]. 
This change in mobility is consistent with the significant loss of positively charged residues 
of apoB100, consistent with the loss of His, Lys and Arg residues [302, 305, 306]. Likewise, 
SDS-PAGE studies demonstrated the formation of high-molecular mass aggregates from 
LDL after exposure to HOCl [304]. These aggregates were shown to be resistant to 
reduction by dithiothreitol (or β-mercaptoethanol), which eliminates disulfide formation as 
a source of these crosslinks [304]. The formation of di-Tyr was also detected within the 
aggregates. However, the presence of this product was not sufficient to account for all the 
crosslink formation [304]. In this case, tyrosyl radical-mediated aggregation is an inefficient 
reaction [307]. 
An alternative pathway proposed to account for HOCl-mediated aggregation is the 
generation and reaction of carbonyl groups resulting from the decomposition of Lys-
derived chloramines [300]. Decomposition of chloramines through the hydrolysis of an 
intermediate imine results in the formation of aldehydes and the release of ammonia 
[308]. The reactive aldehydes formed can react with an ε-amino group, present in the same 
apoB100 structure or a different apoB100 protein, resulting in the formation of Schiff base 
products. The Schiff base product can be further hydrolysed or reduced to form secondary 
amine, which results in the formation of inter- or intra-molecular crosslinks [309]. Blocking 
the oxidation of Lys through the methylation of these residues inhibited the formation of 
crosslinks, which supports the suggestion that Lys-derived chloramines may be crucial in 
the formation of LDL aggregates [300]. 
 
1.6.3.1b Lipid Modification 
HOCl has also been shown to oxidise the lipid moieties of LDL, resulting in the formation of 
primary and secondary lipid peroxidation products when high molar excesses (> 100-fold) 
of oxidant are added [111]. Reaction of HOCl with the phospholipids present within the LDL 
molecule, results in the accumulation of conjugated dienes, hydroperoxides, and 
thiobarbituic acid-reactive substances [111]. However, the mechanism behind the 
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formation of these products is controversial, with evidence for both non-radical reactions 
observed upon interaction of HOCl with fatty acid side chains containing alkenic double 
bonds together with a radical-mediated mechanism [217]. Thus, lipid peroxidation is 
reported to occur as a secondary event arising from the decomposition of chloramines-
derived from Lys residues by both thermal and transition metal ion-catalysed processes to 
give nitrogen-centred radicals, that can mediate secondary damage to lipids within LDL 
[102]. Cholesterol has also been observed to be an important target for HOCl-mediated 
oxidation. In-vitro studies showed that exposure of cholesterol located within the 
phospholipid bilayer to HOCl, yields several lipid oxidation products including 5,6-epoxides, 
4-hydroxycholesterol, hydroxyl- and keto-derivatives [107].  
Aside from the apparent formation of lipid peroxidation products, the formation of 
chlorohydrins was also observed when lipids were exposed to HOCl, which includes LDL-
derived fatty acids [301, 310]. Chlorohydrins are formed when HOCl was exposed to 
phosphatidylcholine, with evidence that this oxidant targets the oleic, linoleic and 
arachidonic acids present within the lipid moiety [310]. These data are consistent with a 
study performed by Jerlich et al., in which exposure of LDL phospholipids to HOCl or the 
enzymatic MPO system resulted in the formation of chlorohydrins. In this case, lipid 
peroxidation was not observed, which may be attributed to the lower concentrations (at 
μM amounts, < 100-fold excess) of the HOCl or the enzymatic MPO system used [301]. 
Studies by Hazen et al also showed the formation of chlorinated cholesterol after 
treatment of LDL with the MPO/H2O2/Cl
- system [311]. 
 
1.6.3.1c Consequences of HOCl Modification 
With extensive evidence showing oxidative modification of LDL after treatment with HOCl, 
cell studies have been carried out to examine whether these oxidative modifications could 
promote and enhance lipid accumulation within macrophages. It was shown that exposure 
of LDL to a 400-fold molar excess of HOCl resulted in the uncontrolled uptake of cholesterol 
and cholesteryl esters within peritoneal macrophages [302]. This effect was observed after 
4 hours of incubation of the cells in balanced salt solution with HOCl-oxidised LDL [302]. 
Foam cell formation was also demonstrated with varying incubation times on exposure of 
human THP-1, murine macrophage-like P388D1, and mouse peritoneal macrophage cells to 
HOCl-modified LDL [312-314]. However, in this case, decreasing the molar excess (from 400 
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to 100:1) of the oxidant to LDL resulted in a lower extent of lipid accumulation observed 
within macrophage cells [302]. Interestingly, pre-treatment of HOCl-LDL with methionine 
before incubation with macrophage cells attenuated foam cell formation, as shown by 
decreased levels of cholesterol and cholesteryl ester accumulation within the cells [302]. 
This suggests that chloramine formation may play a critical role in the uptake and 
uncontrolled accumulation of lipid within macrophage cells, as methionine rapidly 
quenches these reactive species [302]. 
Studies to examine the recognition and mechanism of HOCl-oxidised LDL uptake by 
scavenger receptors have been performed with THP-1 cells [313]. HOCl-oxidised LDL did 
not attenuate or compete with the recognition of acetylated LDL by the cells, which is a 
specific ligand for the SR-A receptor [313]. However, the presence of HOCl-oxidised LDL did 
compete with the uptake of Cu2+-oxidised LDL, which is a specific ligand for the CD36/SRBI 
receptor [313]. This mechanism was further explored using Chinese hamster ovary cells 
that over express either CD36 or SRBI, and specific blocking antibodies [313]. It was shown 
that decreasing the molar ratio of the oxidant to LDL results in the recognition of the 
modified LDL by both SR-A and CD36/SRBI receptors expressed in Chinese hamster ovary 
cells, which suggests that the recognition of oxidised LDL is not related to the extent of lipid 
peroxidation in this case [315]. 
Exposure of macrophages to HOCl-modified LDL resulted in the onset of apoptosis and cell 
death. Previous studies have shown that exposure of THP-1 [316] and U937 macrophages 
to HOCl-modified LDL [317] induced cellular toxicity by a caspase-dependent pathway [316, 
317]. In this case, LDL was modified by HOCl for 30 min at high molar excess (2000-fold), 
resulting in an extensively modified LDL that induced significant toxicity to cells. HOCl-
modified LDL also appears to have the capacity to enhance inflammation by mediating the 
secretion of proinflammatory molecules. In particular, it has been demonstrated that 
incubation of HOCl-modified LDL with murine macrophage cells results in the expression of 
peroxisome proliferator-activated receptor-γ (PPAR-γ) [318]. PPAR-γ is a critical signalling 
molecule that contributes to inflammation, cell proliferation, and differentiation, 
particularly with monocyte/macrophages [319, 320]. HOCl-modified LDL also increases the 
secretion of TNF-α, another key pro-inflammatory mediator [321]. More importantly, TNF-
α secretion has been associated with the expression of cell adhesion molecules (VCAM-1) 
within endothelial cells, which exacerbates the inflammatory processes behind the 
development of atherosclerosis [322]. 
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HOCl-modified LDL also interacts with endothelial cells, and endothelial cell dysfunction is 
an important process that contributes to the development of atherosclerosis [323]. 
Endothelial cells express scavenger receptors that can interact with HOCl-modified LDL, 
including CD36 and SR-B1 [313, 324]. Although internalisation of HOCl-modified LDL occurs 
in endothelial cells, this process does not appear to lead to the uncontrolled accumulation 
of lipids within these cells [313]. Moreover, HOCl-modified LDL mediates secretion of pro-
inflammatory molecules in endothelial cells [321]. In this case, the exposure of HOCl-
modified LDL to EAhy926 endothelial cells for 48 h resulted in the secretion of IL-8 in a 
time- and dose-dependent manner [321]. IL-8 serves as a chemoattractant that recruits 
inflammatory cells to the site of secretion [325], can also activate 
monocytes/macrophages, and can contribute to the secretion of TNF-α by these cells [325]. 
1.6.3.2 Low-density Lipoprotein and SCN- derived Oxidants 
There is some evidence for a correlation between SCN- levels, for example in the plasma of 
smokers, with specific markers of atherosclerosis. Studies have shown that smokers who 
exhibit elevated plasma SCN- have higher lesion area compared to non-smokers with low 
plasma SCN- [326, 327]. Furthermore, foam cell numbers in lesions were also demonstrated 
to be higher in smokers, which contributes to the notion that SCN- and the oxidants 
produced from this substrate may contribute to the pathogenesis of atherosclerosis [326].    
The formation of SCN- derived oxidants by MPO has been recently linked to the 
carbamylation of LDL, which may occur via the formation of OCN- from the enzymatic 
MPO/H2O2/SCN
- system, and is also believed to play a role in the development of 
atherosclerosis [24]. Thus, patients with renal dysfunction have an elevated risk of 
developing cardiovascular disease, which is thought to be associated with the 
carbamylation of lipoproteins, as in uremic patients urea exists  in equilibrium with OCN- 
[328, 329]. Furthermore, LDL isolated from uremic patients has elevated homocitrulline 
(HCit), showing significant carbamylation of Lys residues [330-332]. In this case, 
carbamylation is not a reaction specifically mediated by the enzymatic MPO/H2O2/SCN
- 
system. 
As previously mentioned, the MPO/H2O2/SCN
- system was postulated to contribute to the 
production of OCN- [24]. Recent studies, using the enzymatic MPO/H2O2/SCN
- system, were 
conducted to investigate the capacity of this system to carbamylate apoB100 [24] and 
induce pro-atherogenic effects, including LDL receptor inhibition, scavenger receptor 
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recognition, and cholesterol accumulation in macrophages [24]. In this study, Lys 
modification was demonstrated through the detection of HCit in apoB100. The levels of 
HCit detected after exposure to the enzymatic MPO/H2O2/SCN
- system were comparable to 
that found in uremic LDL (<800 µmol per mol of Lys) [24]. Furthermore, studies looking at 
the inhibition of LDL receptor recognition showed that carbamylation of LDL by both the 
MPO/H2O2/SCN
- system and OCN- reagent can alter the recognition site and render the 
modified LDL unrecognisable by the LDL receptor [24]. Thus, this allows carbamylated LDL 
to accumulate within the circulation and the artery walls [24]. 
Binding studies with mouse peritoneal macrophage cells were carried out to examine the 
ability of carbamylation to induce foam cell formation. It was demonstrated that incubation 
with carbamylated LDL (induced by both reagent KOCN and MPO/H2O2/SCN
- system) 
resulted in increased binding and uptake of the modified particle by peritoneal macrophage 
cells, which were deficient in the CD36 receptor. This suggests that macrophage cells bind 
to carbamylated LDL through the SR-AI receptor. This was supported by studies with 
fucoidin, an SR-AI inhibitor, which resulted in the attenuation of the binding and uptake of 
LDL within peritoneal macrophage cells [24]. 
However, it is important to note that the carbamylation reaction induced by OCN- only 
accounts for only 10% of the SCN- consumed by MPO/H2O2. There are a lack of studies 
performed to examine the reactivity and the consequences of the interaction of HOSCN 
with LDL. Thus, further work is necessary to investigate the effects of HOSCN on LDL, given 
that this oxidant is formed by MPO under physiological conditions in significant amounts 
[82]. 
1.6.4 Other Pathways of LDL Modification 
1.6.4.1 Transition Metal Ions 
LDL modification by transition metal ions represents an important pathway that has 
contributed extensively to our understanding of the oxidative events involving LDL and the 
progression of atherosclerosis [333-337]. Early studies reported that modification can occur 
when LDL is incubated with smooth muscle cells in the presence of transition metal ions 
[335]. The use of transition ion metal chelators led to the inhibition of these modifications 
[336, 337], and the absence of cells did not attenuate or eliminate modifications mediated 
35 
 
by the presence of transition metal ions [335, 337]. Additionally, protein-bound metal ions 
in ceruloplasmin and hemin were also shown to contribute to LDL modification [333, 334]. 
Although a significant literature exists relating to LDL oxidised by either copper (Cu2+) or 
iron (Fe2+) oxidised LDL, the relevance of these reactions in vivo is still unclear. In particular, 
there is no convincing evidence supporting the detection of transition metal ions within the 
healthy human plasma (reviewed in [338]). Moreover, albumin, a major protein present in 
plasma, has been shown to inhibit LDL oxidation mediated by transition metal ions [339]. 
Clinical studies showed that there were inconsistent correlations between elevated iron 
stores and the incidence of developing atherosclerosis [340-343]. Furthermore, 
hemochromatosis and Wilson’s disease, characterised by elevated levels of both iron and 
copper in plasma, respectively, did not contribute to the development and progression of 
atherosclerosis [344-346]. 
Cu2+-modified LDL has been linked to several pro-atherogenic effects, all of which are 
similar to that found with HOCl-modified LDL (reviewed in [325]). Initially, it was 
demonstrated that Cu2+-modified LDL is recognised and taken up by macrophages, resulting 
in an uncontrolled accumulation of lipids within macrophage cells [347]. Similar to HOCl-
modified LDL, Cu2+-modified LDL is recognised by CD36 and SR-B1 that are overexpressed in 
the presence of modified LDL [348]. The uncontrolled accumulation of modified LDL was 
postulated to be associated with the inhibition of lysosomal enzymes that are responsible 
for the hydrolysis of LDL within cells. In this case, it was shown that exposure of lysosomal 
enzymes to Cu2+-modified LDL can inhibit their function [70].  
Apoptosis is another cellular consequence observed on exposure of macrophages [349, 
350] and endothelial cells [351] to Cu2+-modified LDL. Unlike HOCl-modified LDL, the 
induction of apoptosis mediated by Cu2+-modified LDL stems from caspase-dependent 
processes [350-352]. It was demonstrated that both an extrinsic, involving the activation of 
death receptors and downstream activation of caspase 8/3, and an intrinsic pathway, 
involving the activation of Bcl-2, cytochrome c and caspase-3, are involved in the apoptotic 
process induced by Cu2+-modified LDL [350-352]. In contrast, HOCl-modified LDL-induced 
apoptosis stems from the translocation of Bax protein from the cytoplasm to the 
mitochondria, which leads to the release of cytochrome c and the downstream activation 
of caspase enzymes [353]. 
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Cu2+-modified LDL also contributes to the synthesis and release of pro-inflammatory 
molecules (e.g. [319, 320, 354]). It has been demonstrated that Cu2+-modified LDL can lead 
to the transformation of monocytes to macrophages through the overexpression of PPAR-γ 
[319, 320], similar to HOCl-modified LDL. As previously mentioned, expression of PPAR-γ 
contributes to inflammation, cell proliferation and differentiation, which can collectively 
exacerbate the development of atherosclerosis [319, 320]. Cu2+-modified LDL can also 
induce the expression of IL-8 and TNF-α [354]. Additionally, Cu2+-modified LDL can induce 
the expression of other pro-inflammatory factors in macrophages, endothelial cells and 
smooth muscle cells, including activator protein 1 (AP1) [355, 356], nuclear factor-κ B  (NF-
κB) [357, 358], nuclear factor of activated T-cells (NFAT) [359, 360] and hypoxia-inducible 
factor-1 (HIF1) [361]. 
1.6.4.2 Thiols 
The role of thiols in LDL modification was initially observed after the exposure of LDL to 
smooth muscle cells that were supplemented with L-cystine [362]. In this case, the 
autoxidation of thiols is believed to contribute to the formation of reactive oxygen species, 
including superoxide (O2
.-), which contributes to LDL modification [363, 364]. This pathway 
was not observed on exposure of LDL to smooth muscle cells that were cultured in the 
absence of L-cystine [362]. Furthermore, LDL oxidation induced by thiol exposure was also 
observed in the absence of smooth muscle cells [363, 364]. This effect is associated with 
the autooxidation of thiols in the presence of metal ions, which results in the generation of 
superoxide [363, 364]. The proposal that autoxidation of thiols represent a pathway of 
modification was further supported by the treatment of LDL with thiols prone to 
autoxidation. Furthermore, macrophages and endothelial cells were shown to generate 
extracellular thiols that may contribute to LDL oxidation [365].  
In vivo studies contribute to the notion that thiols play a role in LDL modification. 
Homocystinuria is a disorder that is characterised by elevated plasma and urine levels of 
homocysteine [366]. There are positive correlations between the onset of premature 
atherosclerosis, thrombosis, and endothelial damage in homocystinuria patients [366]. 
Furthermore, animal studies using primates showed that homocysteine supplementation 
led to vascular damage [367]. Thus, these studies may implicate the onset of LDL 
modification, which can elicit pro-atherogenic effects. However, in this case, no evidence 
for lipid peroxidation was detected and thus the contribution of homocysteine to the 
development of atherosclerosis may be independent of LDL oxidation [366, 368, 369]. 
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1.6.4.3 Superoxide (O2
.-) 
O2
.- is a well characterised oxidant generated after a one-electron reduction of molecular 
oxygen. The ability of O2
.- to mediate LDL modification was observed after incubation of LDL 
with cells cultured in transition metal ion containing media [370]. Supplementation of 
media with superoxide dismutase (SOD) modulated this pathway, contributing to the 
notion that O2
.-  plays a role in LDL modification [362, 370-372]. Furthermore, there is 
correlation between levels of O2
.- generated by the system and the rate of cell mediated 
oxidation of LDL [362, 370-372]. 
Although most of these studies suggest a role of O2
.-, there are several problems and 
inconsistencies that were apparent in these studies. For example, the action of SOD in 
inhibiting modification may also be reflected by its ability to bind transition metal ions [339, 
373]. This characteristic allows for the elimination of transition metal ions that also 
contribute to LDL modification. Furthermore, stimulated macrophages that raise 
extracellular levels of O2
.- showed inconsistencies in several studies with LDL modification 
[371-373]. Thus the role of O2
.- in mediating LDL modification is still unclear.  
1.6.4.4 Lipoxygenase 
Lipoxygenase is a cytosolic enzyme that is present in several cells that are actively involved 
in the development of atherosclerosis, including macrophages, endothelial cells and 
smooth muscle cells [374]. Studies in vitro have shown that lipoxygenases can directly 
target LDL phospholipids, resulting in the modification of fatty acid chains [374-376]. This 
effect was shown to be mediated by both 15-lipoxygenase and 12-lipoxygenase [374-376]. 
Furthermore, 12-lipoxygenase was shown to contribute to cholesterol accumulation in 
macrophage cells, and may therefore have a proatherogenic role [377]. Studies using 
lipoxygenase inhibitors have contributed to the notion that lipoxygenase mediates 
modification of LDL [378, 379]. However, there was no positive correlation between levels 
of lipoxygenase and the extent of LDL modification [380]. 
Although the action of lipoxygenase is still currently under debate, the detection of 
lipoxygenase products in the cell membranes of monocytes has led to the belief that there 
is transfer of the oxidised fatty acids from cell membrane phospholipids to LDL [378, 381]. 
In vivo evidence supports the contribution of lipoxygenase in the development of 
atherosclerosis. In particular, both protein and mRNA of lipoxygenase have been detected 
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in lesions [382]. Furthermore, epitopes that match the fingerprint of oxidation 
characterised by modification of LDL by lipoxygenase are found in lesions, which supports 
an in vivo role in LDL oxidation [382]. 
1.6.4.5 Glucose 
Diabetes mellitus is characterised by elevated levels of glucose in plasma. It was previously 
suggested that glucose exposure can enhance modification of LDL mediated by transition 
metal ions, yielding advanced glycation end (AGE) products [383, 384]. Elevated levels of 
AGE and conjugated dienes were also detected within LDL isolated from people with non-
insulin dependent diabetes [385]. A recent study showed that direct reactions of glucose 
did not transform LDL into a high uptake form and hence may not contribute to the 
formation of foam cells, but glycation reactions of reactive aldehydes such as 
glycoaldehyde or methylglyoxal can contribute to foam cell formation after reaction with 
LDL [386]. It is important to note, however, that the reactions mediated by glucose are 
slow, which indicate that these processes may still be relevant in the long-term 
accumulation of damage arising from exposure to chronic high glucose levels [386]. Lipid 
peroxidation in plasma was elevated in mice supplemented with streptozotocin, a drug that 
induces the destruction of insulin-producing beta cells in the pancreas, a model of Type I 
diabetes [387, 388]. Isolated LDL from these mice also showed cytotoxic properties [389, 
390]. Supplementation with lipid soluble antioxidants reversed of these effects [389, 390].  
1.6.4.6 Nitric Oxide/Peroxynitrous acid 
The role of nitric oxide (NO) in LDL modification has been attributed to its ability to 
generate peroxynitrite on reaction with O2
.- [391]. NO is synthesised by endothelial cells by 
the release of a group of enzymes called nitric oxide synthase (NOS). NO is converted to 
peroxynitrous acid after reaction with O2
.-. Peroxynitrous acid is a strong oxidant that is 
capable of modifying LDL in vitro, resulting in lipid peroxidation [392-394]. Peroxynitrous 
acid was also reported to contribute to the formation of nitrated tyrosyl residues (3-nitro-
tyrosine; 3-nitro-Tyr) within the apoB100 component of LDL [395]. 3-nitro-Tyr has been 
detected in atherosclerotic lesions, which implicates a possible role of peroxynitrous acid in 
LDL modification [396, 397], though this modification can also be induced by MPO [398]. 
Furthermore, peroxynitrous acid was also shown to deplete lipid-soluble antioxidants [399, 
400] and contribute to foam cell formation by the elevated recognition and uptake of 
peroxynitrous acid-modified LDL [398]. 
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Other studies have shown that NO plays a crucial role in inhibiting lipid peroxidation [401, 
402]. Similar results were obtained when NO production was stimulated during cell-
mediated oxidation of LDL [401, 402]. Suppression of LDL modification by NO was 
attributed to its role in reacting and inhibiting important enzymes and proteins, responsible 
for the modification of LDL including heme-containing proteins, enzymes, O2  
 -, lipid radicals, 
and cellular enzymes [403]. The ability of NO   to suppress development of atherosclerosis 
was also demonstrated in hypercholesterolemic rabbits, with elevated levels of NO   resul ng 
in inhibited fatty streak formation [404]. 
1.6.5 Proatherogenic Effects of Oxidised LDL 
Oxidative modification of LDL can occur to various extents, depending on the system of 
interest [259]. Minimally oxidised LDL is associated with the oxidation of only the lipid 
component of LDL, including cholesterol and phospholipids. In contrast, extensive 
modification of LDL is usually attributed to both lipid and protein oxidation, which is 
generally referred to as oxidised LDL. The extent of LDL modification can outline its role 
within atherosclerosis. For example,  minimally oxidised LDL can initiate the expression of 
monocyte chemoattractant protein-1 (MCP-1) by both smooth muscle cells and endothelial 
cells [405]. This particular chemokine initiates the migration and maturation of circulating 
monocytes within the intima into macrophages, which is a crucial step in the development 
of atherosclerosis [406, 407]. This potentiated effect of minimally oxidised LDL is mainly 
attributed to the oxidised lipid fraction contained in the molecule [408]. 
Similarly, more extensively oxidised LDL has been shown to initiate a profound effect on 
the progression of atherosclerosis [408]. It was observed that oxidised LDL reinforces the 
recruitment of both monocytes and leukocytes, through the expression of cell adhesion 
molecules present within endothelial cells [409, 410], which may involve generation of 
lysophosphatidylcholine [337]. Furthermore, enhancement of macrophage recruitment 
[281] and impaired egress out of the lesion site is also mediated by oxidised LDL [219]. In 
addition, the inhibition of NO produced by endothelial cells is also observed in the presence 
of oxidised LDL [411]. This enhances the migration of both macrophages and T lymphocytes 
to infiltrate the artery wall, which increases the inflammatory response associated with the 
disease [412]. 
In support of these effects observed with the oxidative modification of LDL, several studies 
looking at the gene expression pattern within the arterial wall elevated expression of genes 
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associated with inflammation on exposure to oxidised LDL [259]. These inflammatory 
processes include the initiation of MCP-1, serum amyloid A, ceruloplasmin, and heme 
oxygenase-1 [413]. Moreover, an additional proatherogenic effect observed from oxidised 
LDL was also shown with the expression of the PPAR-γ. The induction of this particular 
process can affect the expression of the scavenger receptor CD36, and can also induce 
several inflammatory genes [414]. Thus, outlining the importance of oxidised LDL in the 
initiation and progression of atherosclerosis.  
 
Table 1.1 – The different types of modified LDL and their pro-atherogenic effects 
Types of 
Modified LDL 
ApoB100 
Modification 
Lipid 
Modification 
Proatherogenic Effects 
Hypochlorous 
acid (HOCl) 
Charge 
modification and 
formation of 
aggregates [300] 
Chloramine 
formation [102], 
side chain 
modification [102, 
300, 302, 415, 416] 
Chlorohydrin 
formation [301, 
310] and lipid 
peroxidation 
[102] 
Foam cell formation [302], 
expression of scavenger receptors 
(CD36, SR-B1) [313, 324], cellular 
apoptosis (macrophage) [317], 
release of pro-inflammatory 
cytokines (TNF-α, IL-8) [321, 325], 
lysosomal enzyme inactivation 
(cathepsin B) [67] 
SCN-derived 
Oxidants 
Carbamylation [24] Lipid peroxidation 
[82] 
Foam cell formation and impaired 
LDL receptor recognition [24] 
Transition 
Metal Ion (Cu 
and Fe) 
Charge 
modification 
Amino acid side 
chain modification 
[335-337] 
Lipid peroxidation 
[335-337] 
Foam cell formation [347], 
expression of scavenger receptors 
(CD36, SR-B1) [348], cellular 
apoptosis (macrophage, 
endothelial cells) [350-352], 
release of pro-inflammatory 
cytokines (PPAR-γ, TNF-α, IL-8, 
AIF-1, NF-κB, HIF1) [319, 320, 
354], lysosomal enzyme 
inactivation (cathepsin B) [70] 
Thiol Charge 
modification [363, 
364] 
Lipid peroxidation 
[363, 364]  
Vascular damage [367] 
Superoxide N/A Lipid peroxidation 
[362, 370-372] 
Foam cell formation [362, 370-
372] 
Lipoxygenase N/A Lipid peroxidation 
[374-376] 
Foam cell formation [377] 
Glucose Glycation [383, 
384] 
Lipid peroxidation 
[385] 
Foam cell formation [386], 
cytotoxicity [387, 388] 
Peroxynitrous 
Acid 
Nitration [395] Lipid peroxidation 
[392-394] 
Foam cell formation [398], 
deplete lipid-soluble antioxidants 
[399, 400] 
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1.6.5.1 Cellular Dysfunction 
The role of macrophage apoptosis in atherosclerosis has been investigated extensively 
[417]. Apoptosis is a programmed cell death that cells undergo after being rendered 
dysfunctional [417]. Macrophage apoptosis was shown to be induced by the accumulation 
of free cholesterol within cells, due to impaired metabolism by ACAT (acyl-coenzyme A: 
Cholesterol Acetyl Transferase). ACAT is an enzyme that plays a role in the conversion of 
free cholesterol to cholesteryl esters [417]. The induction of apoptosis within 
atherosclerosis is a multi-factorial process that may involve different cell death pathways, 
which depend on the extent of the disease. Moreover, the consequences of macrophage 
apoptosis appear to be markedly different between early lesional development compared 
to advanced stages [417]. 
During the formation of early lesions, macrophage apoptosis may be beneficial, in that the 
lesion becomes less cellular, which may slow the development of atherosclerosis [418]. 
Within advanced lesions, however, the consequences were found to be markedly different 
[419]. Studies showed that macrophage apoptosis occurs at a higher rate during the later 
stages of the disease, and that this enhanced apoptosis leads to the formation of an 
extracellular lipid pool containing lipoprotein-derived lipids and cellular debris, which 
characterise vulnerable plaques [236]. 
These differences between the apoptotic consequences during the early and advanced 
stages of atherosclerosis may be related to how these apoptotic macrophages are cleared. 
During the early stages, the removal of apoptotic cells appear to be efficient, as infiltrating 
phagocytes are present to remove apoptotic cells [419-421]. These phagocytes then 
establish an anti-inflammatory environment, which could contribute to the reduction of 
lesions [420]. Apoptosis in the advanced stages may not as efficient, and hence can result 
in secondary necrosis. Necrosis refers to a cell death mechanism that involves the leakage 
of cellular contents into the extracellular matrix that can invoke further inflammatory 
processes. Enhancement of inflammation in this scenario could contribute to the 
acceleration of atherosclerotic lesion development [422].  
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Figure 1.6 – A model describing the functional consequences of macrophage apoptosis 
during early (left) and advanced stages (right) of atherosclerosis [419] (Extracted from 
Tabas, 2005, Consequence and Therapeutic Implications of Macrophage Apoptosis in 
Atherosclerosis, 2255-2264) 
 
1.7   Prevention of LDL Modification 
1.7.1 Lipid Antioxidants 
There has been a major interest in the efficacy of lipid-soluble antioxidants in the 
prevention of atherosclerosis, given that lipid oxidation products are elevated in LDL 
isolated from human lesions. However, in general, lipid antioxidants, particularly Vitamin E 
(α-tocopherol), have not been proven to be efficacious in either animal or clinical studies in 
the treatment of atherosclerosis [423-426]. It was shown in two large primary prevention 
trials, the ATBC (the Alpha-tocopherol, Beta carotene, Cancer prevention) and the PPP 
(collaborative group of the Primary Prevention Project) groups, that supplementation with 
α-tocopherol (Vitamin E) did not elicit any protective effect on cardiovascular disease, 
including the prevention of myocardial infarction [423, 425]. Additionally, other small 
studies, such as the ASAP (the Antioxidant Supplementation in Atherosclerosis Prevention) 
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and VEAPS (Vitamin E Atherosclerosis Prevention Study), also showed that α-tocopherol did 
not show any protective effect on the progression of disease [424, 426]. The only 
exceptions to this were the CHAOS (Cambridge Heart and Antioxidant Study) and SPACE 
trials. The CHAOS study reported that Vitamin E supplementation results in a significant 
decrease of risk in myocardial infarction. Likewise, the SPACE study has shown that vitamin 
E supplementation to haemodialysis patients correlates with a major decrease in acute 
myocardial infarction (reviewed in [259, 427]). Hence, the contribution of lipid peroxidation 
to any pro-atherogenic effects of LDL remains to be convincingly shown. 
 
1.7.2 Other Potential Agents to Inhibit LDL Oxidation 
Other potential antioxidants, besides Vitamin E, have been examined for their ability to 
exhibit anti-atherogenic effects. In particular, the effects of probucol, carotenoids and 
Vitamin C have been investigated in in vitro and in vivo studies. More recently, there is also 
a growing interest in the ability of flavonoids and other phenolic substances to mediate 
athero-protective properties.  
1.7.2.1 Probucol 
Probucol is a potent antioxidant that has multiple atheroprotective properties [428]. 
Protective effects of probucol have been reported in several animal model studies using 
Watanabe Heritable Hyperlipidemic (WHHL) rabbits and non-human primates [429, 430]. 
However, these findings were questioned owing to the use of doses, which are beyond the 
highest dose allowed for human supplementation [431, 432]. Although there are 
discrepancies between different probucol supplementation studies, one study has shown 
that the supplementation can alleviate restenosis [433]. However, the role of probucol was 
not clearly established, with no correlation observed between probucol supplementation 
of probucol and lowering of cholesterol ester-derived hydroperoxide concentrations [434]. 
Thus, probucol may not contribute to the inhibition of lipid peroxidation that occurs during 
the development of atherosclerosis, but may contribute to reendothelialisation [435]. 
Other potential anti-atherogenic effects mediated by probucol, include the inhibition of 
smooth muscle cell proliferation [436] and the expression of cell adhesion molecules in 
endothelial cells [437]. Furthermore, probucol also induced endothelium-dependent 
vasomotion, which can improve endothelial cell function [438, 439]. In this case, the effect 
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of probucol may be associated with the enhancement of endothelial nitric oxide synthase 
(eNOS), contributing to the synthesis of NO [440]. NO has been shown to regulate 
endothelial cell function and inhibit smooth muscle cell migration, which reflects the effect 
mediated by probucol [441, 442]. However, there is no evidence to link the association of 
probucol and the production of eNOS and NO.   
1.7.2.2 Carotenoids 
The effects of carotenoids have also been investigated by assessing the anti-atherogenic 
properties of β-carotene and lycopene against singlet oxygen and scavenging of other 
oxidants (reviewed in [440]). However, with the presence of other natural and more 
effective antioxidants, studies using carotenoids are scarce and the effects of these 
antioxidant are not clearly elucidated. Furthermore, there are no significant findings 
showing a decreased risk of developing cardiovascular disease, following carotenoid 
supplementation [440]. 
1.7.2.3 Vitamin C 
Vitamin C (ascorbate) is a water soluble antioxidant with postulated anti-atherogenic 
effects. In vitro and in vivo studies have examined the inhibition of LDL lipid peroxidation 
[443, 444], as ascorbate is known to scavenge water soluble radicals that promote lipid 
peroxidation [443, 444]. It has been demonstrated that plasma levels of ascorbate can 
provide crucial information on oxidative stress, particularly in smokers [445]. Furthermore, 
it was shown that low ascorbate levels are predictive of unstable coronary syndrome [446]. 
Ascorbate has been demonstrated to improve endothelial cell function by stabilising 
tetrahydrobiopterin [447, 448]. Tetrahydrobiopterin is a key cofactor in the NOS enzyme 
that contributes to the generation of NO. The oxidation of tetrahydrobiopterin prevents NO 
formation and thus, compromise endothelial cell function [448]. Since ascorbate 
supplementation increases NO formation [447, 448], this antioxidant may play an 
important role in the improvement of endothelial cell function, which may prevent the 
onset of restenosis [449]. 
1.7.2.4 Flavonoids and Phenolic Extracts 
Flavonoids and other phenolic compounds can inhibit damage mediated by the 
alkyl/peroxyl radicals, hydroxyl radicals and peroxynitrite [450, 451]. There is considerable 
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interest in the ability of flavonoids and other polyphenols to prevent the development of 
disease states, including CVD (reviewed in [452, 453]). 
It has been previously reported that polyphenols can protect LDL from oxidation mediated 
by endothelial cells and macrophages in the presence of Cu2+ (e.g. [454-456]).  This 
protective effect is attributed to the ability of polyphenols to scavenge oxidising species 
that are responsible for the modification of LDL [457]. Furthermore, polyphenol 
supplementation of animals and humans increases the resistance of LDL to oxidation after 
supplementation [458-460]. However, these studies were not consistent with other 
reports, which may reflect the type of phenolic substance used [461, 462]. 
Supplementation of polyphenols derived from red wine, quercetin, catechin and green tea 
extracts in apoE-deficient and hypercholesterolemic rabbits resulted in the reduction of 
atherosclerotic lesions by 31 – 52% [463, 464]. 
Epidemiology studies also support the protective effects of polyphenols. An inverse 
correlation with the intake of flavonoids has been reported for the development of 
coronary heart disease (reviewed in [452]) in individuals who are supplemented with 
polyphenol rich beverages, including catechin-rich green tea [465] and red wine [466, 467]. 
1.7.3 MPO Inhibitors 
1.7.3.1 Azide, Cyanide and Aryl Hydroxamic Acids 
With the growing evidence for a role for MPO in generating oxidants that may play a role in 
the oxidative modification of LDL, the use of MPO inhibitors may also be another option in 
preventing oxidative damage to LDL. A number of MPO inhibitors have been assessed for 
their ability to reduce damage to the apoB100 component of LDL [468]. Jerlich et al. 
investigated the effects of multiple MPO inhibitors, including azide, cyanide, aryl 
hydroxamic acids (salicylhydroxamic acid; SHA and benzohydroxamic acid; BHA) and p-
hydroxy benzoic acid hydrazide (pHBAH) [468]. 
Azide and cyanide were able to delay and attenuate damage to LDL, as assessed the loss 
Trp residues present within apoB100, at very low concentrations (20 – 50 μM). In 
particular, the use of azide reduced Trp damage by 32 %, when compared to samples 
treated in the absence of azide [468]. However, although both azide and cyanide can 
attenuate MPO-mediated damage to LDL, these inhibitors were also demonstrated to be 
non-specific, preventing therapeutic use [468]. 
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Aryl hydroxamic acids have been assessed for their ability to attenuate MPO-oxidant 
mediated damage [468]. In particular, SHA and BHA have been shown to be effective and 
specific inhibitors of MPO [469, 470], with SHA more effective than BHA in preventing 
MPO-oxidant mediated damage to LDL [468]. Differences between SHA and BHA were 
attributed to the higher binding affinity of SHA to MPO, compared to BHA [470]. In addition 
of aryl hydroxamic acids, the inhibitory effect of pHBAH was also investigated, and at very 
low concentrations (0.3 – 0.75 μM), pHBAH was shown to attenuate Trp loss within LDL 
[468]. It has been suggested that pHBAH may be oxidised by MPO into a radical product 
that can convert native MPO to its ferrous intermediate and thus inhibit oxidant formation 
[471].  
These studies of MPO inhibitors may provide possible options in reducing the oxidative 
damage mediated by MPO-oxidants. Although the in vitro studies above has provided 
strong evidence for attenuating the damage to LDL mediated by MPO-oxidants, further 
studies are required to assess their effects in vivo [468]. 
1.7.3.2 Nitroxides 
Nitroxides are stable free radicals that have the capacity to protect against inflammatory 
damage in animal models [472]. These nitroxide compounds have low toxicity, which may 
contribute to their important therapeutic applications [472]. Although the mechanism of 
the action of nitroxides is not clear, recent reports have shown that this may arise via the 
inhibition of MPO activity [127, 473, 474]. In particular, HOCl production was inhibited on 
addition of nitroxides to the enzymatic MPO/H2O2/Cl
- system and neutrophils [127]. 
Furthermore, protein nitration mediated by MPO was also inhibited by the addition of 
nitroxide compounds [474]. The mechanism behind the effects mediated by nitroxide 
compounds was attributed to the ability of nitroxides to convert MPO compound I to 
compound II, which promotes the peroxidation cycle instead of halogenations and HOCl 
formation [127, 474]. The effects observed in these studies are particularly important in 
relation to the ability of nitroxide compounds to inhibit LDL modification and thus, 
influencing the development of atherosclerosis. 
1.7.3.3 Acetaminophen 
Acetaminophen (paracetamol) is well known for its ability to relieve pain and the onset of 
fever [475]. However, recent reports have shown that paracetamol is also capable of 
47 
 
inhibiting the enzymatic activity of MPO through interaction with compound I and II [476]. 
It was demonstrated that paracetamol can compete with Cl- and potentially with Br- in its 
interaction with compound I, which inhibits the generation of hypohalous acids  [477, 478]. 
However, the conversion of compound II to native MPO has cast doubts on the inhibitory 
effect mediated by addition of acetaminophen to MPO. In this case, the regeneration 
process of native MPO can stimulate the production of hypohalous acid [476]. It has been 
proposed that the supplementation of acetaminophen at therapeutically relevant 
concentrations can stimulate the production of HOCl [476]. However, Koelsch et al. have 
shown that the addition of acetaminophen at this concentration can still inhibit the 
production of HOCl and HOBr [479]. Thus, this compound may be an effective therapeutic 
treatment for the prevention of atherosclerosis, though its ability to prevent LDL oxidation 
has yet to be assessed. 
1.8 Project Outline 
MPO plays a crucial role in the immune system by the generation of oxidants that combat 
invading pathogens. However, misplaced and excessive generation of these oxidants may 
also contribute to the development of several diseases, particularly CVD. Substantial 
evidence supports a major role for MPO-derived oxidants in the modification of LDL. This 
process may render the LDL particle pro-atherogenic. Moreover, HOSCN is known to be a 
major product of MPO-catalysed reactions [4, 17], yet studies examining its role in 
lipoprotein modification and atherosclerosis are lacking [82, 105]. Smokers, who are at risk 
of developing cardiovascular disease, have elevated plasma levels of SCN-, which is 
predicted to result in greater HOSCN production in vivo [24]. 
1.8.1 Project Hypothesis 
The hypothesis of the present study was that HOCl, HOSCN and its major decomposition 
product OCN- can induce significant modifications of LDL, converting it from a non-
atherogenic to a pro-atherogenic biomolecule. Furthermore, this modified LDL was also 
postulated to enhance and exhibit several pro-atherogenic properties when exposed to 
macrophage cells, including enhanced formation of foam cells, induction of cellular 
apoptosis, and inactivation of proteases involved in cellular metabolism. 
1.8.2 Project Aims 
The aims of the present study were the following: 
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 To characterise and compare the LDL modification mediated by HOCl, HOSCN and 
OCN- at a range of relevant concentrations 
 To examine whether HOCl, HOSCN and OCN- modified LDL induce cellular 
dysfunction with uncontrolled uptake of LDL and induction of cellular apoptosis. 
 To determine whether LDL modified by HOCl, HOSCN and OCN- can perturb the 
activity of lysosomal enzymes responsible for cellular processing of LDL. 
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Chapter 2: Materials and Methods 
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2.1 General Information 
In this chapter, the details of materials and general methods used throughout the thesis 
are described in detail. Additional information regarding alterations in the experiments are 
indicated in the Figure Legends of the relevant sections. Indicated concentrations for 
reagents and solutions within the methodology are the resulting final concentrations for 
the relevant experiments, unless stated otherwise. The concentrations of LDL quoted are 
based on the concentrations of apoB100  in each case. 
2.2 Materials 
All aqueous reagents were prepared in nanopure water, filtered through a four stage Milli-
Q system [Millipore; Darmstadt, GER]. Solvents used for buffers and mobile phases are of 
HPLC grade. Reagents, buffers and general solutions prepared and used in experiments are 
listed in the Tables below: 
Table 2.1 – List of Reagents 
Name of reagent Abbreviation Company Location 
5’5-Dithiobis-(2-nitrobenzoic) Acid DTNB Sigma Aldrich Missouri, USA 
9-Hydroxy-10E,12Z-octadecadienoic Acid 9-HODE Cayman Chemical Michigan, USA 
4-Methylumbelliferone 4-MU Sigma Aldrich Missouri, USA 
4-Methylumbelliferyl Oleate 4-MUO Sigma Aldrich Missouri, USA 
Acetic acid (glacial) - Sigma Aldrich Missouri, USA 
Acetone - Mallinckrodt Baker New Jersey, USA 
Acetonitrile - Mallinckrodt Baker New Jersey, USA 
Amino Acid Standards - Sigma Aldrich Missouri, USA 
Aprotonin - Sigma Aldrich Missouri, USA 
Barbituric Acid - Fluka Sigma Aldrich Steinhein, GER 
Barbitone Sodium - Fluka Sigma Aldrich Steinhein, GER 
BCA Protein Assay Reagent A - Thermoscientific Illinois, USA 
Benzamidine - Sigma Aldrich Missouri, USA 
Brilliant Blue R - Sigma Aldrich Missouri, USA 
Bovine Serum Albumin BSA Sigma Aldrich Missouri, USA 
Butylated Hydroxytoluene BHT Aldrich Chemical Winconsin, USA 
Catalase (from bovine liver) - Sigma Aldrich Missouri, USA 
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Name of reagent Abbreviation Company Location 
Chelex 100 Resin - Biorad California, USA 
Chloramphenicol - Sigma Aldrich Missouri, USA 
Chloroform - Sigma Aldrich Missouri, USA 
Cholesterol and esters - Sigma Aldrich Missouri, USA 
Deoxycholic Acid DOC Sigma Aldrich Missouri, USA 
Desferrioxamine DFO Sigma Aldrich Missouri, USA 
Dibasic Potassium Phosphate   -  Sigma Aldrich Missouri, USA 
Dibasic Sodium Phosphate - BDH Laboratory Poole, GBR 
Dimethyl Sulfoxide DMSO Sigma Aldrich Missouri, USA 
Dithiothreitol DTT  Thermoscientific      Illinois, USA  
Dulbecco's Modified Eagle's Media DMEM JRH Biosciences Kansas, USA 
E64 - Sigma Aldrich Missouri, USA 
Ethylenediaminetetraacetic acid EDTA Sigma Aldrich Missouri, USA 
Fat Red 7B - Sigma Aldrich Missouri, USA 
Fetal Bovine Serum FBS Invitrogen Auckland, NZL 
Glutathionine, reduced GSH Sigma Aldrich Missouri, USA 
Hexane - Sigma Aldrich Missouri, USA 
High Molecular Mass Marker (for SDS-
PAGE) - Invitrogen Auckland, NZL 
Homocitrulline HCit Bachem Bulbendorf, SUI 
Hydrogen Peroxide H2O2 Merck Darmstadt, GER 
Isopropyl Alcohol (isopropanol) - Mallinckrodt Baker New Jersey, USA 
Lactoperoxidase LPO Calbiochem Victoria, AUS 
Lipid Hydroperoxide Standard LOOH Cayman Chemicals Michigan, USA 
Methanesulfonic Acid MSA Sigma Aldrich Missouri, USA 
Methionine Sulfoxide MetSO Sigma Aldrich Missouri, USA 
Methyl Alcohol (methanol) MeOH Mallinckrodt Baker  New Jersey, USA 
Monobasic Potassium Phosphate  - Sigma Aldrich Missouri, USA 
Monobasic Sodium Phosphate - BDH Laboratory Poole, GBR 
Myeloperoxidase MPO Planta Vienna, AUT 
Nicotinamide Adenine Dinucleotide  NADH Roche Diagnostics Indiana, USA 
o-Phthaldialdehyde OPA Sigma Aldrich Missouri, USA 
Pepstatin-A PepA Sigma Aldrich Missouri, USA 
Phosphate Buffered Saline (20 x) PBS Astral Scientific NSW, AUS 
Potassium Bromide KBr Sigma Aldrich Missouri, USA 
Potassium Cyanate KOCN Sigma Aldrich Missouri, USA 
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Name of reagent Abbreviation Company Location 
PPACK - Merck Victoria, AUS 
Roswell Park Memorial Institute media RPMI Millipore Darmstadt, GER 
Sodium Acetate NaAc Sigma Aldrich Missouri, USA 
Sodium Chloride NaCl Sigma Aldrich Missouri, USA 
Sodium Hydroxide NaOH AMRESCO Ohio, USA 
Sodium Hypochlorite NaOCl Sigma Aldrich Missouri, USA 
Sodium Pyruvate - Sigma Aldrich Missouri, USA 
Sodium Thiocyanate NaSCN Sigma Aldrich Missouri, USA 
Soybean Trypsin Inhibitor - Sigma Aldrich Missouri, USA 
Tetrahydrofuran THF Merck Victoria, AUS 
Thioglo1 -  Millipore Darmstadt, GER 
Tin (II) Chloride SnCl2 Sigma Aldrich Missouri, USA 
Trichloroacetic Acid TCA Sigma Aldrich Missouri, USA 
Tris(hydroxymethyl)aminomethane 
Acetate Tris acetate AMRESCO Ohio, USA 
Triton-X 100 - Sigma Aldrich Missouri, USA 
Tween-80 - Sigma Aldrich Missouri, USA 
Trypan Blue - Sigma Aldrich Missouri, USA 
 
Table 2.2 – List of mobile phases used in HPLC experiments 
Name Assay Ingredients 
205 HPLC Mobile Phase Cholesterol and 
ester Analysis 
70% v/v Isopropanol and 30% v/v Acetonitrile 
234 HPLC Mobile Phase 9-HODE 
Detection HPLC 
54% v/v Isopropanol, 44% v/v Acetonitrile 
Amino Acid Analysis HPLC 
Buffer A 
Amino Acid 
Analysis 
20% v/v methanol, 2.5% v/v Tetrahydrofuran, 
50 mM Sodium Acetate (pH 5.3) 
Amino Acid Analysis HPLC 
Buffer B 
Amino Acid 
Analysis 
80% v/v methanol, 2.5% v/v Tetrahydrofuran, 
50 mM Sodium Acetate (pH 5.3) 
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Table 2.3 – List of buffers used in experimental assays 
Name Assay Ingredients 
1.006 Density Solution LDL Isolation 150 mM NaCl (150 mM),  3.4 mM EDTA and 
0.31 mM Chloramphenicol 
1.0247 Density Solution LDL Isolation 5.5 % v/v 1.347 density solution and 94.5 % v/v 
1.006 density solution 
1.0538 Density Solution LDL Isolation 14.07 % v/v 1.347 density solution and 85.93 % 
v/v 1.006 density solution 
1.063 Density Solution LDL Isolation 17.79 % v/v 1.347 density solution and 82.21 % 
v/v 1.006 density solution  
1.085 Density Solution LDL Isolation  23.26 % v/v 1.347 density solution and 76.74 % 
v/v 1.006 density solution 
1.347 Density Solution LDL Isolation  2.62 M NaCl, 3.4 mM EDTA, 0.31 mM 
Chloramphenicol and 2.98 M KBr 
Barbitone Buffer (pH 8.6) Agarose Gel 
Electrophoresis 
100 mM Sodium Barbitone, 27.5 mM Barbituric 
Acid and 12.6 mM EDTA 
Fat Red/Sudan Red Stain Agarose Gel 
Electrophoresis 
2.8 g/L Fat Red/Sudan Red 7B in 95 % v/v 
Methanol 
Cathepsin B Buffer Cathepsin B 
Assay 
100 mM Potassium Phosphate, 2.5 mM EDTA 
and 0.005 % v/v Brij35 (pH 5.5) 
Cathepsin L Buffer Cathepsin L 
Assay 
100 mM Monobasic Potassium Phosphate, 2.5 
mM EDTA and 0.005 % v/v Brij35 (pH 6) 
Cathepsin D Buffer Cathepsin D 
Assay 
 100 mM Acetate buffer, 2.5 mM EDTA, and 
0.005 % v/v Brij 35 (pH 4.2) 
Coomassie Blue Stain 
(stock) 
SDS-PAGE 
Electrophoresis 
10 % w/v SDS, 10 % v/v glycerol, 2.5 % v/v 
saturated Bromophenol Blue 
Coomassie Blue Stain 
(diluted) 
SDS-PAGE 
Electrophoresis 
25% v/v Coomasie Blue stock, 5% v/v Acetic 
Acid  
Lactate Dehydrogenase 
(LDH) Working Reagent 
LDH Assay 0.15 mg mL-1 NADH and 2.5 mM Sodium 
Pyruvate in PBS 
Loading Buffer SDS-PAGE 
Electrophoresis 
10 % w/v SDS, 10 % v/v Glycerol, 2.5 % v/v 
saturated Bromophenol Blue, and 5% v/v 2-
Mercaptoethanol in 300 mM pH 6.8 Tris-HCl 
Lysosomal Acid Lipase 
(LAL) Buffer 
Lysosomal Acid 
Lipase Assay 
 0.2 M Sodium Acetate containing 0.01 % v/v 
Tween-80 (pH 5.5) 
Lysosomal Acid Lipase 
(LAL) Stop Reaction Buffer 
Lysosomal Acid 
Lipase Assay 
0.75 M Tris (pH 8.0) 
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2.3 Methodology 
2.3.1 Isolation of LDL 
Blood was drawn from willing, healthy individuals, aged 20-40 yrs old, with informed 
consent and local ethical approval (Sydney South West Area Health Service protocols X09-
0013, X12-0375, HREC/09/RPAH/19). Collected blood was dispensed into tubes containing 
0.01 mM EDTA, 1 μl mL-1 aprotonin, 0.04 μM PPACK and 20 μg mL-1 soybean trypsin 
inhibitor. Plasma was separated from blood cells through centrifugation (Beckman Coulter 
Allegra-X) at 2000 g for 20 min at 10 oC. Plasma was collected and the density was adjusted 
to 1.24 by adding potassium bromide (KBr) at 0.3816 g ml-1. Nine mL of nitrogen gassed 
density solutions (1.0247, 1.0538, 1.085) were underlayed with plasma in centrifuge tubes. 
LDL was isolated between the density gradient 1.0247 and 1.0538 after ultracentrifugation 
(L-80 Optima; Beckman, Palo Alto, CA, USA) using a vTi50 rotor (Beckman, Palo Alto, CA 
USA) for 2.5 h at 206000 g [386, 480]. This allows the separation of LDL from other 
lipoproteins present within the plasma. LDL was collected using a syringe and dispensed 
into new centrifuge tubes. LDL fraction was mixed with 1.063 density solution. Tubes were 
centrifuged in an ultracentrifuge overnight (20+ h) using Ti70 rotor (Beckman, Palo Alto, 
CA, USA) at 184000 g for further purification. Purified LDL was isolated and dialysed four 
times in PBS containing 1 g L-1 EDTA and 0.1 g L-1 chloramphenicol. LDL was sterilised using 
0.45 μm filters (Pall Life Sciences; New York, USA) and protein concentration was quantified 
using the bicinchoninic (BCA) assay [481]. Integrity of isolated LDL was confirmed using 
agarose gel and SDS-PAGE electrophoresis. Freshly isolated LDL was stored in the dark at 4 
oC, to be used within 3-4 weeks. 
2.3.2 Protein Quantification 
Protein concentration was determined using the BCA assay by detecting the conversion of 
cupric into cuprous ions upon the reaction with proteins [481]. Bovine serum albumin (BSA) 
standards (0 – 1 mg mL-1) were freshly prepared prior to assay. Twenty five μL of standards 
and diluted samples were transferred to individual wells of a 96 well tissue culture plate 
(Corning CoStar, New York, USA). Protein assay working reagent was prepared by mixing 
BCA protein assay reagent A (1 % sodium bicinchoninate, 2 % sodium carbonate, 0.16 % 
sodium tartrate, 0.4 % sodium hydroxide, 0.95 % sodium bicarbonate) and 4% w/v cupric 
sulfate solution at a 50 : 1 ratio. Two hundred μL of working reagent was transferred to 
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standards and samples prior to incubation at 60 oC for 20 min. Absorbance readings of 
standards and samples were assessed using an absorbance plate reader (Sunrise Tecan; 
Grodig, Austria) at 562 nm. A standard curve was generated from the BSA standards. 
2.3.3 Generation of MPO-derived Oxidants 
MPO-derived oxidants were freshly generated prior to the modification of LDL. HOSCN was 
formed enzymatically using LPO or MPO [82, 136]. HOCl was prepared by dilution of a 
concentrated solution of sodium hypochlorite (NaOCl; 0.491 M) into chelex-treated PBS. 
2.3.3.1 Formation of HOSCN 
HOSCN was prepared enzymatically using LPO (from bovine milk) [136]. LPO (1.5 – 2 μM) 
was incubated with hydrogen peroxide (H2O2; 3.75 mM) added in 5 aliquots a minute apart 
and sodium thiocyanate (NaSCN; 7.5 mM) in 10 mM potassium phosphate buffer (pH 6.6) 
for 15 min. Catalase (10 μg) was added to the reaction to scavenge any unreacted H2O2. 
HOSCN was filtered using a 10 KDa molecular mass cut-off filters (Pall Life Sciences, New 
York, USA) for 5 min at 10000 g and 4 oC to remove LPO and catalase. HOSCN concentration 
was quantified using the TNB assay [136].  
2.3.3.2 Quantification of HOSCN: TNB Assay 
The concentration of HOSCN was quantified through the consumption of TNB (5-thio-2-
nitrobenzoic acid). The TNB reagent was freshly prepared by dilution of concentrated TNB 
reagent 50-fold using chelex-treated sodium phosphate buffer (0.1 M, pH 7.4). 
Concentrated TNB was prepared by alkaline hydrolysis of DTNB (0.1 mM in 50 mM NaOH). 
Five μL of HOSCN was added to 995 μL of TNB reagent and incubated for 5 min prior to 
measurement of the absorbance change at 412 nm. The concentration of TNB consumed 
on reaction with HOSCN was determined using a molar absorption coefficient (ε) of 14150 
M-1 cm-1 [482]. Further dilutions to desired concentrations were made in chelex-treated 
PBS prior to addition to LDL. 
2.3.3.3 Quantification of HOCl 
Quantification of stock NaOCl was determined by measuring the absorbance at 292 nm at 
pH 11 using a molar extinction coefficient (ε) of 350 M-1 cm-1 [483]. Stock solutions were 
diluted into chelex-treated PBS immediately before use. 
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2.3.4 Preparation of Modified LDL 
2.3.4.1 Isolated Oxidants 
Control and modified LDL were prepared in chelex-treated PBS. EDTA and chloramphenicol 
were removed from the stock isolated LDL using a PD-10 column (GE Healthcare, NSW 
Australia) immediately prior to use, with protein concentration quantified using the BCA 
assay and adjusted to 2 mg mL-1. Equal volumes of LDL and either PBS (control), HOSCN (0 – 
750 μM), HOCl (0 – 1250 μM) or OCN- (0 – 2500 μM) were incubated for 30 min and 24 h at 
37 oC. LDL was only exposed to concentrations of reagent OCN- for 24 h. Excess unreacted 
oxidant was eliminated from samples using either PD-10 columns or 10 KDa molecular-
mass cut off filters with 3 washes (Millipore, Darmstadt, Germany) with centrifugation at 
13000 g for 10 min. 
2.3.4.2 Enzymatic System 
LDL was also modified by exposure to the enzymatic MPO system. LDL (1 mg protein mL-1) 
in chelex-treated PBS (containing 140 mM Cl-) was exposed to MPO (100 nM), H2O2 (200 
μM) and NaSCN (0 – 200 μM) for 24 h at 37 oC. 
2.3.5 Characterisation of Modified LDL 
2.3.5.1 Assessment of ApoB100 Charge 
Ten μg protein of LDL in 5 separate aliquots were transferred to wells of pre-cast 1.0% w/v 
agarose gels (Helena Laboratories Pty Ltd; VIC, Australia). The agarose gels were set up and 
run in a Ciba Corning gel apparatus containing barbitone buffer (100 mM sodium 
barbitone, 27.5 mM barbituric acid and 12.6 mM EDTA) at 90 V for 45 min [484]. The gel 
was fixed in 100% v/v methanol for 30 s and stained with fat red stain (2.8 g L-1 Sudan Red 
7B in 95% v/v methanol) for 5 to 10 min. The gel was destained using 70% v/v methanol 
and dried at 60 oC for 30 min. Charge modification was determined by changes in relative 
electrophoretic mobility (REM) of the protein [485]. REM was calculated as the distance 
migrated by modified LDL relative to the control (Figure 2.1). 
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Figure 2.1 – Separation of control and acetylated LDL using agarose gel electrophoresis to 
assess the relative electrophoretic mobility of LDL.  
 
2.3.5.2 Assessment of ApoB100 Aggregation and Fragmentation 
Ten μg protein of LDL samples were mixed with 13 μL loading buffer (10 % w/v SDS, 10 % 
v/v glycerol, 2.5 % v/v saturated bromophenol blue and 5 % v/v 2-mercaptoethanol in 300 
mM pH 6.8 Tris-HCl) and 2 μL 10x reducing agent (500 mM dithiothreitol, DTT). For reduced 
conditions, samples were incubated at 22 oC for 1.5 h. Non-reduced samples were prepared 
without the addition of a reducing agent. Both reduced and non-reduced samples (20 µL) 
were transferred to individual wells of a precast 3 – 8 % w/v Tris acetate gel (Invitrogen, 
California, USA). Unstained high molecular mass markers were run with the LDL samples. 
The upper and lower chamber of the gel apparatus were loaded with both running (1x Tris 
Acetate SDS running buffer; Invitrogen, California, USA) and loading buffer (1x Tris Acetate 
SDS running buffer containing 0.25 % NuPAGE antioxidant; Invitrogen, California, USA), 
respectively, prior to run. Gels were run at 150 V for 1 h. Protein bands were stained using 
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Coomassie Blue stain (25 % v/v coomassie blue stock and 5 % v/v acetic acid) for 1-2 h, and 
destained using a destain solution containing 12.5 % isopropanol, 10% acetic acid for 24 h. 
Gels were fixed in a fixative solution (50 % v/v methanol and 5 % v/v glycerol) and scanned 
using a UMAX PowerLook 112 scanner. 
2.3.5.3 Quantification of ApoB100 Amino Acids 
Amino acid composition was quantified using HPLC after protein hydrolysis with 4 M 
methanesulphonic acid (MSA). MSA hydrolysis was used to preserve amino acids of interest 
susceptible to destruction by other hydrolysis methods, including methionine, methionine 
sulphoxide and tryptophan [486]. Two hundred μL of individual LDL samples were 
delipidated and apoB100 was precipitated through the treatment of samples with 0.027 % 
(w/v) deoxycholic acid (DOC) and 9 % (w/v) trichloroacetic acid (TCA), respectively, at 4 oC 
for 5 min. Proteins were pelleted through centrifugation (Eppendorf 5415R centrifuge) for 
2 min at 7000 g. Pellets were washed twice with ice cold acetone and pelleted at 7000 g for 
2 min between washes. Excess acetone solution present in the tubes was evaporated using 
a gentle stream of N2 gas after the final wash. The resulting pellets were resuspended in 
150 µL 4 M methanesulphonic acid containing 0.2% w/v tryptamine (sealed in ampoules; 
Sigma Aldrich, Missouri, USA) and transferred into PicoTag hydrolysis vials. Vials were 
placed under vacuum and back flushed 3 times with N2 to ensure removal of oxygen prior 
to hydrolysis under vacuum overnight at 110 oC for 16-18 h. Following the incubation, 
samples were neutralised by the addition of 4 M NaOH and filtered through a 0.22 µm 
centrifugal filtration device (Millipore; Darmstadt, Germany) with centrifugation at 10000 g 
for 2 min. Prior to analysis, apoB100 samples were diluted 20-fold with nanopure water. 
Amino acid standards containing each amino acid, methionine sulfoxide and homocitrulline 
were prepared at 0 – 40 pmol. The OPA derivatisation reagent vial was prepared by mixing 
1 mL OPA (o-phthalaldehyde; Sigma Aldrich; Missouri, USA) with 5 μL β-mercaptoethanol 
prior to analysis. Forty μL of standards and samples were transferred into individual glass 
vial tubes and 20 μL of OPA was added immediately using an autosampler prior to injection 
(15 μL). Amino acids were quantified by fluorescence (λEX 340 nm, λEM 440 nm) and 
concentration was determined from standards of known concentration. 
Two mobile phases (Buffer A and B) were prepared for the HPLC run. Buffer A contains 20 
% v/v methanol, 2.5 % v/v tetrahydrofuran, and 50 mM sodium acetate (pH 5.3). Buffer B 
contains 80 % v/v methanol, 2.5 % tetrahydrofuran, and 50 mM sodium acetate (pH 5.3). 
The HPLC column used was a Beckman Coulter Ultrasphere ODS, 4.6 mm x 25 cm, 5 µm 
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pore size (part # 235329) fitted with a Beckman Coulter Ultrasphere ODS guard column, 4.6 
mm x 4.5 cm (part # 243533). The flow rate was set at 1 mL min-1 and the column was 
equilibriated and incubated at 30 oC. 
 
 
Figure 2.2 – Graphical representation of the HPLC trace showing separation of individual 
amino acids. ApoB100 was hydrolysed to individual amino acids after hydrolysis with MSA 
in the presence of tryptamine overnight. Individual amino acids were quantified using 
fluorescence after derivatisation with o-phthaldialdehyde (OPA) prior to injection onto the 
HPLC column. Amino acid standards with methionine sulphoxide and homocitrulline at 0 – 
40 pmol was run with samples to determine the concentration of individual amino acids. 
Amino acids were separated using a gradient solvent system using two buffers: Buffer A 
(20% v/v methanol, 50 % v/v tetrahydrofuran, 2.5 mM sodium acetate; pH 5) and Buffer B 
(80% methanol, 50 v/v % tetrahydrofuran, 2.5 mM sodium acetate; pH 5). Peaks were 
detected using fluorescence at λEX 340 nm and λEM 440 nm. Modification of amino acids 
results in an altered retention time, which represents a different peak within the HPLC 
chromatogram (e.g. Met and MetSO)  
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2.3.5.4 Quantification of ApoB100 Cys Residues 
LDL free Cys residues were assessed using ThioGlo-1. This assay was performed separately 
from amino acid analysis due to the loss of Cys residues during hydrolysis with MSA [486]. 
Levels of Cys residues were assessed through use of the ThioGlo-1 fluorescent tag that 
binds selectively to free Cys residues resulting in a change in fluorescence. Control and 
modified LDL samples were prepared after treatment of 1 mg mL-1 of LDL with 0 – 10 μM 
HOSCN and HOCl for 30 min at 37 oC. In samples modified by the enzymatic system, 1 mg 
mL-1 of LDL was treated with the enzymatic system consisting of 5 nM MPO, 10 μM H2O2 
and 0 – 200 μM NaSCN for 30 min at 37 oC. Standards at a concentration range of 0 – 5 μM 
were prepared by dilution of 0.5 mM glutathione (GSH). ThioGlo-1 fluorescent reagent (2.6 
mM) was prepared in acetonitrile and was stored in the dark at 4 oC until use. Prior to 
assay, ThioGlo-1 was diluted 100-fold into chelex-treated PBS to generate a working 
fluorescent reagent. Fifty μL of standards or samples were mixed with 50 μL ThioGlo-1 
reagent in individual wells of a 96 well culture plate (Corning, Costar). The plate was mixed 
briefly using a plate shaker and was incubated in the dark for 5 min. Levels of Cys were 
detected using a fluorescence plate reader with λEX 384 nm and λEM 513 nm [486].  
2.3.5.5 Quantification of LDL Cholesterol and Cholesteryl Ester 
Loss 
Modification of the lipid moiety of LDL by HOSCN and HOCl was assessed by investigating 
the loss of cholesterol and cholesteryl esters. Several cholesteryl esters are present in the 
LDL molecule, including cholesteryl arachidonate, linoleate, oleate, palmitate, and stearate 
[487]. Prior to extraction, LDL (1 mg mL-1) was transferred to clean glass tubes containing 
10 μL 0.2 mM BHT (in ethanol) and 10 μL 200 mM EDTA to minimise artifactual oxidation. 
Cholesterol and cholesteryl esters were extracted from LDL through the addition of 2.5 mL 
methanol and 5 mL hexane into glass tubes. Each tube was vortexed for 30 s and 
centrifuged at 1500 g for 5 min. Four mL of the upper hexane layer was transferred to fresh 
clean tubes. Hexane was removed from each sample by drying in a Speedivac system (John 
Morris; New South Wales, Australia) for 30 min, with the resulting dry lipid pellets 
reconstituted in 200 μL reverse phase HPLC mobile phase (70 % v/v isopropanol and 30 % 
v/v acetonitrile) [487]. 
Standards for cholesterol and cholesteryl esters (Sigma Aldrich, California, USA) were also 
prepared prior to analysis. Two hundred μL of standards, prepared in 70 % isopropanol and 
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30 % acetonitrile, and samples were transferred into individual glass vials for HPLC analysis. 
Response factors for cholesterol and individual cholesteryl esters (arachidonate, linoleate, 
oleate, palmitate and stearate) were determined owing to poor stability on storage to 
calculate the concentration of these in the LDL samples. The HPLC column used was a 
Supelco Supercosil LC-18, 25 cm x 4.6 mm x 5 μm column. The flow rate was set at 1 mL 
min-1 at 25 oC and the elution of material detected by their UV absorption at 205 nm [386]. 
Representation of the chromatogram formed from HPLC analysis is shown in Figure 2.3. 
 
 
Figure 2.3 – Graphical representation of the HPLC trace showing the separation of 
cholesterol and cholesteryl esters from injected LDL samples.  Cholesterol and cholesteryl 
esters were extracted by mixing LDL samples into a methanol:hexane solvent mixture. The 
hexane fraction was dried and lipid pellets were reconstituted in the HPLC mobile phase 
(70 % isopropanol and 30 % acetonitrile). Cholesterol and cholesteryl esters were 
separated using an isocratic elution with a mobile phase consisting of 70 % isopropanol and 
30 % acetonitrile). Peaks were detected using UV absorbance at 205 nm. 
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2.3.5.6 Detection of LDL Lipid Hydroperoxides 
Lipid hydroperoxides (LOOH) are a major product of lipid peroxidation with increased levels 
detected as a result of oxidative injury in several diseases including atherosclerosis 
(reviewed in [259]). LOOH were measured using a commercially available kit (Cayman, 
Michigan, USA). In this kit, LOOH in the samples react with ferrous ions, resulting in the 
formation of the ferric form. The presence of ferric ions was detected using thiocyanate as 
a chromogen. Prior to the assay, oxygen (O2) was removed from methanol and chloroform 
by continuous flushing with nitrogen (N2) for the duration of the assay. LOOH extract R 
(0.5% w/v; crystalline solid used for extraction) was prepared by dissolving extract R 
crystalline solid into deoxygenated methanol, followed by vortexing thoroughly for 2 min. 
Two hundred μL of Extract R and LDL samples were mixed thoroughly in a fresh glass tube. 
One mL of deoxygenated chloroform was added to each tube and was centrifuged at 1500 
g and 0 oC for 5 min. The chloroform layer was collected and diluted 5-fold with 
chloroform/methanol (50:50) solvent. The samples were stored at 4 oC until analysed 
(approximately 5 min). 
Standards were prepared from the provided LOOH standard stock. Standards were diluted 
to the desired concentrations (0 – 5 nmol) using a chloroform/methanol (50:50) solvent. 
Prior to assay, the chromogen was prepared by mixing equal volumes of FTS reagent 1 (4.5 
mM ferrous sulfate in 0.2 M hydrochloric acid) and 2 (3 % methanolic solution of 
ammonium thiocyanate). Chromogen was added to standards and samples, and was 
incubated at 21 oC for 5 min. LOOH was detected using a UV-VIS spectrophotometer 
(Shimadzu, UV-2550; Kyoto, Japan) at 500 nm. 
2.3.5.7 Quantification of LDL 9-HODE Formation 
9-Hydroxyoctadecaenoic acid (9-HODE) is an alcohol product derived from the modification 
of cholesteryl linoleate [488-490]. 9-HODE has been detected in atherosclerotic lesions and 
its generation is postulated to be due to the non-enzymatic oxidation of cholesteryl 
linoleate [491-493]. In this case, hydroperoxides were postulated to be generated upon 
treatment of LDL with oxidants. However, hydroperoxides are unstable and can degrade 
easily before analysis through HPLC. Thus, prior to extraction of lipids from LDL, 
hydroperoxides were converted to alcohols, which are more stable. Assessment of 9-HODE 
formation was performed using HPLC after oxidation of LDL for 24 h. Two hundred μL of 1 
mg mL-1 control and modified LDL were treated with 10 μL of 20 mM tin (II) chloride (SnCl2) 
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for 30 min. 9-HODE was extracted as described above (refer to section 2.3.5.5) for 
cholesterol and cholesteryl ester analysis using a methanol/hexane layer. Tubes were 
vortexed for 30 s and centrifuged at 1500 g for 5 min. The upper hexane later was collected 
and removed by drying using a Speedivac system (John Morris; New South Wales, Australia) 
for 30 min. Lipid pellets were reconstituted in reverse phase HPLC mobile phase (54 % v/v 
isopropanol and 44 % v/v acetonitrile) [494]. 
9-HODE standards (Cayman Chemical; Michigan, USA) were prepared and diluted to the 
desired concentrations (0 – 15 nmol) in absolute ethanol. Two hundred μL of standards and 
samples were transferred into individual glass vials for HPLC analysis (Shimadzu; Kyoto, JP). 
A standard curve for 9-HODE was generated and concentrations of 9-HODE in samples 
were quantified from the standard curve. The HPLC column used for analysis was a 
Beckman Coulter Ultrasphere, 25 cm x 4.6 mm x 5 μm column with the flow rate set at 1.5 
mL min-1 at 25 oC and eluted materials detected by their UV absorbance at λ 234 nm [494]. 
9-HODE was separated using an isocratic elution with a mobile phase containing 54 % 
isopropanol and 44 % acetonitrile. A representation of the chromatogram formed from 
HPLC analysis is shown in Figure 2.4. 
 
Figure 2.4 – Graphical representation of the HPLC trace showing the detection of 9-HODE 
formation in LDL samples. 9-HODE was extracted by mixing LDL samples into a 
methanol:hexane solvent mixture. The hexane fraction was dried and lipid pellets were 
reconstituted in the HPLC mobile phase (54 % isopropanol and 44 % acetonitrile). 9-HODE 
was separated by HPLC using an isocratic elution with mobile phase containing 54 % 
isopropanol and 44 % acetonitrile. Peaks were detected using UV absorbance at 234 nm. 
64 
 
2.3.5.8 Detection of LDL F2-isoprostane Formation 
F2-isoprostanes (F2-Isop) are lipid oxidation products derived from the oxidation of 
arachidonic acid by secondary radicals [495, 496]. Detection of F2-isoprostanes was 
performed in collaboration with Prof. Kevin Croft and Dr. Julie Proudfoot (School of 
Medicine and Pharmacology, University of Western Australia). LDL samples were prepared 
as described above (refer to section 2.3.4.1). After oxidation, samples were diluted to 0.5 
mg mL-1 in a 500 μL volume. F2-isoprostane formation was quantified by gas 
chromatography [497]. Four hundred μL of LDL sample was spiked with 2 ng 15-F2t-IsoP-d4 
(8-iso-PGF2a-d4). Samples were flushed with N2 and were hydrolysed with 1 M potassium 
hydroxide in methanol for 30 min at 40 oC. The pH of samples was adjusted to 4.6 and 
samples were spun using a centrifuge. The supernatant from each sample was collected 
and applied to pre-washed Certify II cartridges (Varian, Lake Forrest, CA). Samples were 
washed with methanol/water (1:1), followed by hexane/ethyl acetate (75:25). The F2-IsoP 
extracts were eluted with ethyl acetate/methanol (90:10) and dried under vacuum. Pellets 
were derivatised using pentafluorobenzylbromide and N,N-diisopropylethylamine, and 
were dried under a stream of N2. Samples were treated with a silylating agent, N, O-bis 
(trimethylsilyl) trifluoroacetamide containing 1 % trimethylchlorosilane. F2-IsoP extracts 
were quantified using gas chromatography/mass spectrometry using electron capture 
negative ionisation and selected ion monitoring. Ions monitored were m/z 569 and 573 for 
F2-IsoP and 15 F2t-IsoP-d4 respectively [497]. 
2.3.5.10 Consumption of HOSCN by LDL 
The rate of HOSCN consumption/degradation in the presence and absence of LDL was 
assessed using the TNB assay, as described in section 2.3.3.2. HOSCN 
consumption/degradation was performed over the course of 24 h with selected time points 
(5, 10, 30, 60, 120, 240 min and 24 h) to assess the change in concentration of HOSCN with 
time.    
2.3.5.11 Assessment of Chloramine Formation and Degradation 
Chloramines are reactive products arising from the reaction of HOCl with amine groups 
present on amino acids, peptides, proteins and other amine containing compounds (e.g. 
DNA bases, phospholipid head groups) [53, 55, 73]. Formation of chloramines is important 
in the oxidative mechanisms mediated by HOCl, resulting in further modification of 
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biomolecules including proteins and lipids [102]. Their formation on exposure of LDL to 
HOCl and their subsequent stability was assessed over 24 h. Chloramine concentration was 
quantified using a TNB assay as described above in section 2.3.3.2 with slight modification. 
In this case, 20 μL of LDL sample (1 mg mL-1) was added to 980 μL TNB reagent. 
2.3.6 Tissue Culture 
Both J774A.1 murine macrophage-like cells and human monocyte-derived macrophages 
(HMDM) were used to assess LDL-induced cellular dysfunction through changes in cell 
viability and lipid metabolism with cellular accumulation of cholesterol and cholesteryl 
esters. 
2.3.6.1 Murine Macrophage-like cells (J774A.1) 
The J774A.1 murine macrophage-like cell line (A.T.C.C. TIB 67) was grown in Dulbecco’s 
modified Eagle’s medium (DMEM; JRH Biosciences; Kansas, U.S.A.) containing 10% (v/v) 
fetal bovine serum (Invitrogen, Eugene, OR, U.S.A.) in a culture flask in a humidified 
atmosphere containing 5% CO2. During growth, cells were split continuously between 
passage 15 to 40 after 3 days, as they reached confluence. Prior to cell experiments, 
confluent J774A.1 cells were plated down at a density of 0.5 x 106 cells/well in a 6 or 12-
well culture plates with 2 or 1 mL cell suspension, respectively. 
2.3.6.2 Human Monocyte-derived Macrophage cells 
Isolation of monocytes was performed by Mr. Pat Pisansarakit (Tissue Culture Support, The 
Heart Research Institute) through elutriation of white cell concentrates provided by 
Australian Red Cross Blood Bank (Sydney, Australia). The elutriation system consists of a 
centrifuge (Beckman Coulter Avanti J20-XPI) with an integrated rotor (Beckman Coulter, JE-
5.0) in an elutriation chamber (4.2 mL), and a peristaltic pump (Masterflex; Illinois, USA). 
The buffer used for elutriation is a calcium and magnesium deficient HBSS with 0.1 g L-1 
EDTA supplementation (Sigma Aldrich; Missouri, USA). Initially, white cell concentrates 
were diluted 2-fold in HBSS  and 30 mL was underlaid with 15 mL Lymphoprep (Axis-Shield 
PoC AS; Oslo, Norway). Tubes were centrifuged at 2060 g for 40 min at 21 oC. Peripheral 
blood mononuclear cells were isolated from the lymphoprep interface. The mononuclear 
suspension was washed once with HBSS, resuspended in 30 mL HBSS and loaded into the 
elutriation system at 2150 g with an initial flow rate of 9 mL min-1 and run at 21 oC. During 
the run, the flow rate was increased by 1 mL min-1 every 10 min and cell fractions were 
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collected. The purity of cells were examined using a Shandon Cytospin 4 (Thermo Scientific) 
of cell suspension smears with use of Diff Quick staining kits (Lab Aids Pty Ltd; NSW, 
Australia) according to the manufacturer’s instructions. Fractions containing pure 
monocytes were pooled and counted by microscopy after the addition of 0.4 % w/v trypan 
blue (Sigma Aldrich, Missouri, USA). Isolated monocytes were plated at 1 – 1.2 x 106 cells 
mL-1 in 6 well culture plates (CellBind, Corning). The original serum-free media was replaced 
after 2 h with RPMI-1640 media containing 10 % heat inactivated human serum (HIHS), 2.5 
mM L-glutamine, 100 U mL-1 penicillin and 0.1 mg mL-1 streptomycin. Media was initially 
replaced after 3 – 4 days and was subsequently replaced every second day. Human 
monocytes were left to differentiate into macrophages for 9 – 11 days after plating into 6 
well culture plates. Cells were used at day 9 – 11 for experiments [498].   
2.3.6.3 Exposure of LDL to cells 
LDL (1 mg protein mL-1) was exposed to either 250 or 500 μM HOSCN, HOCl and 2500 μM 
OCN- for 30 min or 24 h at 37 °C. Excess oxidants were removed using filtration (PD-10 
column or 10K molecular weight cut off filters), prior to addition to cells. LDL was sterile 
filtered before addition to cell media (DMEM for J774A.1 or RPMI for HMDM) containing 10 
% lipoprotein-deficient serum (LPDS; prepared by Dr. Bronwyn Brown at the Heart 
Research Institute) at a final concentration of 100 μg mL-1. J774A.1 and HMDM (0.5 x 106 
cells mL-1) were exposed to 100 μg protein mL-1 of LDL for 24 or 48 h, respectively. 
2.3.7 Assessment of Macrophage Cellular Dysfunction 
2.3.7.1 Assessment of Macrophage Cellular Viability: Lactate 
Dehydrogenase Assay 
Cellular viability was determined after exposure of J774A.1 and HMDM cells to native and 
each type of modified LDL as described in section 2.3.6.3. After exposure to modified LDL, 
the cell media was collected, and cells were washed twice with warm PBS. Cold Baxter 
water (Baxter Healthcare, New South Wales, Australia) was added into each well to 
facilitate cell lysis. Plates were left in a rocking platform for 30 min and cells were lysed by 
scraping using a syringe plunger. 
To assess viability, the release of LDH from cells into the media was expressed as 
proportion of the total cellular LDH (lysate + media). LDH is a cellular enzyme that catalyses 
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the conversion of pyruvate into lactate in the presence of NADH [499]. LDH working 
reagent was prepared containing 2.12 mM NADH and 2.5 mM sodium pyruvate in PBS. Ten 
μL of cell media or cell lysate was transferred into individual wells of a 96 well tissue culture 
plate. Two hundred μL of LDH reagent was added to each well and the LDH activity was 
measured by determining the rate of absorbance changes at 340 nm over time for 30 min 
at 7 min intervals using a plate reader (Tecan Sunrise; Grodig, Austria) [499].   
2.3.7.1 Assessment of Macrophage Cellular Viability: Annexin 
V/Propidium Iodide Assay 
The induction of cell death by apoptosis and necrosis on treatment of macrophages with 
modified LDL was assessed using flow cytometry with Annexin V and Propidium iodide 
staining (BD Pharmigen; New Jersey, USA). During apoptosis, the phospholipid 
phosphatidylserine is translocated extracellularly, which specifically binds to annexin V. 
Necrotic cells take up propidium iodide, owing to the loss of membrane integrity in cells 
[500, 501]. Cells were washed twice with PBS before the addition of binding buffer (10 mM 
HEPES/NaOH pH 7.4, 140 mM NaCl and 2.5 mM CaCl2). Cells were harvested gently using a 
cell scraper and 100 μL of the resulting cell suspension was transferred into individual 
culture tubes. Five μL of annexin V and propidium iodide (50 μg mL-1) was added to each 
tube, followed by the addition of 400 μL binding buffer containing 10 mM HEPES/NaOH (pH 
7.4), 140 mM NaCl and 1.5 mM CaCl2. Tubes were vortexed thoroughly and cells were 
identified as apoptotic that stain with annexin V, necrotic that stain with propidium iodide, 
or neither (healthy) without staining, using a flow cytometer (Beckman Coulter Cytomics 
FC-500) [501-503]. 
2.3.7.2 Quantification of Cholesterol and Cholesteryl Ester 
Accumulation in Macrophages 
The extent of cholesterol and cholesteryl ester accumulation observed on exposure of 
macropages to modified LDL was quantified using reverse phase HPLC [386]. Cells were 
treated with each type of LDL as described in section 2.3.6.3. After 24 h (J774A.1) or 48 h 
(HMDM) incubation, cells were washed twice with heat-treated PBS before lysis in 1 mL 
water. Heat-treated PBS is used to keep the environment of cells sterile throughout the 
experiment. Cell lysates were transferred to glass tubes containing 10 μL 0.2 mM BHT (in 
ethanol) and 10 μL 200 mM EDTA. Methanol (2.5 mL) and hexane (5 mL) was added to each 
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tube and vortexed thoroughly for 30 s. The hexane layer, which contains the lipid portion of 
LDL was removed and dried using a Speedivac system. The resulting lipid pellets were 
reconstituted in reverse phase HPLC mobile phase (70 % v/v isopropanol and 30% 
acetonitrile). The cholesterol and cholesteryl esters were quantified by HPLC as described 
in section 2.3.5.5. 
Cellular cholesterol and cholesteryl esters were normalised to cell protein, in the cell 
lysates as assessed by the BCA assay (section 2.3.2). 
2.3.8 Assessment of Lysosomal Enzyme Function 
Inactivation of macrophage lysosomal enzymes was assessed in cell lysates and intact cell 
systems on exposure to modified LDL. 
2.3.8.1 Preparation of Cell Lysates 
Cells were plated in 6 well tissue culture plates as described in section 2.3.6.1. After 
allowing cells to adhere overnight after plating, cells were washed with PBS and were 
scraped into suspension in heat treated PBS. Cells were pelleted down through 
centrifugation at 1500 g for 5 min and were resuspended in 1 mL cold water. The cell 
suspension was left for 30 min and lysed using three cycles of freeze (10 s in liquid 
nitrogen) and thaw (45 – 50 s in 37 oC water bath). The cell debris was separated from the 
suspension by centrifugation at 1500 g at 4 oC. The supernatant was removed and 
transferred into a clean Eppendorf tube. The cell lysate was kept till use at 4 oC.  
2.3.8.2 Treatment of Cell Lysates with Modified LDL 
Control and modified forms of LDL were filtered using a 10K molecular mass cut-off filter 
and, washed twice to remove any excess unreacted oxidants present in the solution. One 
hundred μL of cell lysate and LDL samples were incubated for 15 min at 22 oC. Activities of 
lysosomal enzymes were assessed as described below in section 2.3.8.3 – 5. 
2.3.8.3 Treatment of Intact Cells 
Cells were plated in 6 well tissue culture plates as described in 2.3.6.1. Prior to exposure to 
control and modified LDL samples, cells were washed with heat-treated PBS. Cells were 
exposed to media (DMEM for J774A.1 or RPMI for HMDM) containing 10 % LPDS and 100 
μg mL-1 control and modified forms of LDL. After incubation, cells were washed with heat-
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treated PBS and were scraped into suspension in PBS. The cells were pelleted by 
centrifugation at 2000 g for 5 min at 22oC. Cell pellets were resuspended in 500 μL cold 
water and left to incubate at 4 oC for 30 min. The cell suspension was passed through a 
freeze (10 s liquid nitrogen) and thaw (45 – 50 s in 37 oC water bath) cycle three times. Cell 
debris was removed through centrifugation at 2000 g for 5 min at 4 oC. Activities of 
lysosomal enzymes were assessed as described below in section 2.3.8.3 – 5. 
2.3.8.3 Assessment of Cys-dependent Cathepsin Enzyme Activity 
Cys-dependent cathepsin activity was investigated by assessing the activity of both 
cathepsin B and L enzymes in cell lysate and intact cell systems. Cathepsin B and L are 
known to contribute to the processing of proteins in lysosomes arising from the 
endocytosis of particles by macrophage cells [69]. Twenty five μL of cell lysate were 
transferred to wells of a 96 well tissue culture plate. Buffers for the assessment of 
cathepsin B (100 mM potassium phosphate, 2.5 mM EDTA and 0.005 % v/v Brij35; pH 5.5) 
or L (100 mM monobasic potassium phosphate, 2.5 mM EDTA and 0.005 % v/v Brij35; pH 6) 
activity was prepared by the addition of specific fluorescent substrates, Z-Arg-Arg-AMC 
hydrochloride (cathepsin B; Bachem; Bulbendorf, Switzerland) or Z-Phe-Arg-AMC 
hydrochloride (cathepsin L; Bachem Bulbendorf, Switzerland) at 10 μM. One hundred and 
eighty μL of cathepsin B or L buffer was added into individual wells. Cathepsin B/L enzyme 
activity was determined by examining the release of profluorescent species AMC by 
monitoring the change in fluorescence over 20/10 min with 2/1 min intervals, respectively, 
using a fluorescent plate reader (SpectraMax M2; Molecular Devices) at λ EX 360 and EM 460 
nm. 
2.3.8.4 Assessment of Arg-dependent Cathepsin Enzyme Activity 
Arg-dependent cathepsin enzyme activity was investigated by assessing cathepsin D activity 
in cell lysates and intact cell systems. Cathepsin D has been shown to contribute to the 
degradation of damaged proteins in cells [504]. Fifteen μL of cell lysate was transferred to 
96 well tissue culture plate and mixed with equal volumes of the inhibitor vehicle DMSO or 
2 mg mL-1 pepstatin-A to inhibit other proteases. Cathepsin D buffer was prepared by 
mixing cathepsin D buffer (100 mM acetate buffer, 2.5 mM EDTA and 0.005 % v/v Brij35) 
with 10 μM E64, 50 μM benzamidine, and 10 μM cathepsin D substrate (7-
methoxycoumarin-4-acetyl-Gly-Lys-Pro-Ile-Leu-Phe-Phe-Arg-Leu-Lys(DNP)-D-Arg-amide; 
Sigma Aldrich; Missouri, USA). Eighty μL was added into each well and cathepsin D enzyme 
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activity was determined by recording the change in fluorescence over 5 min with 30 s 
intervals in a fluorescent plate reader (SpectraMax M2; Molecular Devices) at λ EX 320 and 
EM 410 nm. 
2.3.8.5 Assessment of Lysosomal Acid Lipase Activity 
Lysosomal acid lipase (LAL) is responsible for the hydrolysis of exogenous cholesteryl esters 
to free cholesterol and fatty acids in the lysosomes of macrophage cells {Goldstein, 1975 
#402}. A working stock of 1 mM 4-methylumbelliferone (4-MU) was prepared in DMSO and 
further diluted in 4% v/v triton-X at 0 – 10 μM. A stock solution of the substrate of 2.26 mM 
4-methylumbelliferyl oleate (4-MUO; Sigma Aldrich; Missouri, USA) was prepared and 
diluted 100-fold by mixing 50 μL of 2.26 mM 4-MUO in 5 mL 4 % v/v Triton-X, just prior to 
the assay. Twenty five μL of standards and samples were transferred into wells of a 96 well 
culture plate. Fifty μL of diluted substrate were added to wells and 125 μL of lysosomal acid 
lipase buffer (0.2 M sodium acetate and 0.01 % v/v Tween 80; pH 5.5) was added. The plate 
was incubated for 30 min at 37 oC in the dark and 100 μL of stop buffer (0.75 M Tris; pH 
8.0) was added to each well. The plate was read using a fluorescent plate reader 
(SpectraMax M2; Molecular Devices) at λ EX360 and EM460 nm. LAL activity was determined 
from the standard curve generated from 4-MU over the concentration range 0 – 10 μM. 
2.3.9 Data Analysis 
Statistical analyses were performed using GraphPad Prism 5 (GraphPad Software, San 
Diego, California, USA) with p < 0.05 taken as significant. Details of the specific tests used in 
each case are provided in the Figure Legends and in the Results sections. 
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Chapter 3: Characterisation of LDL 
Modification by Myeloperoxidase-
derived Oxidants 
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3.1 Introduction 
Oxidative modification of LDL is a major pathway that contributes to the development of 
atherosclerosis. Although a number of products of oxidative modifications have been 
detected in isolated human atherosclerotic lesions (reviewed in [505]), the type of LDL 
modifications important in the development of atherosclerosis remains unclear. Previous 
studies have proposed that multiple sources of LDL modification may contribute to the 
development of atherosclerosis, including transition metal ions (Cu2+ and Fe2+) [333-337], 
lipoxygenase [374-376], superoxide/nitric oxide (eg [392, 506]), glucose [386], thiols [362-
364], and MPO-derived oxidants [217, 300, 302]. Out of all the possible pathways, LDL 
modified by transition metal ions, primarily Cu2+, has been extensively examined in the 
literature [333-335, 339, 507-509]. Comparatively, the pattern of oxidation is quite 
different to that seen with MPO-derived oxidant exposure at high molar excesses (> 400x) 
[50, 102, 106, 300, 302, 307, 416, 506]. Cu2+ ion-mediated oxidation is marked by major 
modifications to the lipid component of LDL [335-337]. Modifications were represented by 
loss of polyunsaturated cholesteryl esters and formation of lipid hydroperoxide moieties. 
Changes in apoB100 were also prominent with this form of modified LDL [335-337]. It was 
demonstrated that hydroperoxides generated during lipid peroxidation contribute to 
apoB100 modification, resulting in changes to LDL relative electrophoretic mobility (REM) 
[335-337]. 
Unlike transition metal ions, HOCl-mediated oxidation of apoB100 was not preceded by the 
formation of lipid hydroperoxides and lipid radicals derived from polyunsaturated 
cholesteryl esters [217, 300]. HOCl was demonstrated to react directly with apoB100 [302]. 
At high molar excess of oxidant, several key amino acid residues were shown to be 
modified including Cys, Met, Trp, Lys, His and Tyr [102, 299, 302]. Modification of Tyr 
residues is responsible for the chlorinated tyrosine residues detected within atherosclerotic 
lesions [50]. Furthermore, changes in REM and the structure of LDL (fragmentation and 
aggregation) were also apparent after exposure to this oxidant [217, 300]. Following 
apoB100 modification, lipid modification and antioxidant depletion are also observed 
[102]. The resulting lipid oxidation has been proposed to be mediated by secondary 
radicals formed from reactive apoB100 chloramines, after initial exposure of LDL to HOCl 
[102]. 
Preliminary studies investigating the effects of SCN- derived oxidants on LDL have been 
performed [82]. Exposure of LDL to MPO/H2O2/SCN
- system resulted in modification of the 
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lipid component of LDL [82]. However, the effects of SCN- derived oxidants were not 
investigated in detail. There remains a lack of data relating to the interactions of HOSCN 
with apoB100 [82]. Thus, further studies need to be performed to characterise the effects 
of SCN- derived oxidants, including HOSCN, on exposure to LDL. 
3.2 Aims 
This chapter aims to discuss the modification observed on exposure of LDL to the MPO-
derived oxidants HOCl and HOSCN at physiologically-relevant concentrations. The 
modifications to both the protein and lipid component of LDL have been comprehensively 
assessed. 
3.3 Results 
3.3.1 Consumption of HOSCN by LDL 
HOCl is known to react readily with LDL, resulting in rapid consumption of the oxidant 
added [102, 299, 302]. In contrast, less is known about the reactivity of HOSCN with LDL. 
Initial experiments therefore examined the consumption of HOSCN over time. LDL (1 mg 
protein mL-1) was exposed to 250 μM HOSCN for 24 h. Assessment of HOSCN levels was 
performed using the TNB assay at specific time points: 0, 10, 20, 30, 60, 120, 160 min, and 
24 h. Figure 3.1 shows the loss of HOSCN over time in the presence or without LDL for 24 h. 
Consumption of HOSCN was exhibited in the first 30 min of reaction in the presence of LDL, 
with a lower extent of loss detected in the absence of LDL. Comparatively, there was a drop 
of 26 % in HOSCN in the presence of LDL, while in the absence of LDL a drop of 16 % in 
HOSCN concentration was observed. This significant decrease suggests reactivity of HOSCN 
with targets present on LDL. The consumption did not appear to increase significantly 
compared to the decomposition of HOSCN in the absence of LDL after the initial 30 min 
incubation. This experiment was not performed with HOCl, owing to the formation of 
chloramines, which react with TNB [510]. 
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Figure 3.1 – Degradation of HOSCN over time with or without the presence of LDL. LDL (1 
mg protein mL-1) was treated with 250 μM HOSCN for 24 h at 37 oC. Experiment was 
repeated 3 times, each with a different LDL donor (n = 3). Statistical differences were 
assessed using two-way ANOVA (Benferroni post test). *, **, and ** represent significant 
(p<0.05, 0.01, <0.001) difference between LDL with HOSCN and PBS with HOSCN at each 
time point.  
 
3.3.2 ApoB100 Modification by Isolated Oxidants 
3.3.2.1 Charge Modification 
Having shown consumption of HOSCN by LDL, the next series of experiments examined the 
extent of apoB100 modification by assessing changes in charge, after treatment of LDL with 
increasing concentrations of HOSCN, HOCl (0 – 750 μM) and OCN- (0 – 2500 μM). Native 
LDL was not included in the experiment, since the incubation control and native LDL gave 
very similar results. Modification of charged amino acids within apoB100 was investigated 
using agarose gel electrophoresis (Figure 3.2). Modification of apoB100 charge was 
demonstrated by changes in the electrophoretic mobility of LDL relative to control (0 μM). 
This is referred to as the relative electrophoretic mobility (REM). The effects of (A) HOSCN, 
(B) HOCl and (C) OCN- on particle charge on exposure of LDL to these oxidants are shown in 
Figure 3.2 and 3.3. Exposure of HOSCN and OCN- to LDL for 30 min led to a small shift in the 
REM compared to the native LDL. The changes in REM seen on treating LDL with HOCl were 
more marked, consistent with previous reports at higher HOCl concentrations [302, 305, 
306]. Treatment of LDL with HOSCN and OCN- for 24 h showed similar changes compared 
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to 30 min exposure. However, HOCl exposure for 24 h to LDL led to more significant 
changes compared to 30 min exposure, indicative of further oxidation and charge 
modification. 
 
 
Figure 3.2 – Representative agarose gel displaying the relative electrophoretic mobility of 
LDL exposed to (A) HOSCN and OCN-, and (B) HOCl. LDL (1 mg protein mL-1) was treated 
with increasing concentrations of HOSCN (100 – 750 μM), HOCl (100 – 2500 μM) and OCN- 
(500 – 2500 μM) for 30 min or 24 h at 22oC and 37 oC, respectively. Relative electrophoretic 
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mobility of LDL was calculated relative to control LDL. Experiment was repeated 3 times, 
each with a different LDL donor and representative gels are shown. 
 
 
Figure 3.3 – Modification of apolipoprotein B100 charge residues after exposure to 
HOSCN (A), HOCl (B) and OCN- (C). LDL (1 mg protein mL-1) was treated with increasing 
concentrations of HOSCN (100 – 500 μM), HOCl (100 – 500 μM) and OCN- (500 – 2500 μM) 
for 30 min at 22 OC (white bars) or 24 h (black bars) at 37 oC. The relative electrophoretic 
mobility of LDL was calculated relative to control LDL. Experiment was repeated 3 times, 
each with a different LDL donor. Statistical differences were assessed using one-way ANOVA 
(Dunnett’s posthoc test). *, ** and *** represent significant (p <0.05, <0.01 and <0.001) 
difference compared to the incubation control (0 μM). Two-way ANOVA (Bonferroni’s 
posthoc test) was also performed to assess significance between 30 min and 24 h modified 
LDL. # represents significant (p<0.05) difference comparing 30 min vs 24 h modified LDL at 
the same oxidant treatment. 
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To complement the findings obtained with the use of isolated oxidants, LDL was also 
exposed to the enzymatic MPO/H2O2/SCN
-/Cl- system to assess its effects on LDL. Figure 3.4 
shows the effects of the enzymatic MPO/H2O2/SCN
-/Cl- system on LDL particle charge after 
reaction with LDL. Exposure of LDL (in PBS containing 140 mM Cl-) to the enzymatic MPO 
system in the presence of increasing concentrations of SCN- led to an increase in particle 
charge modification. The change observed was independent of SCN- concentration. The 
charge of apoB100 residues was also found to be reduced on treatment of LDL with the 
MPO system containing 0 μM SCN-, exemplifying the effects induced by the presence of 
HOCl. Increasing concentrations of SCN- shifts the ratio of oxidants produced to increase 
HOSCN, which did not further alter apoB100 charge. Thus, decreasing the amount of HOCl 
and increasing HOSCN did not reduce the extent of LDL charge modification after the 
exposure of LDL to the enzymatic MPO/H2O2/SCN
-/Cl- system. 
 
 
Figure 3.4 – Modification of apolipoprotein B100 charged residues after exposure to the 
enzymatic MPO/H2O2/SCN
-/Cl- system. LDL (1 mg protein mL-1) was treated with the 
enzymatic MPO system containing 100 nM MPO, 200 μM H2O2, 140 mM Cl
- and 0 – 200 μM 
SCN- for 24 h at 37 oC. The relative electrophoretic mobility of the LDL samples was 
calculated relative to the incubation control. Experiment was repeated 3 times, each with a 
different LDL donor. Statistical differences were assessed using one-way ANOVA (Dunnett’s 
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posthoc test). ** shows significance (p <0.01) compared to the incubation control (white 
bar). 
3.3.2.2 Structural Changes in ApoB100 
Structural changes in apoB100 were investigated using SDS-PAGE as exposure of LDL to 
oxidants may result in apoB100 aggregation, fragmentation or both [300]. Several key 
amino acids are important for maintaining the structural conformation of proteins. 
Targeting of these residues may hence result in changes to apoB100 structure. Changes in 
apoB100 structure were assessed in LDL treated with HOSCN, OCN- and HOCl for 30 min or 
24 h. 
Figure 3.5 shows the structural changes of apoB100 after treatment of LDL with (A) HOSCN, 
OCN- and (B) HOCl for 30 min at 22 oC as detected by SDS-PAGE. The apoB100 band is 
shown as a dark band at 500 kD, which is particularly apparent in the non-treated control. 
Addition of increasing concentrations of HOSCN and OCN- to LDL did not show any 
significant changes in apoB100 stucture with no apparent fragmentation and aggregation 
observed. However, HOCl treatment was very effective in modifying the structural 
conformation of apoB100, showing a marked loss of apoB100 band at 500 kD with 
increasing concentrations of HOCl (50 – 500 μM). At the 250 μM treatment, the apoB100 
was completely lost with increasing formation of a smear distributed throughout the lane. 
These data show the capacity of HOCl to induce fragmentation and aggregation of LDL in a 
non-specific manner. The effect induced by HOCl was observed to be dose-dependent.    
Changes in apoB100 structure were also observed when LDL was exposed to HOSCN, OCN- 
and HOCl for 24 h at 37 oC (Figure 3.6). Addition of increasing concentrations of HOSCN to 
LDL resulted in a slight diminishing of the parent protein band and the formation of lower 
molecular mass fragments below 500 kD. In particular, the formation of a faint band at 100 
kD was observed with increasing concentration of HOSCN treatment (100 – 500 μM), 
consistent with the formation of a specific LDL fragment. Fragments observed just below 
500 kD and the 100 kD band may constitute the loss observed at 500 kD, reflecting 
apoB100 structural changes. The formation of these fragments may be quantified by 
cutting the gel containing the protein fragment and assessed using mass spectrometry. LDL 
modified by OCN- did not show any clear structural changes with no apparent 
fragmentation and aggregation of LDL, and no significant changes observed with the 500 kD 
band. In contrast, the effect of HOCl treatment of LDL for 24 h was similar to that found 
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when LDL was modified for 30 min. HOCl was very effective in modifying the structural 
conformation of apoB100, resulting in the formation of aggregates and fragments. 
 
Figure 3.5 – Fragmentation and aggregation of apolipoprotein B100 observed by SDS-
PAGE under reducing conditions after exposure to (A) HOSCN, OCN- and (B) HOCl for 30 
min. LDL (1 mg protein mL-1) was treated with increasing concentrations of HOSCN (50 – 
500 μM), HOCl (50 – 500 μM), and OCN- (500 – 2500 μM) for 30 min at 22 oC. Prior to 
loading of the LDL samples to the gel, LDL was treated with DTT (50 mM) to keep samples in 
a reduced state. LDL (13 μg protein) was added to each well of the SDS-PAGE gel. LDL was 
separated on Tris-acetate gels (3 – 8 %) with running buffer for 1 h at 150 V. The gels were 
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visualised by Coomassie Blue staining and the parent apoB100 band is represented at ~500 
kD. The experiment was repeated 3 times, each with a different LDL donor and a 
representative gel is shown. 
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Figure 3.6 – Fragmentation and aggregation of apolipoprotein B100 observed by SDS-
PAGE under reducing conditions after exposure to (A) HOSCN, OCN- and (B) HOCl for 24 h. 
LDL (1 mg protein mL-1) was treated with increasing concentrations of HOSCN (50 – 500 
μM), HOCl (50 – 500 μM), and OCN- (500 – 2500 μM) for 24 h at 37 oC. Prior to loading of 
the LDL samples to the gel, LDL was treated with DTT (50 mM) to keep samples in a reduced 
state. LDL (13 μg protein) was added to each well of the SDS-PAGE gel. LDL was separated 
on Tris-acetate gels (3 – 8 %) with running buffer for 1 h at 150 V. The gels were visualised 
by Coomassie Blue staining and the parent apoB100 band is represented at ~500 kD. The 
experiment was repeated 3 times, each with a different LDL donor and a representative gel 
is shown. 
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Characterisation of aggregation and fragmentation of LDL after exposure to isolated 
oxidants was also performed under non-reducing conditions. It was previously observed 
that HOSCN treatment of isolated proteins can cause reversible disulfide formation and 
hence formation of aggregates, which can be reversed on DTT addition. Figure 3.7 shows 
the aggregation and fragmentation of LDL after exposure to (A) HOSCN, OCN- and (B) HOCl. 
There was a significant increase in fragmentation observed with increasing concentrations 
of HOSCN, together with increased staining of high molecular mass material (> 500 kD). 
This is consistent with the formation of reversible aggregates formed by apoB100 exposure 
to HOSCN. Furthermore, formation of a fragment at ~100 kD was also apparent in non-
reduced conditions with increasing concentrations of HOSCN.  
LDL exposure to OCN- resulted in no significant increase in fragmentation and aggregation 
of apoB100, even under non-reducing conditions. This may reflect the specificity of OCN- to 
mediate carbamylation reactions. 
Exposure of LDL to HOCl showed extensive changes in fragmentation and aggregation of 
LDL under non-reduced conditions. There was more aggregation observed in this condition 
compared to the gels run under reducing conditions, showing the formation of reversible 
aggregates mediated by apoB100 amino acid modifications. Fragmentation was also 
apparent in apoB100 run under non-reducing conditions. However, there were no 
significant differences between fragmentation between apoB100 run under non-reducing 
and reducing conditions. Similar to the apoB100 run under reducing conditions, the parent 
band of apoB100 was completely diminished at the highest concentration, indicating the 
high reactivity of HOCl with apoB100. 
Overall, aggregation and fragmentation of apoB100 in reducing and non-reducing 
conditions showed similar outcomes. The main difference was the formation of 
considerable aggregation mediated by the formation of reversible products. Most of the 
aggregates mediated by HOSCN were shown to be reversible, while HOCl showed 
formation of both reversible and non-reversible aggregates consistent with previous data 
[300]. 
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Figure 3.7 – Fragmentation and aggregation of apolipoprotein B100 observed by SDS-
PAGE under non-reducing conditions after exposure to (A) HOSCN, OCN- and (B) HOCl. LDL 
(1 mg protein mL-1) was treated with increasing concentrations of HOSCN (50 – 500 μM), 
HOCl (50 – 500 μM), and OCN- (500 – 2500 μM) for 24 h at 37 oC. LDL (13 μg protein) was 
added to each well of the SDS-PAGE gel. LDL separated on Tris-acetate gels (3 - 8 %) with 
running buffer for 1 h at 150 V. The gels were visualised by Coomassie Blue staining. The 
band at ~500 kD is visualised as the parent apoB100. The experiment was repeated 3 times, 
each with a different LDL donor and a representative gel is shown. 
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The effects of LDL exposure to the MPO/H2O2/Cl
-/SCN- system were also examined. Figure 
3.8 shows the ability of the MPO system to exhibit changes in the structure of apoB100. In 
this case, formation of predominantly HOCl, at 0 μM SCN-, led to a diminished apoB100 
band at 500 kD. Increasing the concentration of SCN- (50 – 200 μM) slowly inhibited the 
effects of structural changes mediated by HOCl, as the oxidant formation shifted more to 
HOSCN. Although the apoB100 band was also diminished at the highest concentration of 
SCN- (200 μM), there was no evidence of fragmentation or aggregation in contrast to the 
studies with HOSCN. This may be related to the ability of MPO to bind to LDL [511], which 
results in the differences in the reactivity of the oxidants, or the lower overall oxidant 
concentration in this case. 
 
 
 
Figure 3.8 – Fragmentation and aggregation of apolipoprotein B100 after exposure to the 
MPO/H2O2/Cl
-/SCN- system. LDL (1 mg protein mL-1) was treated with the MPO system 
containing 100 nM MPO, 200 μM H2O2, 140 mM Cl
- and SCN- (0 – 200 μM) for 24 h at 37 °C. 
Prior to loading of the LDL samples to the gel, LDL was treated with DTT (50 mM) to keep 
samples in reducing conditions. LDL (13 μg protein) was added to each well of the SDS-PAGE 
gel.  LDL was separated on Tris-acetate gels (3 – 8 %) with running buffer (1x) for 1 h at 150 
V. The gels were visualised by Coomassie Blue staining. The band at ~500 kD is visualised as 
the parent apoB100. The experiment was repeated 3 times, each with a different LDL donor 
and a representative gel is shown. 
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3.3.2.3 Chloramine Formation 
The changes in REM and structure of apoB100 after exposure of LDL to HOCl for 24 h 
compared to 30 min may be associated with the generation of reactive chloramines, which 
mediate secondary reactions and contribute to the loss of charged amino acids and 
fragmentation or aggregation. Thus, chloramine formation and stability was assessed using 
the TNB assay (described in section 2.3.3.2). Figure 3.9 shows the formation and stability of 
reactive chloramines over time after exposure of LDL to HOCl (500 μM). On initial exposure, 
350 μM of the HOCl was converted to chloramines, which represents 70 % of the initial 
HOCl dose. The chloramines decompose significantly over time, with almost total loss of 
chloramines seen at 24 h. This is consistent with the chloramines reacting with other 
targets present within LDL causing further changes to the LDL. 
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Figure 3.9 – Formation and decomposition of LDL chloramines after exposure of LDL to 
HOCl. LDL (1 mg protein mL-1) was treated with 500 μM HOCl for 24 h at 37 oC. LDL 
chloramine concentration was assessed using the TNB assay. Initial rate of chloramine 
formation is very rapid (Monochloramine 3.7 x 108 , N-Chloromethylamine 3.0 x 1010 and N-
Chlordimethylamine 3.0 x 1010 [512]. Experiment was repeated 3 times, each with a different 
LDL donor (n = 3). Statistical differences were assessed using one-way ANOVA (Dunnett’s 
posthoc test). ** and *** represented significant (p<0.01 and <0.001) differences compared 
to the incubation control (0 μM). 
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3.3.2.4 Quantification of ApoB100 Cys-residues 
The effect of MPO oxidants on LDL apoB100 was examined in more detail by measuring 
changes to individual amino acid residues. ApoB100 Cys residues were assessed due to the 
reported specificity of HOSCN for these residues [4].  Modification of Cys residues was 
quantified using the ThioGlo1 assay as described in section 2.3.5.4. LDL was exposed to 
increasing concentrations of HOSCN and HOCl for 30 min (0.5 – 10 μM). Figure 3.10 shows 
the loss of Cys residues after exposure of LDL to HOSCN and HOCl. Both HOSCN and HOCl 
exposure resulted in the loss of free Cys residues, with a more dramatic loss seen with 
HOSCN treatment.  Complete consumption of the Cys residues was observed with 5 μM 
HOSCN treatment. In contrast with 5 μM HOCl treatment more than half of free Cys 
residues were left unmodified. These findings are consistent with the ability of HOSCN to 
specifically target Cys residues [4]. 
 
Figure 3.10 – Loss of apolipoprotein B100 cysteine (Cys) residues on exposure to HOSCN 
and HOCl. LDL (1 mg protein mL-1) was treated with increasing concentrations of HOSCN 
(white bars) and HOCl (black bars) at 0.5 – 10 μM with ThioGlo 1 fluorescence used to 
assess Cys loss (384 λEX and 513 λEM ). The concentration of Cys in the non-treated control 
LDL is 0.25 – 0.3 μM. The experiment was repeated 3 times, each with a different LDL donor. 
Statistical differences were assessed using one-way ANOVA (Dunnett’s posthoc test) with * 
and ** representing significant (p<0.05 and <0.01) differences compared to the incubation 
control (0 μM). Two-way ANOVA (Bonferroni’s posthoc test) was conducted to assess 
significant differences between HOSCN and HOCl treatment. ## and ### represent 
significant (p<0.01 and <0.001) difference comparing HOSCN vs HOCl.   
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These studies were extended to quantify free Cys residues after exposure to the 
MPO/H2O2/Cl
-/SCN- system. LDL was initially exposed to the MPO system containing 25 nM 
MPO, 50 μM H2O2, and 0 – 200 μM SCN
- in the presence of Cl- ions (140 mM). In this case, 
extensive loss of Cys residues were observed, which was independent of HOSCN production 
(Figure 3.11). Moreover, the negative controls used when LDL was exposed to the MPO 
system without H2O2 and SCN
-, and the MPO system without H2O2 were also shown to 
significantly decrease Cys residues. This contributes to the notion that the interaction of 
MPO with LDL [511] may contribute to the possible oxidation of Cys residues. Thus, further 
optimisation led to the exposure of LDL to the MPO system containing much lower 
amounts of MPO and H2O2, consistent with the lower oxidant doses used in previous 
experiments with preformed HOSCN and HOCl. LDL was exposed to the MPO system 
containing 5 nM MPO, 10 μM H2O2 and 0 – 200 μM SCN
- for 30 min at 37 oC (Figure 3.12). In 
this case, further losses in Cys residues were observed with increasing SCN- levels. This loss 
of Cys was significant compared to native LDL and the absence of SCN-. This is consistent 
with increased Cys oxidation due to greater HOSCN and reduced HOCl formation. However, 
there were still significant reductions in Cys residues when LDL was exposed to the MPO 
system without H2O2 and SCN
-, and the MPO system without H2O2. 
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Figure 3.11 – Loss of apolipoprotein B100 cysteine (Cys) residues after exposure to the 
enzymatic MPO/H2O2/Cl
-/SCN- system. LDL (1 mg protein mL-1) was treated with the 
enzymatic MPO/H2O2/SCN
- system containing 25 nM MPO, 50 μM H2O2, 140 mM Cl
- and 0 – 
200 μM SCN-. Negative controls were included in the experiment using MPO only, no H2O2, 
and no MPO conditions (black bars). The experiments were repeated 3 times, each with a 
different LDL donor. Statistical differences were assessed using one-way ANOVA (Dunnett’s 
posthoc test). * and *** represent significant (p<0.05 and <0.01) differences compared to 
the LDL treated with the enzymatic MPO system in the absence of SCN- (0 μM). ## and ### 
represent significant (p<0.01 and <0.001) differences compared to the incubation control 
(no MPO/H2O2/Cl
-/SCN-; white bar).   
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Figure 3.12 – Loss of apolipoprotein B100 cysteine (Cys) residues after exposure to the 
enzymatic MPO/H2O2/Cl
-/SCN- system. LDL (1 mg protein mL-1) was treated with the 
enzymatic MPO/H2O2/SCN
- system containing 5 nM MPO, 10 μM H2O2, 140 mM Cl
- and 0 – 
200 μM SCN-. Negative controls were included in the experiment using MPO only, no H2O2, 
and no MPO conditions (black bars). The experiments were repeated 3 times, each with a 
different LDL donor. Statistical differences were assessed using one-way ANOVA (Dunnett’s 
posthoc test). * and *** represent significant (p<0.05 and <0.01) differences compared to 
the LDL treated with the enzymatic MPO system in the absence of SCN- (0 μM). ## and ### 
represent significant (p<0.01 and <0.001) differences compared to the incubation control 
(no MPO/H2O2/Cl
-/SCN-; white bar).   
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3.3.2.5 Quantification of Other ApoB100 Amino Acids 
Other amino acids within apoB100 were also quantified after exposure of LDL to HOSCN, 
HOCl and OCN-. These residues were assessed using HPLC, as described in section 2.3.5.3, 
after delipidation and precipitation of the protein with 9% (w/v) trichloroacetic acid and 
0.027% (w/v) deoxycholic acid, followed by hydrolysis with methanesulfonic acid (MSA). 
The resulting free amino acids were then derivatised with the fluorescent tag OPA, prior to 
HPLC separation. This treatment enables the quantification of the majority of amino acid 
residues with the exception of Cys, which is degraded by the acid hydrolysis conditions. LDL 
was modified for 30 min at 22 °C, or 24 h at 37 °C using HOSCN, HOCl and OCN- (only at 24 
h) prior to hydrolysis.  
Treatment of LDL with HOSCN resulted in a significant loss of Trp after 30 min incubation, 
shown in Figure 3.13. Quantification of the other amino acid residues within apoB100 did 
not show any significant reduction after treatment with HOSCN, consistent with the 
reported specificity of HOSCN [66]. 
In contrast, HOCl exposure resulted in significant losses in Trp, Met, Tyr and Lys, showing its 
greater reactivity with multiple targets within apoB100 [102, 300, 302].  Trp and Met, in 
particular, were readily oxidised by HOCl, with significant loss detected with oxidant 
concentrations of > 100 μM. Loss of Met was reflected by an increase in MetSO formed 
after exposure to HOCl. However, at the higher oxidant concentrations, MetSO appeared to 
be oxidised further, perhaps to methionine sulfone, in accord with previous studies [46]. 
Lys and Tyr were less readily oxidised by HOCl and significant loss of these residues was 
only apparent at HOCl > 500 μM. No loss of parent His was observed, which was 
unexpected given the sensitivity of this residue to HOCl with other proteins. This could be 
associated with the rapid decomposition of His-derived chloramines back to parent His 
residues, given the incubation times of 30 min and 24 h [49].  
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Figure 3.13 – Loss of apolipoprotein B100 amino acid residues after exposure of LDL to 
HOSCN and HOCl for 30 min. LDL (1 mg protein mL-1) was treated with increasing 
concentrations (0 – 750 μM) HOSCN (white bars) and HOCl (black bars) at 22 oC for 30 min. 
(A) Trp, (B) Met, (C) Lys, and (E) Tyr loss were assessed, and formation of (D) MetSO was 
detected using HPLC after MSA hydrolysis and OPA derivatisation. The experiments were 
repeated 3 times, each with a different LDL donor. Statistical differences were assessed 
using one-way ANOVA (Dunnett’s posthoc test). * and ** represent significant (p<0.05 and 
<0.01) differences compared to the incubation control (0 μM). Two-way ANOVA was 
performed to assess significance between HOSCN and HOCl. #, ##, and ### represent 
significant (p<0.05, 0.01, 0.001) difference comparing the reactivity between HOSCN and 
HOCl. 
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Figure 3.14 shows the quantification of amino acid residues after exposure to HOSCN and 
HOCl for 24 h at 37 oC. Trp (A), Met (B), Lys, (C), and Tyr (E) were quantified together with 
the formation of the Met oxidation product, MetSO (D). No evidence was obtained for the 
loss of other amino acid residues under these conditions. Treatment of LDL with HOSCN did 
not result in a significant loss of Trp on 24 h incubation compared to the incubation control 
LDL. This is attributed to extensive degradation of parent Trp residues during the 24 h 
incubation at 37 oC, which may have masked the effect of HOSCN on Trp (70 % of Trp 
parent residues lost comparing 30 min and 24 h). LDL exposure to HOCl resulted in 
modification of Trp, Met, Lys and Tyr residues (Figure 3.14). A similar extent of Met and Trp 
oxidation were observed on incubation of LDL with HOCl for 24 h compared to 30 min. This 
is consistent with the rapid rate of reaction of HOCl with these residues [52]. Furthermore, 
there were no significant increases in MetSO observed, unlike the situation with the 30 min 
exposure. These differences may also be associated with the excessive loss of the parent 
Trp and Met residues seen in the incubation control LDL. In contrast, a more significant 
reduction of Lys and Tyr were observed after treatment of LDL with HOCl for 24 h. Similar 
to the 30 min treatment, incubation of LDL with HOCl for 24 h resulted in modification of 
Lys and Tyr residues only at high oxidant concentrations. Comparatively, modifications of 
Lys and Tyr were greater on incubation of LDL for 24 h than 30 min. This may reflect greater 
modification by chloramines, which are known to play a role in Tyr chlorination [46, 307, 
506, 513]. 
The effect of OCN- on apoB100 residues was also examined. Previous studies have shown 
that exposure of LDL to OCN- results in carbamylation of apoB100 Lys residues [24]. Figure 
3.15 shows the level of Lys residues and the formation of homocitrulline (HCit); the product 
of Lys carbamylation after exposure of LDL to increasing concentrations of OCN-. No 
significant loss in Lys residues was found with the concentratons of OCN- used. However, 
HCit, a product formed from OCN- mediated carbamylation, was formed on treatment of 
LDL with high levels of OCN-. The low levels of HCit detected under the conditions used in 
this study may not result in sufficient Lys modification for an apparent reduction in parent 
Lys residues. Looking at the absolute levels of HCit formed from Lys residues, there were 
only 3 – 4 pmol detected using HPLC, even at high concentrations (1000 μM) of OCN-. 
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Figure 3.14 – Loss of apolipoprotein B100 amino acid residues after exposure of LDL to 
HOSCN and HOCl for 24 h. LDL (1 mg protein mL-1) was treated with increasing 
concentrations (100 – 750 μM) of HOSCN (white bar) or HOCl (black bar) at 37 oC for 24 h. 
(A) Trp, (B) Met, (C) Lys and (E) Tyr loss, and formation of (D) MetSO were quantified using 
HPLC after MSA hydrolysis and OPA derivatisation. The experiments were repeated 3 times, 
each with a different LDL donor. Statistical differences were assessed using one-way ANOVA 
(Dunnett’s posthoc test). * and ** represent significant (p<0.05 and <0.01) differences 
compared to the incubation control (0 μM). Two-way ANOVA was performed to assess 
significance between HOSCN and HOCl. #, ##, and ### represent significant (p<0.05, 0.01, 
0.001) difference comparing the reactivity between HOSCN and HOCl. 
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Figure 3.15 – Quantification of apolipoprotein B100 Lys residues and formation of HCit 
after exposure of LDL to OCN- for 24 h. LDL (1 mg protein mL-1) was treated with increasing 
concentrations (0 – 1000 μM) of OCN- at 37 oC for 24 h. Loss of Lys (white bar) and 
formation of HCit (black bar) was quantified using HPLC after MSA hydrolysis. The 
experiment was repeated 3 times, each with a different LDL donor. Statistical differences 
were assessed using one-way ANOVA (Dunnett’s posthoc test). *** represents significant 
(p<0.001) difference compared to the incubation control (0 μM). 
 
Oxidation of apoB100 amino acid residues were also investigated after exposure of LDL to 
the enzymatic MPO/H2O2/Cl
-/SCN- system. LDL (1 mg protein mL-1) was exposed to the 
enzymatic MPO system containing 100 nM MPO, 200 μM H2O2, 140 mM Cl
- and 0  - 200 μM 
SCN- for 24 h at 37 oC. Most amino acids (except for Cys) were quantified, with only Trp, 
Met, Lys and Tyr showing modifications after treatment with the enzymatic MPO system. 
The formation of MetSO and HCit was quantified to further assess Met and Lys 
modifications, respectively. Figure 3.16 shows the loss of apoB100 amino acid residues 
after exposure to the enzymatic MPO/H2O2/Cl
-/SCN- system. There was no significant loss in 
Trp observed after exposure of LDL to the enzymatic MPO/H2O2/Cl
-/SCN- system. The non-
significant losses observed may be associated with the greater loss of parent Trp residues 
due to the incubation of LDL at 37 °C and the lower amounts of HOCl and HOSCN generated 
in this case. 
There was a significant loss in Met observed when LDL was treated with the enzymatic 
system without addition of SCN-. This condition allows for the generation of HOCl, with Cl- 
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present in the chelex-treated PBS. Introduction of 50 μM SCN- into the enzymatic system 
led to a similar decrease in the levels of Met in apoB100. In this case, HOSCN is formed 
when SCN- competes with Cl- as a substrate for the system. However, this situation would 
still result in a significant amount of HOCl compared to HOSCN. Increasing the 
concentration of SCN- to 100 or 200 μM led to the preservation of the Met residues, with 
no significant loss of Met observed relative to the incubation control. This is associated 
with having much greater production of HOSCN by the enzymatic MPO system as Met is 
not rapidly oxidised by HOSCN [4, 66]. The loss of Met correlated with the formation of 
MetSO. There was significant formation of MetSO observed when LDL was exposed to the 
enzymatic MPO system containing 0 and 50 μM SCN-. In contrast, introducing SCN- at 100 
and 200 μM resulted in no significant formation of MetSO. These results are consistent 
with the results seen with reagent HOCl and HOSCN, where HOSCN did not induce Met 
loss. 
Possible loss of Lys residues and the formation of HCit were also assessed after exposure of 
LDL to the enzymatic MPO/H2O2/Cl
-/SCN- system. In this case, there was no significant 
reduction in Lys observed in all treatments including the MPO system containing 0 μM SCN-
, where HOCl is formed predominantly. No loss of Lys was observed with increasing 
concentrations of SCN- added into the system. Consistent with these observations, there 
was no significant HCit formation observed when LDL was exposed to the enzymatic 
MPO/H2O2/Cl
-/SCN- system, though OCN- has been reported as a by-product of this system 
[24]. 
Potential loss of Tyr was also assessed after exposure of LDL to the enzymatic 
MPO/H2O2/Cl
-/SCN- system, as modification of Tyr by HOCl may be important in the 
development of atherosclerosis, with 3-chloro Tyr being detected in lesion samples [50, 
190]. There was no significant loss of Tyr residues from LDL detected under any of the 
enzymatic MPO/H2O2/Cl
-/SCN- conditions tested, even when the enzymatic MPO system 
contained 0 μM SCN-, where HOCl formation would be expected to predominate. This may 
reflect the lower dose of HOCl produced by the enzymatic MPO system with 200 μM H2O2, 
as significant Tyr oxidation as only seen with > 500 μM reagent HOCl. 
Overall, most amino acid residues, besides Met and Cys, were not lost after exposure of 
LDL to the enzymatic MPO/H2O2/SCN
- system. This may be associated with the limited 
production of HOSCN and HOCl oxidants at the concentrations of the enzymatic MPO 
system used. The loss in Met may be associated with its rapid reaction with HOCl [52, 53]. 
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Figure 3.16 – Loss of apolipoprotein B100 amino acid residues after exposure of LDL to the 
enzymatic MPO/H2O2/Cl
-/SCN- system. LDL (1 mg protein mL-1) was treated with the 
MPO/H2O2/Cl
-/SCN-  system containing 100 nM MPO, 200 μM H2O2 and 0 – 200 μM SCN
- in 
the presence of 140 mM  Cl- ions at 37 oC for 24 h. Trp (A), Met (B), Lys (C), and Tyr (F) loss 
were assessed and formation of MetSO (D) and HCit (E) were detected using HPLC after 
MSA hydrolysis and OPA derivatisation. Negative controls for the experiments were 
included with MPO only, no H2O2 and H2O2 only conditions (black bars). The experiment was 
repeated 3 times, each with a different LDL donor. Statistical differences were assessed 
using one-way ANOVA (Dunnett’s posthoc test). * and ** represent significant (p<0.05 and 
<0.01) differences compared to the incubation control (white bars).  
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3.3.3 Cholesterol and Cholesteryl Ester Modification 
3.3.3.1 Time-dependent Loss of LDL Cholesterol and Cholesteryl 
Esters 
The lipid portion of LDL is mainly composed of cholesterol stored as cholesteryl esters in its 
lipid core. LDL plays a crucial role in the transport of cholesterol from the liver to the 
tissues. Thus, the reactivity of HOSCN with LDL cholesterol and cholesteryl esters was 
assessed and quantified using HPLC. Figure 3.17 shows the loss of (A) cholesteryl linoleate, 
(B) arachidonate, (C) oleate, (D) palmitate, and (E) free cholesterol over time after exposure 
of LDL to 250 μM HOSCN. An incubation control LDL was also included in the experiment to 
investigate the loss observed when LDL is incubated for 24 h at 37 °C (dashed line). In this 
case, there was a significant loss in parent cholesterol and cholesteryl esters with the 
exception of cholesteryl palmitate. There was a loss of cholesteryl linoleate and 
arachidonate observed after treatment of LDL to HOSCN over time. However, this loss was 
only significant relative to the incubation control after 24 h of HOSCN treatment. The levels 
of cholesteryl oleate and cholesterol were also shown to be reduced over time. In this case, 
however, the loss were not significant compared to the incubation control LDL, which 
indicates that the loss observed were mainly associated with the incubation of LDL for 24 h 
at 37 °C. One characteristic feature observed within the results is the initial dip, followed up 
by a hump in the loss of cholesteryl linoleate, arachidonate, oleate and unesterified 
cholesterol after treatment of LDL with HOSCN for 120 min. This change may be related to 
sample processing and that the time courses were run with different samples on different 
days.  
Since the reactivity of LDL cholesteryl esters with HOSCN was mainly significant at 24 h, 
these were shown to be a slow process consistent with previous studies with HOCl [102]. 
Further experiments were performed by incubating LDL with HOCl or HOSCN for 24 h. 
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Figure 3.17 – Time dependent loss of cholesterol and cholesteryl esters after exposure of 
LDL to HOSCN. LDL (1 mg protein mL-1) was treated with 250 μM HOSCN for 24 h at 37 °C. 
Loss (A) Cholesteryl linoleate, (B) cholesteryl arachidonate, (C) cholesteryl oleate, (D) 
cholesteryl palmitate and (E) cholesterol was detected using HPLC after lipid extraction and 
resuspension in mobile phase consisting of 70 % isopropanol and 30 % acetonitrile. An 
incubation control (dotted line) was included to assess background oxidation due to 
incubation at 37 oC for 24 h. The experiments were repeated 3 times, each with a different 
LDL donor. Statistical differences were assessed using one-way ANOVA (Dunnett’s posthoc 
test). * and ** represent significant (p<0.05 and 0.01) difference compared to 0 min. ## 
represent significant (p<0.01) difference compared to untreated LDL incubation control 
(dotted line). 
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3.3.3.2 Dose-dependent Loss of LDL Cholesterol and Cholesteryl 
Esters 
The loss and modification of cholesterol and cholesteryl esters were assessed in HOSCN- 
and HOCl-modified LDL after 24 h treatment. Cholesterol and cholesteryl ester modification 
was quantified using HPLC after treatment of LDL with HOSCN and HOCl (100 – 750 μM) for 
24 h at 37 oC. Figure 3.18 shows the loss of cholesteryl linoleate (A), cholesteryl 
arachidonate (B), cholesteryl oleate (C), cholesteryl palmitate (D) and cholesterol (E) after 
exposure of LDL to HOSCN (white bars) and HOCl (black bars).  
HOSCN exposure resulted in decreases in polyunsaturated cholesteryl esters, exemplified 
by cholesteryl linoleate and arachidonate. Polyunsaturated cholesteryl esters are 
characterised by the presence of double bonds in their fatty acid chains, with cholesteryl 
linoleate and arachidonate having 2 and 4 double bonds, respectively. Significant loss of 
cholesteryl linoleate and arachidonate was observed after treatment of LDL with HOSCN at 
250 μM. Furthermore, HOSCN exposure also resulted in the loss of cholesteryl oleate, a 
monounsaturated cholesteryl ester containing 1 double bond in its fatty acid chain. HOSCN 
was less reactive with cholesteryl oleate, only showing significant loss after treatment of 
LDL with 500 μM HOSCN. HOSCN was unreactive with cholesteryl palmitate, which is a 
saturated cholesteryl ester containing no double bonds in its fatty acid structure. Levels of 
cholesterol were also quantified, with a significant reduction observed at 500 μM HOSCN 
treatment, but no other concentration including higher levels. Thus, the observed 
difference may likely be a statistical aberration. 
HOCl treatment also resulted in decreased concentrations of cholesteryl esters present 
within LDL. The polyunsaturated cholesteryl esters, exemplified by cholesteryl linoleate and 
arachidonate, were significantly reduced after the treatment of LDL with HOCl. Significant 
reduction was observed in cholesteryl linoleate and arachidonate at 500 and 750 μM HOCl 
treatments, respectively. Cholesteryl oleate was also a target for HOCl-mediated lipid 
oxidation, with significant loss observed at 750 μM HOCl treatment. The saturated 
cholesteryl ester, cholesteryl palmitate, and cholesterol were not lost after exposure of LDL 
to HOCl. 
Collectively, both isolated HOSCN and HOCl were reactive with the unsaturated cholesteryl 
esters of LDL. Comparatively, there were no significant differences between the loss of 
unsaturated cholesteryl esters after exposure to HOSCN and HOCl at the same dose.  
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Figure 3.18 – Loss of cholesteryl linoleate and arachidonate after exposure of LDL to 
HOSCN and HOCl for 24 h. LDL (1 mg protein mL-1) was treated with increasing 
concentrations (100 – 750 μM) of HOSCN (white bars) and HOCl (black bars) for 24 h at 37 
°C. (A) Cholesteryl linoleate, (B) cholesteryl arachidonate, (C) cholesteryl oleate, (D) 
cholesteryl palmitate and (E) cholesterol was detected using HPLC after lipid extraction and 
resuspension in mobile phase consisting of 70 % isopropanol and 30 % acetonitrile. 
Cholesteryl stearate was not detected in LDL samples. The experiment was repeated 3 
times, each with a different LDL donor. Statistical differences were assessed using one-way 
ANOVA (Dunnett’s posthoc test). * and ** represents significant (p<0.05 and <0.01) 
differences compared to the incubation control (0 μM). Two-way ANOVA was performed to 
compare reactivity of HOSCN and HOCl to cholesterol and cholesteryl ester, but no 
significant difference was observed. 
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Cholesterol and cholesteryl ester modification were also investigated after exposure to the 
enzymatic MPO/H2O2/Cl
-/SCN- system. LDL (1 mg protein mL-1) was exposed to the MPO 
system consisting of 100 nM MPO, 200 μM H2O2, 140 mM Cl
- and 0 – 200 μM SCN-. Figure 
3.19 shows the loss of cholesteryl linoleate (A), cholesteryl arachidonate (B), cholesteryl 
oleate (C), cholesteryl palmitate (D), and cholesterol (E) after exposure to the 
MPO/H2O2/Cl
-/SCN- system. A significant loss of cholesteryl linoleate was observed after 
exposure of LDL to the enzymatic system. The other cholesteryl esters assessed and 
cholesterol itself did not show significant changes after exposure to the MPO system. 
Formation of HOSCN by the enzymatic MPO system with increasing concentrations of SCN- 
resulted in the loss of cholesteryl linoleate, which was consistent with previous studies 
performed with isolated HOSCN. However, the loss in cholesteryl arachidonate was not 
shown to be significant. Negative controls used, including MPO only, no H2O2 and no MPO 
contributed to any loss in cholesterol and cholesteryl ester, showing the contribution of 
HOSCN and SCN- derived oxidants in mediating modification of cholesteryl linoleate.  
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Figure 3.19 – Loss of cholesteryl linoleate and arachidonate after exposure of LDL to the 
enzymatic MPO/H2O2/Cl
-/SCN- system. LDL (1 mg protein mL-1) was treated with the 
enzymatic MPO system containing 100 nM MPO, 200 μM H2O2 and 0 – 200 μM SCN
- in the 
presence of 140 mM Cl- ions for 24 h at 37 oC. Negative controls were included in the 
experiment using MPO only, no H2O2, and no MPO conditions. The experiment was repeated 
3 times, each with a different LDL donor. Statistical differences were assessed using one-
way ANOVA (Dunnett’s posthoc test). * and ** represents significant (p<0.05 and <0.01) 
differences compared to the incubation control (white bar). 
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3.3.3.3 Quantification of Lipid Oxidation Products 
Lipid oxidation is a process that may occur in the development of atherosclerosis, with 
evidence supporting the presence of lipid oxidation products including oxysterols and 
oxidised polyunsaturated fatty acids [514-517]. Exposure of LDL to HOSCN and HOCl 
showed reduction of the parent cholesteryl linoleate and arachidonate. Thus, initial 
experiments were performed to assess the conversion of parent cholesteryl esters into lipid 
hydroperoxides (LOOH). LOOH were assessed using a commercial LOOH assay kit (refer to 
section 2.3.5.6). Figure 3.20A shows the formation of LOOH after exposure of LDL to 
HOSCN and HOCl for 24 h at 37 oC. Exposure of HOSCN to LDL resulted in a significant 
increase in LOOH compared to LDL incubated in the absence of oxidant. Significant 
formation was observed at low oxidant levels (50 μM HOSCN). In contrast, there was no 
significant increase in LOOH detected on reaction of LDL with HOCl, even at the highest 
concentration (750 μM) examined.  
Additional studies into the characterisation of LDL lipid oxidation products were conducted 
by assessing the formation of 9-hydroxy-10E,12Z-octadecadienoic acid (9-HODE). 9-HODE is 
a product derived from the oxidation of cholesteryl linoleate. 9-HODE has been detected in 
isolated lesion samples, which has contributed to the notion that the presence of lipid 
oxidation processes may be important in the development of lipid plaques in 
atherosclerosis [319, 518-523]. Both HOSCN and HOCl were shown to decrease cholesteryl 
linoleate levels after exposure to LDL for 24 h. Thus, 9-HODE was assessed using HPLC 
under these treatment conditions. Figure 3.20B shows the formation of 9-HODE after 
exposure to increasing concentrations of HOSCN and HOCl for 24 h at 37 oC. There was a 
significant increase in 9-HODE formation after exposure to HOSCN. Similarly to the LOOH 
results, this increase was significant after exposure of LDL to 50 μM HOSCN.  Exposure of 
HOCl to LDL under identical conditions, however, did not show any increases in 9-HODE 
formation, reflecting the findings found during LOOH detection. 
 
The formation of F2-isoprostanes was also quantified to assess the extent of lipid 
modification mediated by HOSCN. F2-isoprostanes are regarded as the gold standard lipid-
derived biomarker indicative of oxidative stress in vivo [497]. These products have also 
been found in isolated atherosclerotic lesions [496] and to be elevated in patients with 
cardiovascular disease (reviewed in [524]). Figure 3.20C shows the formation of F2-
isoprostanes after exposure of LDL to HOSCN and HOCl for 24 h at 37 oC. These 
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experiments were performed in collaboration with Prof. Kevin Croft and Dr. Julie Proudfoot 
at the University of Western Australia. A significant dose-dependent formation of F2-
isoprostanes was detected after exposure of LDL to increasing concentrations of HOSCN. 
However, due to high variability between samples, significant changes were only apparent 
after treatment of LDL with 250 μM HOSCN. As with lipid hydroperoxide and 9-HODE 
formation, HOCl treatment of LDL did not contribute to lipid oxidation with no significant 
increases in F2-isoprostane formation compared to the incubation control. 
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Figure 3.20 – Formation of lipid oxidation products after exposure of LDL to HOSCN and 
HOCl. LDL (1 mg protein mL-1) was treated with increasing concentrations (0 – 500 μM) of 
HOSCN (white bars) and HOCl (black bars) for 24 h at 37 oC. Formation of lipid 
hydroperoxides (A), 9-HODE (B) and F2-isoprostanes (C) were detected after LDL oxidation. 
The experiments were repeated 3 times, each with a different LDL donor. Statistical 
differences were assessed using one-way ANOVA (Dunnett’s posthoc test). * and ** 
represent significant (p<0.05 and <0.01) differences compared to the incubation control (0 
μM). Two-way ANOVA was performed to compare reactivity of HOSCN and HOCl. # and ## 
shows significant (p<0.05, 0.01) differences comparing HOSCN and HOCl treatment. 
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Earlier, the reactivity of HOSCN with cholesterol and cholesteryl esters over time was 
assessed, where a time-dependent loss of cholesteryl linoleate was observed on treating 
LDL with HOSCN. Thus, the formation of 9-HODE was also quantified over time using HPLC. 
Figure 3.21 shows the formation of 9-HODE over time after exposure to HOSCN for 24 h. 
There was a time-dependent increase in 9-HODE formed after exposure to the oxidant, 
reaching significance after 60 min and up to 24 h incubation. In contrast, incubation control 
LDL after 24 h showed no significant difference compared to the initial control at 0 min. 
This indicates that formation of 9-HODE over time is independent of the incubation 
conditions that were employed (24 h at 37 oC). 
 
 
 
Figure 3.21 – Time dependent formation of 9-HODE after exposure of LDL to HOSCN. LDL 
(1 mg protein mL-1) was treated with 250 μM HOSCN for 24 h at 37 °C. Formation of 9-HODE 
was quantified using HPLC after lipid extraction using methanol:hexane. Incubation control 
(dotted line) was included after 0 and 24 h incubation. The experiments were repeated 3 
times, each with a different LDL donor. Statistical differences were assessed using one-way 
ANOVA (Dunnett’s posthoc test). *** represents significant (p<0.001) difference compared 
to 0 min. Two way-ANOVA was also performed to assess significance comparing HOSCN 
treated LDL to non-treated LDL after 24 h incubation. ### represent significant (p<0.001) 
difference comparing HOSCN-treated and non-treated LDL after 24 h. 
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The formation of lipid oxidation products was also observed when LDL was exposed to the 
enzymatic MPO/H2O2/Cl
-/SCN- system. LDL (1 mg protein mL-1) was exposed to the 
enzymatic MPO system containing 100 nM MPO, 200 μM H2O2, and 0 – 200 μM SCN
- in the 
presence of 140 mM Cl- ions. Figure 3.22A shows the formation of LOOH after exposure of 
LDL to the enzymatic MPO system. At 0 μM SCN-, with HOCl being formed predominantly, 
there was no significant increase in LOOH formed. Addition of SCN- into the enzymatic MPO 
system resulted in a significant increase in LOOH formed. However, the concentration of 
LOOH was shown to be inversely correlated, with the initial SCN- concentration at 50 μM 
giving the highest yield of LOOH and 200 μM SCN- resulting in lower yields of LOOH. 
Negative controls represented by MPO only and MPO/SCN- in the absence of H2O2 led to no 
significant increase in LOOH formation. Control incubations in the absence of MPO but in 
the presence of 200 μM H2O2 and 200 μM SCN
- resulted in a large extent of peroxidation, as 
H2O2 either induced lipid peroxidation or possibly interferes in the assay. 
9-HODE formation was also investigated after exposure to the enzymatic MPO/H2O2/Cl
-
/SCN- system. Figure 3.22B shows the formation 9-HODE after exposure to the enzymatic 
MPO/H2O2/Cl
-/SCN- system for 24 h at 37 oC. In this case, there was an increase in 9-HODE 
after exposure to the MPO system without SCN-, due to the reaction of LDL with HOCl. In 
this case, HOCl may be produced at high concentrations with 140 mM Cl- ions available to 
be used as a substrate from the chelex-treated PBS. Increasing the concentration of SCN- 
resulted in the formation of HOSCN, and these SCN--derived oxidants led to a further 
increase in 9-HODE formation, which was significant compared to the exposure of the MPO 
system with 0 μM SCN-. Further increases in SCN- did not contribute to further increases in 
9-HODE, which was similar to findings observed with isolated oxidants, where lipid 
oxidation was not shown to be entirely dose-dependent, especially at concentrations > 250 
μM. Similar to LOOH formation, the control incubations in the absence of MPO but in the 
presence of H2O2 and SCN
- also resulted in a large extent of peroxidation. 
Overall, the exposure of MPO-derived oxidants, either using an isolated oxidant (HOSCN 
and HOCl) or using an enzymatic MPO/H2O2/Cl
-/SCN- system led to modifications of 
cholesterol and cholesteryl esters present within LDL, which was mainly associated with the 
loss of polyunsaturated cholesteryl esters. The monounsaturated cholesteryl ester, 
represented by cholesteryl oleate, was affected at a lesser extent. Lipid oxidation products 
were also generated after exposure to MPO-derived oxidants. In this case, formation of 
these products were only associated with HOSCN exposure, while LDL exposure to HOCl did 
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not contribute as significantly to the formation of lipid oxidation products. For the first 
time, it is shown that isolated HOSCN can react with lipids, which contributes to the 
formation of lipid peroxidation products. Further experiments were therefore performed to 
elucidate the mechanism of HOSCN reactivity to lipids in more detail. 
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Figure 3.22 – Formation of lipid oxidation products after exposure of LDL to the enzymatic 
MPO system. LDL (1 mg protein mL-1) was treated with the enzymatic MPO containing 100 
nM MPO, 200 μM H2O2 and 0 – 200 μM SCN
- in the presence of 140 mM Cl- ions for 24 h at 
37 oC. Formation of lipid hydroperoxides and 9-HODE was assessed upon LDL oxidation. 
Negative controls were included in the experiment using MPO only and MPO/SCN- in the 
absence of H2O2, and H2O2 only (black bars). The experiment was repeated 3 times, each 
with a different LDL donor. Statistical differences were assessed using one-way ANOVA 
(Dunnett’s posthoc test). ** and *** represent significant (p<0.01 and <0.001) differences 
compared in the absence of SCN-. 
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3.3.4 Mechanism of Lipid Oxidation by HOSCN 
3.3.4.1 Role of Iron in HOSCN-induced Lipid Oxidation 
The mechanism by which HOSCN induced lipid peroxidation in the absence of the 
peroxidase enzyme is not clear, given HOSCN is a 2-electron oxidant and hence not 
expected to initiate lipid hydroperoxide, 9-HODE or F2-isoprostane formation [494]. At 
physiologically relevant concentrations, HOSCN is an unstable oxidant that degrades over 
time to generate other reactive species that may promote lipid oxidation within LDL. 
Moreover, mM levels of HOSCN were generated from the heme peroxidase enzyme, LPO, 
for the studies with isolated oxidants. It is possible that this high level of HOSCN caused 
iron release from the LPO heme, analogous to that reported for HOCl [525]. The presence 
of this transition metal ion may contribute to HOSCN-induced lipid oxidation. In these 
experiments, the free radical scavenger, BHT and a transition metal chelator, 
desferrioxamine (DFO), were used to examine the lipid oxidation mechanism of HOSCN in 
more detail. 
LDL (1 mg protein mL-1) was exposed to increasing concentrations of HOSCN (0 – 250 μM) 
for 24 h in the presence or absence of either 200 μM BHT or 50 μM DFO. Formation of 
LOOH, 9-HODE and F2-isoprostanes were assessed. Figure 3.23A shows the formation of 
LOOH by HOSCN and the attenuation of these species after exposure to BHT and DFO. In 
the absence of BHT or DFO, there was a significant increase in LOOH formed after exposure 
of LDL to HOSCN. Treatment of LDL in the presence of BHT (black bars) showed complete 
attenuation of the lipid oxidation process mediated by HOSCN. Adding DFO prior to 
exposure of LDL to HOSCN also resulted in a significant attenuation of lipid oxidation. The 
effect mediated by DFO was not as pronounced in terms of prevention of lipid 
hydroperoxide formation compared to BHT, with a significant difference observed when 
LDL was exposed to 250 μM HOSCN. The difference between the inhibitory effect of BHT 
and DFO may be associated with the dose used. In this case, BHT were introduced at a 
higher concentration (200 μM) compared to DFO (50 μM). 
Formation of 9-HODE was also assessed using HPLC after treatment of LDL in the presence 
or absence of BHT and DFO. Figure 3.23B shows the formation of 9-HODE by HOSCN and 
the attenuation of 9-HODE formation after treatment of LDL with BHT and DFO. There was 
an increase in 9-HODE observed after treatment of LDL with HOSCN. This effect was 
completely attenuated on incubation of LDL with HOSCN in the presence of BHT. DFO was 
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also effective in reducing the formation of 9-HODE after exposure of LDL to HOSCN. 
However, the inhibitory effect of BHT was more potent compared to DFO, which was found 
to be significantly different when LDL was exposed to 250 μM HOSCN. 
The effect of BHT and DFO in inhibiting lipid oxidation processes was also investigated by 
examining the formation of F2-isoprostanes. F2-isoprostanes were assessed using gas 
chromatography after exposure of LDL to HOSCN, again in the presence and absence of 
BHT and DFO. Figure 3.23C shows the formation of F2-isoprostanes by HOSCN and the 
reduction of these species in the presence BHT and DFO. There was an increase in F2-
isoprostanes observed after exposure of LDL to HOSCN in the absence of BHT and DFO. 
Addition of BHT prior to HOSCN exposure, however, resulted in the attenuation of the lipid 
oxidation mediated by HOSCN. The reduction in F2-isoprostanes was highly significant 
(p<0.001) when LDL was treated with 250 μM HOSCN. Treating LDL with HOSCN in the 
presence of DFO also led to the attenuation of the lipid oxidation process mediated by 
HOSCN. This effect was particularly seen when LDL was exposed to 250 μM HOSCN.  
Given the efficacy of DFO in reducing lipid peroxidation in LDL treated with HOSCN, UV-VIS 
studies of the LPO/H2O2/SCN
- system used to generate HOSCN were performed to examine 
iron release from LPO. Figure 3.24 shows the change in the UV-VIS spectrum of LPO (50 
μM) on addition of aliquots of H2O2 (3.75 mM) one minute apart in the presence of SCN
- 
(7.5 mM). There was a small decrease in the LPO Soret band at 412 nm, with a new 
absorbance observed at 376 nm with increasing H2O2. This is consistent with the formation 
of OSCN-, rather than heme destruction [5, 84, 526]. Compound I or compound II formation 
was not observed in the spectra with it being short lived and excess SCN- can influence the 
regeneration of the native ferric LPO [5, 84, 526]. In Fig 3.23B, it was demonstrated that 
there is a small loss of the LPO, which may be due to heme destruction and iron release. In 
this case, ~0.5 μM was lost from the 50 μM LPO (i.e. ~1%) used in the preparation of 
HOSCN. 
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Figure 3.23 – Formation of lipid oxidation products by HOSCN after supplementation of 
LDL with butylated hydroxytoluene (BHT) and desferroxamine (DFO). LDL (1 mg protein 
mL-1) was treated with increasing concentrations (100 – 250 μM) of HOSCN with or without 
supplementation with BHT (200 μM; black bars) and DFO (50 μM; stripped bars) for 24 h at 
37 °C.  Experiment was repeated 3 times, each with a different LDL donor (n = 3). Statistical 
differences were assessed using two-way ANOVA (Bonferroni’s posthoc test) to compare 
formation of lipid oxidation products with or without BHT or DFO. * represents significant 
(p<0.05) difference comparing LDL exposed HOSCN in the presence of BHT vs 
desferroxamine. #, ## and ### represent significant (p<0.05, 0.01 and 0.001) difference 
comparing LDL exposed to HOSCN without BHT and desferroxamine vs LDL exposed to 
HOSCN with BHT or desferroxamine. 
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Figure 3.24 – UV-VIS spectrum of the enzymatic LPO/H2O2/SCN
- system detected between 
350 to 650 nm. The enzymatic LPO/H2O2/SCN
- was examined by UV/VIS spectroscopy after 
incubation of LPO (1.5 – 2 μM) with hydrogen peroxide (H2O2; 3.75 mM) added in 5 aliquots 
a minute apart in the presence of sodium thiocyanate (NaSCN; 7.5 mM) in 10 mM 
potassium phosphate buffer (pH 6.6) for 15 min. Solid line: (A) shows the spectrum before 
addition of H2O2 to the mixture of LPO and SCN
- (B) shows the spectrum after the first H2O2 
aliquot, (C) shows the spectrum after second H2O2 aliquot, (D) shows the spectrum after 
third H2O2 aliquot, (E) shows the spectrum after fourth H2O2 aliquot, (F) shows the spectrum 
after fifth H2O2 aliquot and (G) shows the spectrum after incubation for 15 min. Dashed 
lines: represents the negative control without addition of H2O2 Changes in UV-VIS spectrum 
was detected between 350 and 650 nm. Ferric (Fe3+) LPO is detected at 412 nm.  
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3.4 Discussion 
3.4.1 ApoB100 Modification 
LDL modification by MPO-derived oxidants was initially examined by assessing changes in 
the apoB100 protein component of LDL. Functionally, the presence of apoB100 allows for 
the recognition of LDL by the LDL receptor, leading to its regulation and storage in the liver 
[254]. In the pathogenesis of atherosclerosis, the modifications on apoB100 have been 
associated with decreased recognition by the LDL receptor and in turn, these changes also 
allowed recognition by scavenger receptors present within macrophages [527]. In this case, 
increased recognition and binding of these modified particles results in excessive and 
uncontrolled uptake of LDL within macrophage cells [212, 280, 302, 337]. Uncontrolled 
accumulation of LDL in macrophage cells gives rise to a foamy appearance, and thus, these 
cells are referred to as foam cells [212].  
Exposure of LDL to HOSCN, HOCl and OCN- results in the modification of apoB100, which 
was exemplified by modifications observed in apoB100 charge and structure. All modified 
forms of LDL led to changes in REM of LDL, indicative of changes in particle charge, relative 
to the control. Modification of apoB100 charge is associated with the loss of positively 
charged amino acids, including Lys and His residues. Out of all forms of LDL examined in 
this study, HOCl-modified LDL showed the greatest change in REM, consistent with the 
modifications of several amino acid residues including Lys residues. Although there was no 
significant loss in His observed, a significant loss of Lys and corresponding formation of 
chloramines was observed, which may contribute to the extensive changes observed in 
REM.  
A number of studies have investigated the effects of HOCl on LDL modification (e.g. [302, 
305, 306]), most of which are consistent with the data obtained in the current study with 
regard to the quantification of Met, Cys, Lys and Tyr residues. Previous studies showed that 
exposure of LDL to HOCl or the enzymatic MPO/H2O2/Cl
- system leads to similar changes in 
apoB100, indicating that the formation of HOCl by the enzyme is the likely source of the 
oxidative process [102]. It was previously shown that exposure of LDL to HOCl can result in 
extensive changes to LDL REM, attributed to the loss of positively charged amino acid 
residues [302, 305, 306]. In these studies, it was shown that Lys and His were readily 
modified after exposure of LDL to HOCl [302, 305, 306]. This was not completely consistent 
with the data obtained in the present study, which showed only the loss of Lys residues. 
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However, the previous and current studies differ in molar excess ratio between the oxidant 
and lipoprotein molecule. The present study has used a lower molar excess of HOCl : LDL (≤ 
100 : 1) compared to earlier studies with the ratio between 100 and 800 fold molar 
excesses of oxidant [102, 300, 302, 317, 416]. Realistically, the amount of HOCl that may be 
present within lesions would be around the mM levels with the presence of plasma Cl- ions 
at 100 mM [528]. Comparatively, the predicted levels of HOSCN and OCN- in vivo are lower 
compared to HOCl. In this case, the amount of SCN- is ~ 50 μM with non-smokers, which 
can increase up to 250 μM with heavy smokers [327]. Furthermore, OCN- exists in 
equilibrium with urea in plasma, which is particularly elevated in patients with renal 
disease and premature atherosclerosis [329]. It has been reported that plasma urea in 
hypertensive patients can be elevated up to 6 – 8 mM [529], though plama cyanate exist in 
the plasma at a much lower concentration at ~140 nM [530].  Although the realistic levels 
of HOSCN in vivo are very low at μM levels, it is important to note that HOCl can be 
converted to HOSCN in the presence of SCN- [22, 23]. 
HOSCN and OCN- did not induce such dramatic changes in REM, however, the changes were 
still observed to be significant. Unlike HOCl, the reactivity of LDL with HOSCN has not been 
studied in detail previously. It is shown here that HOSCN reacts slowly with LDL over 24 h, 
with only a small proportion of the initial oxidant consumed by LDL on shorter incubation 
times, which contrasts with the reactivity of HOCl. The minimal loss of positively charged 
amino acids detected using HPLC may account for the small change in REM. Previous 
studies have indicated that HOSCN exposure to isolated proteins can contribute to the loss 
of Lys and His residues [66]. Moreover, Lys may also be a possible target that results in the 
formation of amino thiocyanate (RN-SCN) species. Although these were not demonstrated 
to be stable on proteins [92], they have been reported to be formed in experiments using 
poly-Lys [66]. A source of Lys modification associated with the formation of HOSCN is the 
decomposition of this oxidant to OCN-. OCN- exposure was postulated to extensively 
change the REM of LDL, via its ability to carbamylate Lys residues [24]. Previous studies 
showed that both reagent OCN- and the enzymatic MPO/H2O2/SCN
- system can contribute 
to the loss of Lys residues via the formation of HCit [24]. However, the present study only 
showed small change in REM and minimal formation of HCit with no clear modification of 
parent Lys residues, which was not consistent with the previous study showing more 
dramatic changes in carbamylated Lys residues [24]. There are, however, differences 
between the previous and current studies with these being mainly associated with 
differences in the time and concentration of OCN- used to induce carbamylation. Moreover, 
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the compositions of the enzymatic MPO/H2O2/SCN
- used in both studies were significantly 
different, with the present study utilising higher concentrations (at least 2-fold). These 
differences may have influenced the formation of SCN- derived oxidants and the 
decomposition of HOSCN to OCN-. 
Changes in structure were also investigated using SDS-PAGE electrophoresis. Similar to 
particle charge modification, HOCl exposure led to significant alteration of apoB100 
structure, showing extensive aggregation and fragmentation of apoB100 band at 500 kD, 
which was demonstrated under both reducing and non-reducing conditions. The similar 
effects seen under both conditions highlight the irreversible fragmentation and aggregation 
of proteins that occurred during HOCl treatment. Changes in apoB100 structure through 
aggregation and fragmentation are associated with the modification of amino acid residues 
in apoB100. LDL exposure to HOCl led to extensive loss of Cys, Met, Trp, Lys, and Tyr 
residues. Aggregation and fragmentation of apoB100 is associated with the cleavage or 
crosslinking of these or other amino acids. Structural changes were also observed in 
previous studies looking at the effects of HOCl on LDL. Extensive aggregation of proteins 
was observed when LDL was exposed to HOCl at high molar excess [300, 304]. Different 
mechanisms were proposed to contribute to the aggregation of apoB100. One explanation 
is associated with the formation of dityrosine after oxidation of Tyr residues into tyrosyl 
radicals [304, 307]. Another explanation is related to the oxidation of Lys residues, forming 
chloramines. Chloramines derived from Lys were found to hydrolyse into aldehydes in 
which the carbonyl group can further react, causing crosslinks through Schiff base 
formation [302, 531]. Lastly, crosslinks were also associated with sulfenamide formation, 
involving thiol groups, Lys and Arg residues [532]. Collectively, these mechanisms were 
postulated to contribute to the aggregation of apoB100 on exposure of LDL to HOCl, which 
is consistent with the data obtained in the present study. Moreover, quantification of 
apoB100 amino acid residues showed significant loss of Cys, Lys and Tyr, all of which may 
contribute to the mechanisms outlined above. Extensive fragmentation represented by the 
smear of protein bands under 500 kD may be associated with loss of other amino acids in 
the apoB100 structure. 
Structural modification of apoB100 mediated by HOSCN and OCN- did not result in such 
marked changes. Modification of LDL by HOSCN under non-reducing conditions showed 
extensive aggregation of apoB100 with the formation of an aggregate smear of protein 
bands above 500 kD. This was not detected on gels run under reducing conditions. This 
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indicates that the formation of aggregates is reversible on addition of a reducing agent 
(DTT) consistent with the formation of reversible disulfide (S-S) crosslinks, which have been 
reported previously on treatment of proteins with HOSCN [4, 65].  Interestingly, exposure 
of LDL to HOSCN with analysis under both reducing and non-reducing conditions resulted in 
a specific cleavage of the apoB100 protein, with the appearance of a fragment at ~90 kD 
observed. This effect of HOSCN has not been reported previously. This fragmentation may 
be associated with the loss of Cys and/or oxidation of Trp residues. Structural changes in 
LDL mediated by HOSCN and OCN- have not been previously reported in the literature. 
However, experiments with other isolated proteins showed that HOSCN can specifically 
target Cys and Trp residues [65, 66, 87, 91], which may contribute to this specific 
fragmentation of LDL.  
The difference between the reactivity of HOSCN and HOCl with LDL and the observed 
structural changes of apoB100 may be associated with the reported specificity of these 
oxidants. As previously mentioned, HOSCN reacts specifically with Cys and Trp residues [4, 
66], while HOCl reacts extensively with multiple amino acid residues present in proteins 
[45]. This effect is reflected in the experiments with the exposure of LDL to the enzymatic 
MPO/H2O2/Cl
-/SCN- system and the assessment of structural changes in apoB100. In this 
case, the presence of SCN- partially prevented the extensive aggregation and fragmentation 
of apoB100 and associated oxidation of amino acids, particularly Met, induced by HOCl. 
3.4.2 Cholesterol and Cholesteryl Ester Modification 
Lipid modification is a process that may be potentially important in the development of 
atherosclerosis, with extensive evidence for this process in atherosclerotic lesions [514]. 
Lipid peroxidation products associated with human lesions include oxidised forms of 
polyunsaturated fatty acids [533-535], chlorinated lipids [106, 109, 311, 536] and oxysterols 
[507, 508, 537-542]. Thus, investigation of the ability of MPO-derived oxidants to induce 
LDL lipid peroxidation was also investigated. The present study demonstrated that HOCl 
and particularly HOSCN may contribute to lipid modification within LDL, and particularly 
the loss of unsaturated cholesteryl esters. Loss of monounsaturated cholesteryl ester, 
oleate, and unesterified cholesterol were also observed during incubation, which reflect 
LDL aggregation rather than oxidantation, as results are comparable with repeat 
experiments using different LDL donors. It is unlikely to be due to sample loss as the results 
are normalised to protein concentration in each case.  
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LDL exposure to HOCl led to a decrease in unsaturated cholesteryl esters, exemplified by 
the loss of cholesteryl linoleate, arachidonate and oleate. These findings are similar to a 
previous report investigating the ability of HOCl to modify unsaturated fatty acids [102]. 
LDL exposure to HOCl at high molar excess (100 – 400 fold) resulted in the loss of 
unsaturated fatty acids present within phospholipids [102]. Previous studies have shown 
that lipid peroxidation products were formed when LDL is exposed to HOCl, with evidence 
of hydroperoxide and conjugated diene formation [543, 544]. However, the present study 
did not demonstrate formation of lipid peroxidation products, such as the formation of 
lipid hydroperoxides (LOOH), and the oxidation products 9-HODE and F2-isoprostanes. Loss 
of unsaturated fatty acids by HOCl may also be attributed to the formation of chlorohydrins 
[107, 108, 111, 536]. Chlorohydrins involve the addition of Cl+ to the double bonds present 
within unsaturated fatty acids of cholesteryl esters and phospholipids [107, 108, 111, 536]. 
Exposure of phosphatidylcholine to HOCl was shown to target oleic, linoleic and 
arachidonic acids, resulting in the formation of mono- and bischlorohydrin isomers [310]. 
Thus, it is postulated that the loss observed in unsaturated cholesteryl esters may be 
associated with the formation of chlorohydrins, instead of lipid peroxidation. This 
observation is consistent with previous study performed by Jerlich et al. [110]. In this study, 
chlorohydrin and peroxide formation were compared on exposure of LDL phospholipids to 
μM amounts (< 100x molar excess) of isolated HOCl or the enzymatic MPO/H2O2/Cl
- 
system. It was reported that chlorohydrins were formed on LDL phospholipids and that no 
lipid hydroperoxides were formed [110]. The main differences between these previous 
studies showing lipid peroxidation, and the present study is the concentrations of HOCl 
used to modify the LDL. Exposure of HOCl at high molar excess (100 – 400 fold; i.e. >μM 
levels) may initiate lipid peroxidation, in addition to chlorohydrin formation, via formation 
of radicals derived from the secondary reactions of apoB100-derived chloramines [102]. 
Despite the evidence for a role for HOCl in lipid peroxidation, the mechanism proposed is 
controversial with no radicals observed when HOCl interacts with double bonds on 
unsaturated phospholipids [543, 544]. However, peroxyl radical formation was observed 
when HOCl reacts with existing LDL lipid hydroperoxides [545-549]. Thus, exposure of 
linoleic acid hydroperoxides to HOCl resulted in the formation of peroxyl radicals and 
singlet molecular oxygen (|O2) [550]. This mechanism may explain the onset of lipid 
peroxidation mediated by HOCl exposure. However, at lower more physiologically and 
pathologically relevant concentrations, at 50 – 100 x molar excess, chloramine formation 
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may not be sufficient to initiate significant lipid peroxidation. Furthermore, the reactivity of 
HOCl with LDL is associated with a preferential reaction with the apoB100 protein. 
In previous studies, HOCl was also shown to target free cholesterol, which results in the 
formation of 5,6-epoxides, 4-hydroxycholesterol, hydroxyl- and keto-derivatives [107]. 
However, loss of free cholesterol was not observed when LDL was exposed to HOCl in the 
present study. Thus, formation of cholesterol-derived products by HOCl was not assessed. 
Lipid peroxidation has also been observed previously in a study investigating LDL 
modifications after exposure to an enzymatic MPO/H2O2/SCN
- system. In this case, radical 
formation was linked to lipid peroxidation processes with inhibition reported after addition 
of ascorbic acid, which acts as a radical scavenger [82]. However, the exact mechanism of 
lipid peroxidation, whether it comes from the production of HOSCN/OSCN or via SCN- 
acting as a peroxidase substrate, is still unclear [82]. It is not expected that a 2-electron 
oxidant, such as HOSCN, can induce radical modification of LDL lipids. Previously, it has 
been proposed that the formation of radicals from the peroxidase cycle rather than 
halogenation of MPO and SCN- oxidation could contribute to the loss of lipids [89, 494]. In 
this case, a 1-electron oxidation product, thiocyanyl radical (SCN
.
), and the formation of 
protein radical species on MPO was suggested to be responsible for lipid modification [89, 
494]. Another possibility is via the oxidation of Tyr, Trp and Cys residues by Compound I or 
II, which is mediated the peroxidase cycle. In the present study, both isolated HOSCN and 
the enzymatic MPO/H2O2/SCN
- system exposure to LDL led to the loss of unsaturated 
cholesteryl esters, with the subsequent formation of hydroperoxides and the specific 
oxidation products 9-HODE and F2-isoprostanes. The present study has provided evidence, 
for the first time, that the direct exposure of LDL to HOSCN may contribute to lipid 
oxidation. This is consistent with the report by Zhang et al., investigating the role of HOSCN 
and SCN- derived oxidants in lipid peroxidation. In this case, activated neutrophils were 
exposed to plasma containing a range of substrates including SCN-. It was demonstrated 
that lipid peroxidation mediated by the presence of SCN- in plasma contributed to the 
formation of 9-HODE and 9-HETE, which are derived from the oxidation of cholesteryl 
linoleate and arachidonate, respectively [494]. 
Studies were performed to elucidate the mechanisms involved in lipid oxidation mediated 
by HOSCN. Time-dependent studies were performed to elucidate the reactivity of HOSCN 
with unsaturated cholesteryl esters with subsequent formation of 9-HODE. It was 
demonstrated in the present study that HOSCN reacts slowly with unsaturated cholesteryl 
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esters, with significant loss of cholesteryl esters detected after 24 h and significant 
formation of 9-HODE after 1 h. This is consistent with a previous study performed by Exner 
et al. that demonstrated significant formation of conjugated dienes and lipid 
hydroperoxides after exposure of LDL to an enzymatic MPO/H2O2/SCN
- system for 2 h [82].  
The present study showed complete inhibition of lipid peroxidation in the presence of the 
radical scavenger BHT on treatment of LDL with HOSCN. This is consistent with the study 
performed by Exner et al. where inhibition of the oxidative processs was observed after 
treatment of LDL with the enzymatic MPO/H2O2/SCN
- system in the presence of ascorbic 
acid, which is another radical scavenger [82]. However, the protection seen with BHT does 
not shed much light on the exact mechanism of radical formation. 
It was postulated that the release of iron from the heme group of LPO during the 
preparation of isolated HOSCN may result in free iron in the HOSCN preparation used, 
which may catalyse radical formation. This effect would be consistent with previous 
studies, showing the reactivity of HOCl with heme-containing proteins including 
haemoglobin and MPO, which causes the release of iron [525, 551]. Furthermore, a recent 
study also demonstrated that HOSCN can readily react with isolated myoglobin, with a 
different extent of protein oxidation observed in the presence and absence of the haem 
group [66]. The present study demonstrated that there is minor heme loss associated with 
the production of isolated HOSCN, which showed a loss of ~0.53 μM out of the 50 μM LPO. 
In this case, there seem to be a possibility of a reversible effect in the conversion of 
compound I into the native ferric LPO form due to the minimal loss of the heme derived 
from LPO. Furthermore, the present study also demonstrated some attenuation of lipid 
oxidation on additing the iron chelator DFO to remove any free iron released from HOSCN 
preparation. This led to the significant attenuation of lipid oxidation product formation, 
compared to HOSCN modified LDL in the absence of DFO. However, this effect may not be 
entirely associated with the chelation of free iron within the sample, since DFO has also 
been demonstrated to be a radical scavenger [552-554]. Radical formation may be 
associated with the formation of HOSCN decomposition products and formation of protein 
species RS-SCN and RN-SCN which may initiate radical formation [4, 65]. This may indicate a 
role for modified apoB100 in LDL lipid peroxidation, consistent with the process associated 
with HOCl at high molar ratio [102]. Further studies are required to completely elucidate 
the mechanisms associated with HOSCN-mediated lipid peroxidation. 
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Formation of lipid peroxidation products may occur in the development of atherosclerosis, 
with evidence implicating its proatherogenic effects. Previous studies have highlighted the 
important contribution of 9-HODE in signalling and expression of scavenger receptors [319, 
320, 518, 519, 523]. In particular, 9-HODE has been associated with PPAR-γ expression 
resulting in macrophage cell recruitment by increased expression of Vascular Endothelial 
Growth Factor (VEGF) [519, 523], Human Monocyte Chemotactic Protein-3 (MCP-3) [520], 
and Chemokine Receptor type 2 (CCR2) [518], and CD36 scavenger receptor expression 
[319, 320, 555]. Moreover, 9-HODE has been linked with G-protein coupled receptor G2A 
activation, which is involved in promoting cell cycle arrest [521]. Formation of F2-
isoprostanes has been demonstrated to induce proatherogenic effects, including 
expression of scavenger receptor-A1 (SR-A1) and matrix metalloproteinase secretion, which 
is important in the degradation of surrounding matrix in atherosclerotic lesions [556]. 
Furthermore, F2-isoprostanes have been linked to the development of 
ischemia/reperfusion injury mediated by excessive neutrophil adhesion [557]. 9-HODE and 
F2-isoprostanes were detected within HOSCN-modified LDL and this may indicate that this 
form of LDL may have biological reactivity and significance. Given that the oxidation profile 
was different with HOCl-modified LDL, this may result in a completely different outcome. 
In this chapter, modifications of LDL after exposure to HOCl and HOSCN were 
comprehensively assessed, with HOCl and HOSCN shown to give different modifications on 
LDL. The effect of HOSCN was demonstrated to be more specific and was also shown to 
result in more extensive lipid peroxidation compared to HOCl under the conditions 
examined, though the mechanisms involved requires further investigation. These results 
may be important in smokers who have elevated SCN- levels and hence are likely to form 
more HOSCN in vivo [558]. HOSCN can also decompose to OCN- that can contribute to LDL 
modification via carbamylation. It has been previously demonstrated that the enzymatic 
MPO/H2O2/Cl
-/SCN- system can modify Lys residues and form HCit [24]. Modifications 
mediated by OCN- have been implicated in premature atherosclerosis in smokers who have 
elevated plasma SCN- [24] and patients with renal disease [559]. These differences in 
modifications may contribute to disease development via different pathways. 
The oxidative modification of LDL theory defines the important contribution of modified 
LDL in the progression of atherosclerosis. It was previously demonstrated that protein and 
lipid modifications in LDL can transform this molecule into a pro-atherogenic molecule, 
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contributing to cellular dysfunction [302, 317]. The following chapter investigates the 
potential role of HOCl, HOSCN and OCN- modified LDL in cellular dysfunction. 
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Chapter 4: Macrophage Cellular 
Dysfunction by HOSCN, HOCl and 
OCN- Modified LDL 
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4.1 Introduction 
Atherosclerosis is characterised by the build up of plaques within the artery walls of large 
arteries [212, 249]. In the early stages of atherosclerosis, there is a characteristic formation 
of fatty streaks that signifies the early development of plaques. Foam cells are a key 
component of fatty streaks that result from the dysfunctional regulation of lipid uptake by  
macrophages and are widely recognised to be an early hallmark of atherosclerosis [212]. 
Dysfunction of macrophages can also contribute to the development and destabilisation of 
more advanced lesions [560]. There is evidence showing that cell debris are present within 
atherosclerotic plaques, which suggests that foam cells undergo apoptosis and necrosis to 
form complex atherosclerotic lesion plaques [236, 421]. 
Extensive evidence has shown that modification of LDL can result in transformation of this 
particle into a form recognised by macrophage scavenger receptors. This leads to the 
internalisation of LDL and its uncontrolled accumulation within macrophages [284, 302, 
335, 386]. Early studies involved supplementation with transition metal ions, which led to 
the modification of LDL, resulting in its recognition and uptake by macrophage cells [335]. 
More recently, other agents of LDL modification have also been demonstrated to 
contribute to the uncontrolled uptake of LDL, including thiols [364, 365], superoxide [370, 
392], glucose [384, 485, 498], myeloperoxidase [24, 302, 561],  peroxynitrite/NO2
- [393, 
396, 562], and lipoxygenase [375, 563, 564]. Furthermore, certain types of modified LDL 
have also been reported to be involved in the induction of macrophage cell death [565-
567]. In this case, formation of certain oxidative products, once taken up by macrophages, 
can trigger signalling molecules that induce cell cycle arrest and apoptosis [565-567]. 
Treatment of LDL with HOCl at high (mM) concentrations (molar excess of HOCl compared 
to apoB100 of 400 – 800-fold) has been shown to result in the recognition and excessive 
accumulation of LDL within macrophage cells [302]. These modifications also contributed 
to increased cell death with the induction of cellular apoptosis and necrosis [317]. 
However, given that in many cases, the concentration of HOCl used previously to modify 
LDL has been high, it is important to understand the reactivity of LDL modified with more 
physiologically-relevant doses. HOSCN is another major oxidant produced from 
myeloperoxidase after the catalysed oxidation of SCN- [86, 568]. There remains a lack of 
data on the effects of HOSCN-modified LDL upon cellular dysfunction. Thus, further studies 
need to be performed to elucidate the effects of HOSCN modified LDL on macrophage cell 
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dysfunction. This is particularly relevant in the light of data showing that SCN- levels in the 
plasma of smokers correlates with early markers of foam cell formation [326, 327]. 
Cardiovascular disease is often accompanied by the development of renal disease, 
particularly in the context of uremia [559, 569, 570]. Uremic patients display high levels of 
urea in their plasma, which exists in equilibrium with cyanate (OCN-) [559, 570]. OCN- has 
been show to induce carbamylation of Lys residues within proteins [571]. Patients with 
renal disease are known to be at greater risk of developing cardiovascular disease, which 
may be related to carbamylation of Lys residues, which alters the function of LDL [332]. 
MPO-dependent formation of HOSCN, which decomposes to OCN-, may be an alternative 
pathway to LDL carbamylation in vivo [24]. As it has been demonstrated that OCN- -
modified LDL can contribute to cellular dysfunction [24, 331, 332], the role of OCN- was 
compared to that of HOSCN, the major MPO/SCN- derived oxidant. 
4.2 Aims 
The aim of this Chapter is to compare the role of HOCl, HOSCN and OCN- induced 
modifications of LDL in perturbing macrophage function, by assessing modulation of cell 
death pathways and the extent of accumulation of cholesterol and cholesteryl esters in 
J774A.1 macrophage-like cells and primary human monocyte-derived macrophages 
(HMDM). 
4.3 Results 
4.3.1 Cell Viability 
Initial studies examined the extent of macrophage cell death on exposure of J774A.1 cells 
(0.5 x 106 cells) to each type of modified LDL at a fixed concentration of LDL (0.1 mg protein 
mL-1). J774A.1 cells are a well characterised murine macrophage-like cell line that have 
been used extensively in previous studies to monitor cellular dysfunction induced by oxLDL 
[386, 572]. The effect of LDL pre-treated with HOCl and HOSCN for 30 min or 24 h was 
examined, owing to the differing extents of apoB100 and lipid oxidation observed in each 
case. Cell viability was assessed after incubation with each type of modified LDL, using the 
lactate dehydrogenase assay (LDH) assay (described in section 2.3.7.1). The LDH assay 
measures the release of LDH into the media by damaged cells after lysis with results 
presented as a percentage of the total cellular LDH activity.  
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Figure 4.1A shows the viabilities of J774A.1 cells after exposure to HOSCN and HOCl 
modified LDL. LDL was modified for 30 min before purification to remove any residual 
oxidants and exposure to J774A.1 cells for 24 h. There was no loss in viability observed 
when J774A.1 cells were exposed to LDL modified with HOSCN and HOCl (500 μM; 100-fold 
molar excess). Experiments were not performed with LDL exposed to OCN- for 30 min 
owing to the slow reaction of OCN- with LDL, with no significant carbamylation seen over 
this time period [571]. Figure 4.1B shows the viabilities of J774A.1 cells after exposure to 
LDL modified with HOCl or HOSCN for 24 h, prior to addition to J774A.1 cells for a further 
24 h. There were significant losses in the viabilities of J774A.1 cells after exposure to 
control, HOSCN-, and HOCl-modified LDL compared to the no LDL treatment condition 
(shown by #). Thus, the incubation control LDL in the absence of added oxidants has a 
minor effect on cell viability. However, further significant reductions in viabilities were 
observed with the HOSCN- and HOCl-modified LDL compared to the incubation control LDL 
(shown by *). OCN--modified LDL was also examined using LDL treated with OCN- (1 mM for 
24 h), prior to addition to the cells for 24 h. However, OCN--modified LDL did not contribute 
to a further reduction in J774A.1 cell viability, compared to the incubation control LDL.  
The ability of modified LDL to reduce cellular viability was associated with the more 
extensive modifications induced by HOSCN and HOCl over 24 h compared to  30 min, which 
is likely to reflect greater apoB100 modification by HOCl and more extensive lipid oxidation 
with HOSCN (refer to section 3.3.2 and 3.3.3) 
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Figure 4.1 – J774A.1 cell viability after exposure to MPO-oxidant modified LDL. LDL (1 mg 
protein mL-1) was exposed to 500 μM HOSCN or HOCl for 30 min at 22 oC (A) or 500 μM 
HOSCN, 500 μM HOCl or 1000 μM OCN- for 24 h at 37 oC (B). After incubation, excess and 
unreacted oxidants were removed using PD-10 columns. J774A.1 murine macrophage-like 
cells (0.5 x 106 cells mL-1) were treated with 0.1 mg mL-1 of HOSCN-, HOCl- or OCN- -modified 
LDL  for 24 h at 37 oC in DMEM containing 10% lipoprotein deficient serum (LPDS). Viability 
was assessed using the LDH assay, as described in section 2.3.7.1. % cell viability is 
calculated by comparing LDH concentration before (present in media) and after (present in 
cell lysate) cell lysis. The experiments were performed three times, each with different LDL 
donors. Statistical differences were assessed using one-way ANOVA (Dunnett’s posthoc 
test). * and ** represented significance (p<0.05 and p<0.01) compared to the incubation 
control LDL. ## and ### represent significance (p<0.01 and <0.001) compared to no LDL 
treatment. 
The experiments were extended to examine the effect of each type of modified LDL on 
HMDM. Similar to J774A.1 cells, the viability of HMDM was investigated using the LDH 
assay. Incubation of modified LDL with HMDM was extended to 48 h, on the basis of 
previous experiments showing slower cholesterol loading in HMDM compared to J774A.1 
cells [386, 498].  
Initially, LDL pre-treated with HOSCN and HOCl for 30 min was incubated with HMDM for 
48 h. Figure 4.2A shows the viability of HMDM after exposure to this type of modified LDL. 
There were no significant reductions in HMDM viability observed with treatment of the 
cells with modified LDL under these conditions. Similarly, LDL pre-treated with HOSCN, 
HOCl and OCN- for 24 h at 37 oC did not contribute to a reduction in HMDM cell viability 
under the conditions employed in this study. This effect was not comparable to findings 
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observed with J774A.1 cells, which may reflect greater ability of this cell type to metabolise 
internalised molecules, or the differing incubation times employed. 
 
Figure 4.2 – Human monocyte-derived macrophage cell (HMDM) cell viability after 
exposure to MPO-oxidant modified LDL. LDL (1 mg protein mL-1) was exposed to 500 μM 
HOSCN or HOCl for 30 min at 22 oC (A) or 500 μM HOSCN, 500 μM HOCl or 1000 μM OCN- 
for 24 h at 37 oC (B). After incubation, excess oxidants were removed using PD-10 columns. 
Human monocyte derived macrophages (HMDM; 0.5 x 106 cells mL-1) were exposed to 
HOSCN-, HOCl- and OCN- modified LDL for 24 h at 37 oC in RPMI media containing 10 % 
LPDS. Viability was assessed using the LDH assay, as described in section 2.3.7.1. % cell 
viability is calculated by comparing LDH concentration before (present in media) and after 
(present in cell lysate) cell lysis. Experiments were performed three times, each with 
different LDL donors. Statistical differences were assessed using one-way ANOVA (Dunnett’s 
posthoc test). No significant differences were observed in the viability of HMDM after 
exposure to HOSCN-, HOCl- and OCN--modified LDL compared to the incubation control LDL 
or cells treated in the absence of LDL. 
 
4.3.2 Apoptosis and Necrosis 
With evidence for cell lysis on exposure of J774A.1 cells to modified LDL, apoptosis and 
necrosis were assessed in these cells using flow cytometry, with annexin V and propidium 
iodide staining. Apoptosis involves the translocation of the phospholipid, 
phosphatidylserine, to the outside of the cell, which avidly binds to annexin V. Necrosis 
allows for the uptake of the propidium iodide stain, owing to the loss of membrane 
integrity. Figure 4.3 represents the distribution of apoptotic and necrotic cells, as 
determined using flow cytometry. The upper left quadrant (A1) represents necrotic cells, 
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while the lower right quadrant (A4) represents apoptotic cells. Distribution of cell 
populations within the upper right quadrant (A2) represents the binding of both annexin V 
and propidium iodide to the cell, which exhibits both late stage of apoptosis and necrosis. 
Cell populations that were distributed in the lower left quadrant (A3) represent healthy 
cells. The colour scheme shown in the data plot demonstrates the density of cells localised 
in that area, with red representing high density cell distribution and blue representing low 
cell density distribution. 
The induction of apoptosis and necrosis in J774A.1 cells was investigated after exposure to 
HOSCN- and HOCl-modified LDL. Modified LDL was prepared by the exposure of native LDL 
to HOSCN and HOCl for 24 h at 37 oC. Figure 4.4 assesses the distribution of each cell 
population after treatment of J774A.1 cells with LDL pre-treated with 500 μM HOSCN and 
HOCl for 24 h. Cell populations were classified as healthy (A), apoptotic (B) or necrotic (C) 
after assessment using flow cytometry. In this case, populations that stain both apoptosic 
and necrotic were also classified as necrotic (C). Treatment of J774A.1 cells with HOSCN-
modified LDL did not induce apoptosis or necrosis of J774A.1 cells. Similarly, treatment of 
LDL with HOCl-modified LDL did not result in apoptosis of J774A.1 cells. However, there 
was a slight shift in the distribution of cells into the necrotic quadrant, exemplifying an 
increase in necrotic J774A.1 cells with the exposure to HOCl-modified LDL. 
Figure 4.5 shows raw flow cytometry data collected for HOSCN-modified LDL (100 : 1), 
showing the lack of apoptosis or necrosis observed in J774A.1 cells after exposure of these 
cells to this modified LDL (Panel B) for 24 h compared to the non-treated J774A.1 cells 
(Panel D). A positive control was included where cells were exposed to 100 μM HOSCN to 
induce apoptosis as previously (Panel C) [136]. 
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Figure 4.3 – A representative distribution of J774A.1 cells to healthy, apoptotic and 
necrotic populations using flow cytometry. Cell populations were assessed using flow 
cytometry by distributing cells into 4 quadrants (A1, A2, A3 and A4). A1 represents necrotic 
cells that specifically stain for Propidium Iodide. A2 represents cells that are both apoptotic 
and necrotic that stain both Annexin V and Propidium Iodide. A3 represents healthy cells 
that neither stain for Annexin V nor Propidium Iodide. Lastly, A4 represents apoptotic cells 
that stain specifically for Annexin V. Cell population was also coded with colours depending 
on cell density. Red refers to high density areas while blue distribution represents low 
density areas.  
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Figure 4.4 – Induction of apoptosis and necrosis in J774A.1 cell population after exposure 
to LDL modified by HOSCN and HOCl. LDL (1 mg protein mL-1) was exposed to 500 μM 
HOSCN or 1000 μM HOCl for 24 h at 37 oC. Excess oxidants were removed using PD-10 
columns. J774A.1 cells (0.5 x 106 cells mL-1) were treated with 0.1 mg mL-1 HOSCN- or HOCl-
modified LDL for 24 h at 37 oC in DMEM media containing 10 % LPDS. Cells that did not stain 
for either annexin V and propidium iodide (A) are healthy cells, cells that stain for annexin V 
(B) specifically are apoptotic and cells that stain for propidium iodide (C) are necrotic cell 
populations. The experiments were performed 3 times, each with a different LDL donor. 
Statistical analysis was assessed using one-way ANOVA (Dunnett’s posthoc test). ### 
represent significance (p<0.001) compared to no LDL condition. No significant difference 
was found in the reduction of healthy cells J774A.1 cells and increases in necrotic and 
apoptotic cells after exposure to HOSCN- and HOCl-modified LDL compared to the 
incubation control LDL.  
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Figure 4.5 – Raw flow cytometry data of J774A.1 cell populations with Annexin V and 
Propidium Iodide staining. LDL was exposed to 500 μM HOSCN for 24 h at 37 °C. Excess 
oxidants were removed using PD-10 column. J774A.1 murine macrophage-like cells (0.5 x 
106 cells mL-1) were exposed to 0.1 mg mL-1 (A) incubation control and (B) HOSCN-modified 
LDL for 24 h at 37 °C in DMEM media containing 10 % LPDS. Modified LDL was prepared 
after pre-treatment of LDL with 500 μM HOSCN for 24 h. (C) Positive and (D) negative 
controls were included by treatment of J774A.1 with 100 μM HOSCN in PBS and in the 
absence of LDL in DMEM media.  Left and right upper quadrant represent necrotic cells, 
lower right represents apoptotic cells and lower left quadrant represent healthy cells. Data 
are representative of one experiment performed in triplicate with multiple LDL donors. 
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Further experiments were performed with HOCl modified LDL to comprehensively assess 
its ability to induce apoptosis within macrophage cells, as a previous study demonstrated 
that exposure of LDL to HOCl, at higher molar excess, can transform LDL into a particle that 
can induce macrophage apoptotic cell death [317]. Figure 4.6 shows the induction of 
apoptosis and necrosis with the exposure of J774A.1 cells to LDL pre-treated with 5 mM 
HOCl. There was a significant shift in the distribution of cells into the apoptotic and necrotic 
quadrants, demonstrating that HOCl-modified LDL is capable of inducing apoptosis and 
necrosis, when LDL is exposed to a very high molar excess (1000-fold) of HOCl prior to 
incubation with J774A.1. This experiment was not possible with HOSCN, owing to the 
limited concentration of this oxidant generated enzymatically using LPO. 
Overall, the exposure of macrophage cells to modified LDL did not exhibit significant 
induction of apoptosis and necrosis. At low molar excesses (< 100-fold) that are likely to be 
more pathophysiologically relevant, HOSCN-modified LDL did not contribute greatly to 
apoptosis and necrosis observed in J774A.1 and HMDM cells. However, HOCl modification 
of LDL did contribute to a significant increase in necrosis. Analogous to previous studies 
with U937 macrophages [317], modification of LDL using 5 mM HOCl and exposure to cells 
led to increases in both apoptotic and necrotic cell populations. These effects may reflect 
the differing extent and nature of LDL modifications observed with HOCl compared to 
HOSCN reported in Chapter 3. 
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Figure 4.6 – Induction of apoptosis and necrosis in J774A.1 cell population after exposure 
to LDL modified with 5 mM HOCl. LDL (1 mg protein mL-1) was exposed to 5 mM HOCl for 
24 h at 37 °C. Excess oxidant was removed using a PD-10 column. J774A.1 murine 
macrophage-like cells (0.5 x 106 cells mL-1) were exposed to 0.1 mg mL-1 HOCl-modified LDL 
for 24 h at 37 °C. Cells that did not stain for either annexin V and propidium iodide (A) are 
healthy cells, cells that stain for annexin V (B) specifically are apoptotic and cells that stain 
for propidium iodide (C) are necrotic cell populations. The experiments were performed 3 
times, each with a different LDL donor. Statistical analysis was assessed using one-way 
ANOVA (Dunnett’s posthoc test). *, ** represents significance (p<0.05, 0.01) compared to 
cells exposed to the incubation control LDL. #, ## represents significance (p<0.05, 0.01) 
compared to cells exposed in the absence of LDL. 
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4.3.3 Cholesterol and Cholesteryl Ester Accumulation within 
Macrophages 
Having demonstrated that HOCl- and HOSCN- modified LDL do not induce significant 
macrophage toxicity after 24 h treatment periods, the next series of experiments examined 
lipid uptake and accumulation in J774A.1 and HMDM cells. Cholesterol and cholesteryl 
ester accumulation was assessed in both J774A.1 murine macrophage-like cells and HMDM 
using HPLC, after the exposure of these cells to HOSCN, HOCl and OCN- modified LDL. 
Modified LDL was prepared by the exposure of LDL to oxidants for 30 min at 22 oC or 24 h 
at 37 oC. Figure 4.7 demonstrates the accumulation of cholesterol and cholesteryl esters 
after the exposure of J774A.1 cells to LDL pre-treated with HOSCN and HOCl for 30 min at 
22 oC. There was no increase in total cholesterol accumulation after exposure to either 
HOSCN- or HOCl-modified LDL. However, significant increases in cholesteryl ester 
accumulation were observed in J774A.1 cells that were treated with the HOSCN-modified 
LDL. This effect was not observed in HOCl-modified LDL under identical conditions. 
Cellular cholesterol and cholesteryl ester accumulation was also quantified in J774A.1 cells 
exposed to LDL pre-treated with 500 μM HOSCN, HOCl or 1 mM OCN- for 24 h at 37 oC 
(Figure 4.8). The resulting effects on lipid uptake and accumulation were different from 
experiments with LDL modified for 30 min, particularly with HOCl-modified LDL. Exposure 
of HOCl modified LDL to J774A.1 resulted in an increased accumulation of total cholesterol 
and cholesteryl esters, with 2-fold and approximately 4-fold increases observed, 
respectively. Comparatively, HOSCN did not contribute to such a significant accumulation 
of total cholesterol within J774A.1 cells, above that observed with the incubation control 
LDL. However, there were significant increases in cholesteryl ester accumulation observed 
when J774A.1 cells were exposed to LDL pre-treated with HOSCN for 24 h. Exposure of 
J774A.1 cells to OCN--modified LDL gave similar results to HOSCN-modified LDL, only 
showing significant increases in cholesteryl ester accumulation on comparison to the 
incubation control LDL.  
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Figure 4.7 – Cholesterol and cholesteryl ester accumulation in J774A.1 murine 
macrophage-like cells after treatment with HOSCN and HOCl modified LDL for 30 min. LDL 
(1 mg protein mL-1) was exposed to 500 μM HOSCN or HOCl for 30 min at 22 °C. Excess 
oxidants were removed using PD-10 columns. J774A.1 murine macrophage-like cells (0.5 x 
106 cells mL-1) were exposed to 0.1 mg mL-1 HOSCN- or HOCl-modified LDL for 24 h at 37 °C 
in DMEM media containing 10 % LPDS. Cholesterol (A) and cholesteryl esters (C) were 
normalised to cellular protein assessed by the BCA assay. Cholesteryl esters (B) were 
expressed as a percentage (%) relative to total cellular cholesterol. The experiments were 
repeated 6 times, each with a different LDL donor. Statistical analysis was assessed using 
one-way ANOVA (Dunnett’s posthoc test). ** represents significant (p<0.01) difference 
compared to the incubation control LDL ## represents significant (p<0.01) difference 
compared to the treatment in the absence of LDL. “aa” represents significant (p<0.01) 
difference comparing the effect of HOSCN- and HOCl-modified LDL.  
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Figure 4.8 – Cholesterol and cholesteryl ester accumulation in J774A.1 murine 
macrophage-like cells after treatment with HOSCN, HOCl and OCN- modified LDL for 24 h. 
LDL (1 mg protein mL-1) was exposed to 500 μM HOSCN, 500 μM HOCl or 2500 μM OCN- for 
24 h at 37 °C. After treatment, excess oxidants were removed using PD-10 columns. J774A.1 
murine macrophage-like cells (0.5 x 106 cells mL-1) were exposed to 0.1 mg mL-1 HOSCN-, 
HOCl- or OCN- -modified LDL for 24 h at 37 °C in DMEM media containing 10 % LPDS. 
Cholesterol (A) and cholesteryl esters (C) were normalised to cell protein assessed by BCA 
assay. Cholesteryl esters (B) were expressed as a percentage (%) relative to total cellular 
cholesterol. The experiments were performed 6 times, each with a different LDL donor. 
Statistical analysis was assessed using one-way ANOVA (Dunnett’s posthoc test). *, **, and 
*** represent a significant (p<0.05, 0.01, 0.001) difference compared to incubation control 
LDL. “a” and “aa” represent a significant (p<0.05 and 0.01) difference comparing the effect 
of  HOSCN-, HOCl- and OCN- -modified LDL. 
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To extend the findings observed in J774A.1 cells, lipid uptake and accumulation were also 
investigated in HMDM cells. HMDM (0.5 – 0.6 x 106 cells mL-1) were exposed to modified 
LDL for 48 h at 37 oC in RPMI media containing 10 % human serum. Modified LDL was 
prepared by the exposure of native LDL to HOSCN or HOCl for 30 min at 22 oC or 24 h at 37 
oC. Figure 4.9 shows the accumulation of cholesterol and cholesteryl esters after 48 h 
incubation of HMDM with LDL pre-treated with HOSCN or HOCl for 30 min. There were no 
significant increases in total cholesterol observed in HMDM after exposure to all forms of 
modified LDL. Quantification of cellular cholesteryl ester accumulation showed significant 
increases in HMDM exposed to HOSCN- or HOCl-modified LDL. In this case, the extent of 
accumulation was more pronounced with HOCl-modified LDL, differing from previous 
findings observed in J774A.1 cells. Comparatively, there is also a significant difference in 
cholesteryl ester accumulation between HMDM exposed to HOSCN- or HOCl- modified LDL.   
HMDM were also exposed to LDL pre-treated with HOSCN, HOCl or OCN- for 24 h at 37 oC, 
shown in Figure 4.10. Modified LDL samples were incubated with HMDM for 48 h at 37 oC 
in RPMI media containing 10 % human serum. There was elevated total cholesterol 
accumulation when HMDM were exposed to HOSCN, HOCl or OCN- modified LDL. The 
extent of uptake and accumulation was similar between HOSCN and OCN- modified LDL, 
and was greater than that observed with the incubation control LDL. HOCl- modified LDL 
showed the greatest effect with respect to total cholesterol accumulation, resulting in a 2-
fold increase compared to cells exposed to the incubation control LDL. Uptake and 
accumulation of cholesteryl esters were also elevated with the different forms of modified 
LDL. Similar to total cholesterol accumulation, both HOSCN and OCN- modified LDL 
contributed to a significant increase in cholesteryl ester accumulation. However, 
comparatively to HOCl, these effects were shown to be less pronounced, with HOCl-
modified LDL exposure resulting in a 5-fold increase in cholesteryl ester accumulation. 
Cholesteryl ester values were compared in this case by the concentration of cholesteryl 
esters normalised to protein content rather than as a percentage relative to the total 
cholesterol, since the large increase in total cholesterol observed may underestimate the 
uptake and accumulation of these esters within HMDM. Previous experiments with J774A.1 
cells in the present study did not lead to such a significant accumulation of total 
cholesterol. Hence, in this case the cholesteryl esters could be expressed as a percentage 
relative to total cholesterol. 
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Figure 4.9 – Cholesterol and cholesteryl ester accumulation in HMDM cells after 
treatment with HOSCN or HOCl modified LDL for 30 min. LDL (1 mg protein mL-1) was 
exposed to 500 μM HOSCN or HOCl for 30 min at 22 oC. After treatment, excess oxidants 
were removed using PD-10 columns. HMDM cells (0.5 - 0.6 x 106 cells/well) were exposed to 
0.1 mg mL-1 HOSCN- and HOCl-modified LDL for 48 h at 37 oC in RPMI media containing 10 
% LPDS. Cholesterol (A) and cholesteryl esters (C) were normalised to cell protein assessed 
by the BCA assay. Cholesteryl esters (B) were expressed as a percentage (%) relative to total 
cellular cholesterol. The experiments were performed 6 times, each with a different LDL 
donor. Statistical analysis was assessed using one-way ANOVA (Dunnett’s posthoc test). * 
and *** represent a significant (p<0.05 and 0.001) difference compared to the incubation 
control. # and ## represent a significant (p<0.05 and 0.01) difference compared to the 
treatment in the absence of LDL (no LDL). “aa” represents a significant (p<0.01) difference 
comparing the effect of HOSCN- and HOCl-modified LDL.  
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Figure 4.10 – Cholesterol and cholesteryl ester accumulation in HMDM cells after 
treatment with HOSCN, HOCl or OCN- modified LDL for 24 h. LDL (1 mg mL-1 protein) was 
exposed to 500 μM HOSCN, 500 μM HOSCN, and 2500 μM OCN- for 24 h at 37 oC. HMDM 
cells (0.5 – 0.6 x 106 cells mL-1) were exposed to 0.1 mg mL-1 HOSCN-, HOCl- and OCN- -
modified LDL LDL for 48 h at 37 oC in RPMI media containing 10 % LPDS. Cholesterol (A) and 
cholesteryl esters (C) were normalised to cellular protein assessed by the BCA assay. 
Cholesteryl esters (B) were expressed as a percentage (%) relative to total cellular 
cholesterol. Experiments were repeated 6 times, each with a different LDL donor (n = 6). 
Statistical analysis was assessed using one-way ANOVA (Dunnett’s posthoc test). * and *** 
represent a significant (p<0.05 and 0.001) difference compared to the incubation control 
LDL. ## represents a significant (p<0.01) difference compared to the treatment in the 
absence of LDL (no LDL). “aa” represents a significant (p<0.01) difference comparing the 
effects of HOSCN-, HOCl- and OCN- -modified LDL.  
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4.4 Discussion 
Macrophage cellular dysfunction is a major event in the development of atherosclerosis. 
Cellular dysfunction was assessed by investigating the induction of cell death and 
uncontrolled accumulation of lipids. It is well established that oxidative modification of LDL 
is important in mediating cellular dysfunction [280, 302, 567, 573-577]. However, the type 
of LDL modifications responsible for cellular dysfunction in vivo is not well established. 
Evidence of HOCl-modified LDL has been detected in lesions, with the detection of 
chlorinated products including 3-chloro-Tyr from LDL isolated from these sites [415]. It was 
demonstrated previously that LDL modified by HOCl at relatively high doses (> 400-fold 
molar excess) can transform macrophages into foam cells [302]. Furthermore, LDL modified 
by HOCl at higher doses was also able to induce macrophage apoptosis [317]. The ability of 
HOCl to induce these effects when LDL was exposed to lower, perhaps more physiologically 
relevant concentrations is less well characterised.  
HOSCN, another oxidant generated from the enzymatic MPO system under physiological 
conditions, has also been postulated to contribute to the development of atherosclerosis 
[82, 92]. Although there is no direct evidence linking lesion formation with materials 
generated from SCN-, there is compelling evidence establishing a link between smokers and 
elevated plasma SCN-.  Smokers have a higher risk of developing cardiovascular disease and 
these individuals are likely to generate more HOSCN [24, 578]. OCN- is a major 
decomposition product generated from HOSCN, with recent evidence showing a potential 
role of OCN- production in the pathogenesis of atherosclerosis, leading to foam cell 
formation [24, 332, 559, 579]. However, the effect of HOSCN- and OCN- modified LDL in 
macrophage cell dysfunction has not been comprehensively assessed. 
4.4.1 Cell Death 
Cellular dysfunction was initially assessed by investigating the ability of modified LDL to 
induce cell death. Modified forms of LDL were previously shown to contribute to cellular 
toxicity of various cells including macrophages, smooth muscle cells and other vascular cells 
[567, 576, 577, 580, 581]. Previous studies have highlighted the importance of oxidised 
lipids in mediating cellular death, via the formation of oxysterols [573], oxidised fatty acids 
[582, 583], aldehydes [584, 585] and lysophospholipds [586, 587]. In the present study, 
J774A.1 and HMDM cells were used to examine the role of HOSCN- and HOCl-modified LDL 
in the induction of cell death. 
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In Chapter 3, it was demonstrated that MPO-derived oxidant HOCl and HOSCN can induce 
changes within LDL, which was exemplified by protein and lipid modification. LDL modified 
by HOCl at high concentrations has been well characterised in previous studies [102, 300, 
416] and was shown to induce macrophage cell apoptosis, which was exemplified in both 
THP-1 [316] and U937 cells [317]. In these cases, LDL was treated with HOCl with a molar 
excess of 2000-fold for 30 min at 37 oC, which resulted in the extensive modification of LDL. 
The present study investigated the effects of LDL modified by HOCl at lower concentrations 
(< 100-fold molar excess). There was a significant loss of cell viability observed in J774A.1 
cells, particularly with LDL pre-treated with HOCl for 24 h at 37 oC. This loss was reflected 
by an increase in necrotic J774A.1 cells. However, no increase in the apoptotic cell 
population was observed, which was not consistent with the previous study [317]. 
Exposure of HOCl-modified LDL to primary HMDM cells did not contribute to the induction 
of cell death in these macrophages. The present study also investigated the effects of HOCl-
modified LDL at higher molar excess (1000-fold). In this case, a significant increase in both 
apoptotic and necrotic populations was observed in J774A.1 cells. Thus, differences 
between the present and previous studies are likely to be associated with the 
concentration of HOCl employed. With high concentrations of HOCl, more extensive 
protein and lipid oxidation is observed with formation of bioactive aldehydes also playing a 
potential role in cell dysfunction [102].  
Lipid peroxidation mediated by HOCl has been associated with the formation of secondary 
chloramines that can cause further secondary reactions [102]. Lipid peroxidation mediated 
by HOCl was not observed at lower molar excess, which may explain the lack of cell death 
induced in macrophages under the conditions used in the present study. The mechanism 
behind the induction of cell death mediated by HOCl-modified LDL was associated with the 
activation of caspase enzymes, from release of pro-apoptotic factors from the 
mitochondria [316, 317]. Furthermore, overexpression of Bcl-2 in U937 macrophages that 
serves to inhibit caspase-9 activation, led to a decrease in HOCl-modified LDL mediated 
toxicity [317]. Activation of caspase enzymes may be associated with the accumulation of 
oxidised lipids, which led to the induction of apoptosis within macrophage cells. 
HOSCN was demonstrated to induce lipid peroxidation with the observed loss of parent 
unsaturated cholesteryl esters and the subsequent formation of oxidised lipid products. 
Previous studies have highlighted the important contribution of oxidised lipids in the 
induction of cell death [280, 583-588]. Thus, it was postulated that HOSCN-modified LDL 
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may also induce cell death in macrophages. However, the exposure of HOSCN-modified LDL 
to cells did not induce a large extent of cell death, though there was a significant reduction 
in cell viability observed after the exposure of J774A.1 cells to LDL pre-treated with HOSCN 
for 24 h. However, the apoptosis and necrosis assays did not show a reproducible increase 
in macrophage cell death. Similarly, no evidence for cell death was obtained in studies with 
HMDM. Although HOSCN may contribute to both protein and lipid oxidation of LDL, there 
are several factors that may affect the potential cytotoxicity mediated by this modified LDL. 
For instance, recognition and uptake of HOSCN-modified LDL by macrophage scavenger 
receptors is not well established and may limit the amount of oxidised lipids within cells. In 
this case, minimal amounts of oxidised lipids may not be enough to exhibit a toxicity effect. 
Furthermore, most of the cytotoxic studies with oxidised fatty acids were performed on 
endothelial cells, which may respond differently to macrophage cells [582, 583]. Also, the 
forma on of hydroperoxides from oxidised fa y acids were mainly dependent upon the 
presence of transi on metal ions, which can catalyse the conver on of these non-radical 
intermediates into reac ve lipid radicals  (LO   and LOO  ) [589, 590]. Formation of lipid 
hydroperoxides can occur a er H-atom abstrac on by LOO  . Introduction of lipophillic 
antioxidants, such as probucol, BHT and α-tocopherol [591], can remove these reactive 
species and has been shown to eliminate the toxicity of oxidised LDL [582]. This was not 
observed in the present study, as metal ion-free DMEM media was used to examine the 
independent contribution of HOSCN-modified LDL on cells. Thus, in this case, the formation 
of lipid radicals was not likely to be accelerated by the presence of transition metal ions, 
catalysing the conversion of hydroperoxides to reactive radicals.  This may also explain the 
lack of significant cell death observed when cells are treated with HOSCN-modified LDL. It is 
postulated, however, that introducing metal ions in addition to HOSCN-modified LDL may 
exacerbate macrophage cell death. 
Differences between the toxicity associated with HOSCN- and HOCl-modified LDL exposure 
to cells may reflect the extent of modification of apoB100. Extensive changes in apoB100 
are associated with the recognition and uptake of modified LDL [302]. It is postulated that 
toxicity arises from the accumulation of oxidised lipids within macrophage cells that can 
trigger cellular pathways, resulting in growth arrest [280, 583-588]. HOSCN-mediated lipid 
oxidation was determined to be similar to the effect mediated by Cu2+, which led to the 
formation of lipid hydroperoxides at nmol concentrations. Although HOSCN targets the 
lipid portion of LDL, resulting in the generation of lipid oxidation products, its effect on 
apoB100 is minimal, compared to Cu2+ ions, with its specificity towards certain amino acid 
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residues. Minimal modification of apoB100 may result in a lower affinity to scavenger 
receptors expressed by macrophage cells that limits the accumulation of oxidised fatty 
acids within cells. Hence, there were no clear activation of apoptosis and necrosis in these 
cells observed. 
4.4.2 Cholesterol and cholesteryl ester accumulation 
Cellular dysfunction associated with the uptake and accumulation of lipids in macrophages 
was also examined. This process allows the transformation of healthy macrophages into 
dysfunctional lipid-laden foam cells [212]. Extensive studies have been performed 
investigating the role of oxidative modification of LDL on foam cell formation (e.g. [284, 
302, 336, 337, 347, 592]). However, the exact nature of LDL modification in vivo that 
contributes to this process is still unclear. The present study investigated the role of LDL 
modified by HOSCN, HOCl or OCN- on mediating uncontrolled uptake of cholesterol and 
cholesteryl ester uptake. 
The effect of HOCl-modified LDL on cholesterol and cholesteryl ester uptake and 
accumulation in macrophage cells has been established previously after the modification of 
LDL with HOCl at high concentrations [302]. The present study demonstrated the ability of 
HOCl-modified LDL to also induce cholesterol and cholesteryl uptake and accumulation in 
macrophage cells after exposure of LDL to HOCl at lower concentrations. HOCl-modified 
LDL was shown to mediate significant accumulation of cholesterol and cholesteryl esters in 
both J774A.1 and HMDM cells. A greater extent of lipid accumulation was observed in 
HMDM, which may be attributed to the longer incubation time. The extent of HOCl-
induced modification, comparing oxidation of LDL for 30 min and 24 h, had different but 
significant effects on lipid uptake. LDL modified by HOCl for 30 min prior to cell exposure 
showed lesser effects upon cholesteryl ester accumulation. Comparatively, modification of 
LDL by HOCl for 24 h prior to cell exposure showed more extensive and significant 
accumulation of total cholesterol and cholesteryl esters. The difference between the 
effects of LDL modified by HOCl for 30 min and 24 h may be associated with greater 
modifications induced by secondary reactions mediated by chloramines generated after 
initial exposure of LDL to HOCl, which results in more extensive Lys loss and change in 
particle charge. These changes are crucial contributors in LDL recognition and uptake by 
scavenger receptors [302]. A previous study has already highlighted the important 
contribution of HOCl-modified LDL on cholesterol and cholesteryl ester accumulation, 
though in general, LDL has been modified with HOCl at higher concentrations [302]. 
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Significant modifications of several amino acids were observed previously, consistent with 
the modifications observed in the present study [102, 300, 302]. Hazell et al. demonstrated 
that LDL modification by HOCl results in extensive uptake and accumulation of cholesterol 
and cholesteryl esters in mouse peritoneal macrophages, leading to foam cell formation 
[302]. Cholesterol and cholesteryl accumulation within macrophages was associated with 
the formation of chloramines that was demonstrated by the addition of methionine to 
remove these reactive species [102]. Methionine supplementation also inhibited changes in 
the mobility of LDL within the agarose gel, consistent with less charge modification [102]. 
This suggests that Lys modification contributes to the recognition of modified LDL by 
scavenger receptors, as postulated in other studies [283, 284, 336, 337, 347, 592, 593]. The 
present study supports this hypothesis. 
HOSCN-modified LDL also induced significant accumulation of cholesteryl esters within 
J774A.1 and HMDM cells. This effect was greater when macrophage cells were exposed to 
LDL modified for 24 h by HOSCN prior to exposure to cells, and may highlight the role of 
lipid modification, which predominates when LDL is incubated with HOSCN for 24 h 
compared 30 min. Significant accumulation was also observed in HMDM cells with this 
being greater than with J774A.1 cells treated with HOSCN-modified LDL, which again may 
be associated with the longer exposure of the HMDM cells to the modified LDL. It was 
previously demonstrated that HMDM required a longer incubation time compared to 
J774A.1 cells with glycated LDL to achieve a similar extent of lipid loading [498]. The effect 
of HOSCN-modified LDL upon cholesterol and cholesteryl ester accumulation is reflected to 
some extent by the changes in the relative electrophoretic mobility of LDL, which showed a 
small change compared to the incubation control, with this being less than that induced by 
HOCl. There is no existing evidence demonstrating a role of HOSCN-modified LDL on 
cholesterol and cholesteryl uptake, which is shown for the first time in this study. However, 
Wang et al showed that LDL modified by the enzymatic MPO/H2O2/SCN
- system has a 
greater binding affinity to SR-AI transfected CHO cells compared to unmodified LDL, though 
this was mainly attributed to reactions mediated by OCN- rather than HOSCN [24]. 
Collectively both the present and previous study contribute to the notion that HOSCN or 
SCN- derived oxidants can modify LDL leading to the uptake and accumulation of 
cholesterol and cholesteryl esters. This notion complements previous studies investigating 
the correlation of plasma SCN- in smokers and early markers of atherosclerosis [326, 327]. 
146 
 
Carbamylated LDL has been linked with both renal disease and cardiovascular disease [594-
596]. Carbamylated LDL was detected in patients with renal disease, owing to the reaction 
of elevated plasma urea with circulating lipoproteins [331, 559, 571, 597]. It was 
demonstrated that carbamylated LDL can induce pro-atherogenic effects, including vascular 
smooth muscle cell proliferation [598], vascular monocyte adhesion to endothelial cells 
[569, 599], endothelial cell toxicity [331, 600], and accelerated atherosclerosis in mouse 
models [559]. However, the role of carbamylated LDL in foam cell formation has not been 
well elucidated in previous studies. In the present study, carbamylation of LDL induced by 
exposure to OCN- was also demonstrated to contribute to lipid accumulation within 
J774A.1 and HMDM. Exposure of cells to OCN--modified LDL to cells resulted in significant 
recognition and uptake, similar to HOSCN-modified LDL. The extent of uptake was generally 
less than seen with HOCl-modified LDL. This is reflected by the extent of carbamylation that 
occurred within apoB100, showing a minimal increase in HCit and no loss of parent Lys 
residue (refer to section 3.3.2.5; Fig 3.15). As with HOSCN-modified LDL, there is limited 
evidence showing a role of OCN- modified LDL in the induction of cellular dysfunction. One 
previous study elucidated the mechanism of uptake of OCN--modified LDL, using an 
enzymatic MPO/H2O2/SCN
- system and isolated OCN-, on scavenger receptor association. In 
this case, carbamylated LDL were shown to be recognised by SR-AI receptors present on 
CHO cells [24]. Recently, the impact of OCN- on HDL, the other major lipoprotein in vivo, 
was also investigated [601, 602]. It was shown that HDL isolated from atherosclerotic 
lesions was carbamylated and the levels of carbamylated Lys residues reflect the levels of 
3-chloro Tyr [602]. The correlation between carbamylated Lys and 3-chloro Tyr may 
indicate that HDL-induced carbamylation is associated with MPO generation [602]. 
Furthermore, carbamylation of HDL resulted in its altered functionality [601, 602]. In this 
case, carbamylated HDL showed lower associations with lecithin-cholesterol 
acyltransferase (LCAT), reduced antioxidant activity and altered reverse cholesterol 
transport thereby contributing to cholesterol and cholesteryl ester accumulation [601, 
602]. 
The effects of modified LDL upon macrophage cellular dysfunction were shown to be 
dependent on the cell types used. The exposure time of modified LDL to macrophages may 
contribute to the observed differences between J774A.1 (for 24 h) and HMDM cells (48 h). 
Although excess oxidants were removed after incubation with the LDL, these LDL are still 
prone to autoxidation over time at 37 °C. These assumptions, however, were not proven 
experimentally. Both J774A.1 and HMDM cells have been shown to exhibit similar 
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scavenger receptors, with the expression of SR-AI and CD36 [498, 603]. Though, expression 
of scavenger receptors and recognition of each LDL by specific scavenger receptors was not 
examined in this study. 
4.4.3 Conclusion 
Overall, HOSCN, HOCl and OCN- modified LDL contribute to cholesterol and cholesteryl 
ester uptake and accumulation after exposure to J774A.1 and primary HMDM cells. This is 
the first study to demonstrate the ability of LDL modified by HOSCN to induce macrophage 
accumulation of cholesterol and cholesteryl esters. Out of all forms of modified LDL 
examined, HOCl-modified LDL showed the greatest effect, which agrees well with the data 
presented in Chapter 3, showing the most extensive modification of apoB100. OCN- 
modified LDL also contributed significantly to uptake and accumulation, which also 
supports previous data [24]. In the light of these data on intracellular accumulation of 
cholesteryl esters, the next chapter investigates potential mechanisms of impaired LDL 
metabolism within the macrophage cells exposed to each modified LDL. 
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Chapter 5: Inactivation of 
Macrophage Lysosomal Enzymes by 
HOSCN, HOCl and OCN-Modified 
LDL 
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5.1 Introduction 
Uncontrolled accumulation of LDL within macrophage cells is associated with the inability 
of cells to metabolise internalised particles, which can be related to the functionality of 
lysosomal enzymes expressed by these cells [604-606]. Internalisation of particles, 
including LDL, by macrophages initially requires the recognition by cell surface receptors 
[606, 607]. Once bound, these particles are compartmentalised into endocytic vesicles, 
which fuse with lysosomes [605, 608] (Figure 5.1). Lysosomes contain a range of enzymes 
that degrade internalised proteins and lipids, which enables clearance of particles, such as 
LDL, from cells [289, 504]. 
 
 
Figure 5.1 – Scheme showing the internalisation of particles by receptor-mediated 
endocytosis within macrophage cells. 
 
Cathepsin enzymes are important lysosomal enzymes that represent a large family of 
protease enzymes, which hydrolyse amide bonds present in proteins [290]. These enzymes 
are classified into 4 main groups, depending on their active site , including cysteine (Cys), 
aspartate (Asp), serine (Ser) and metallo-proteases (Table 5.1) [290]. Of the cathepsin 
family of proteases, the Cys-dependent cathepsin proteases have been the most implicated 
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in the development of cardiovascular disease (reviewed in [288]). In particular, deficiency 
in the expression and inhibition of these enzymes exacerbates foam cell formation [609, 
610]. The role for Asp-dependent cathepsin proteases has also been demonstrated in 
atherosclerosis, particularly in relation to apoB100 degradation [277, 611].   
Table 5.1 Classification of cathepsin enzymes depending on their active site [290, 609, 
612-618] 
Active Site Cathepsin Classification 
Cysteine B, C, F, H, K, L, O, S, V, W, Z 
Aspartate D, E 
Serine A, G 
 
Lysosomal acid lipase (LAL) is the major lysosomal lipase {Goldstein, 1975 #402}. LAL 
hydrolyses cholesteryl esters into their constituent free cholesterol and fatty acids, which 
are used by the cells or transported out of the cells via the reverse cholesterol transport 
pathway mediated by high density lipoprotein (HDL) [292]. The later pathway only occurs 
when extensive levels of free cholesterol and fatty acids are present within cells [292]. The 
active site of LAL is a polypeptide sequence containing serine residues. Human LAL contain 
two of these sites at residues 99 and 153. Out of these serine residues within the active 
site, it was demonstrated that Ser 153 is crucial for the catalytic function of LAL [619]. 
Inactivation of lipases has been demonstrated in the presence of lipid hydroperoxides 
[620], which are often formed after oxidative modification of LDL [337]. Furthermore, 
deficiency in the expression of LAL was shown to contribute to foam cell formation, with 
impaired ability to degrade cholesteryl esters shown to prevent reverse cholesterol 
transport [621-623]. Similarly, patients who are affected by Wolman disease and 
cholesteryl-ester storage disease (CESD), who express minimal levels of LAL enzymes, have 
been known to develop premature vascular disease [624]. 
Cu2+-modified LDL were shown to be resistant to degradation by lysosomal enzymes, in 
experiments where the modified LDL was exposed to isolated and purified forms of the 
lysosomal enzymes and proteases [70, 625-629]. This effect was particularly striking with 
cathepsin B [70, 625, 627, 628], which is a major cysteine-dependent cathepsin enzyme 
within the lysosomal compartment, together with cathepsin L and cathepsin D, an 
aspartate dependent cathepsin enzyme [630]. It was postulated that the modified epitopes 
of LDL formed on exposure to Cu2+ decrease degradation and hydrolysis. In addition, 
inactivation of lysosomal enzymes may also be a factor in the uncontrolled accumulation of 
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LDL within macrophage cells and the transformation of these cells into foam cells [70, 628]. 
Thus, it was previously demonstrated that in addition to the resistance of Cu2+-modified 
LDL to degradation, these modified LDL can also inactivate cathepsin enzymes [70, 628]. 
The mechanism behind this action is reported to be associated with the generation of 
reactive aldehyde species (e.g. 4-hydroxynonenal), which are a product of lipid oxidation 
[70, 628]. A preliminary study also demonstrated the ability of HOCl-modified LDL to 
inactivate cathepsin enzymes [67]. In this case, it was demonstrated that isolated cathepsin 
B was readily inactivated by HOCl-modified LDL, by a pathway involving the formation of 
reactive chloramines. In the same study, cathepsin D was shown to be resistant to 
inactivation mediated by HOCl-modified LDL [67]. This was attributed to reactivity of LDL 
chloramines with the active site Cys rather than Arg residues [631]. A similar pattern of 
reactivity is reported for Cu2+-modified LDL, which demonstrates the high susceptibility of 
Cys-dependent cathepsins to oxidative modification, compared to Asp-dependent 
cathepsins [70, 628]. Although HOCl-modified LDL has been shown to inactivate Cys-
dependent cathepsins [67], there is a lack of information regarding the reactivity of this 
modified LDL with cathepsins in the cellular environment. Similarly, no data are available 
on the effects of HOSCN- or OCN--modified LDL on lysosomal enzyme activity. 
5.2 Aims 
In this Chapter, the effect of HOCl, HOSCN, and OCN--modified LDL on the activity of 
lysosomal enzymes in macrophages was assessed, with the aim of determining whether 
these processes are involved in the accumulation of cholesterol and cholesteryl esters 
within macrophage cells demonstrated in Chapter 4. 
5.3 Results 
5.3.1 Cys-dependent Cathepsins: Cathepsin B and L 
The effect of each modified LDL on the activity of lysosomal enzymes was initially 
investigated with Cys-dependent cathepsin enzymes, which have been shown previously to 
be sensitive to perturbation by other types of oxidised LDL [67, 70, 628]. In addition, LDL-
derived intermediates such as N-chloramines are known to target protein thiol groups [94, 
631-633], which can alter enzymatic activity, including cathepsin B and L [67]. 
Investigations of changes in enzyme activity were performed in cell lysates, intact J774A.1 
murine macrophage-like cells, and HMDM. 
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5.3.1.1 Cell Lysates 
Exposure of J774A.1 cell lysates to each type of modified LDL was initially investigated to 
examine the interaction of LDL with lysosomal enzymes in the absence of the cell 
membrane. Cathepsin B and L activity was measured by assessing the cleavage of specific 
fluorescently labelled substrates by the changes in fluorescence, which was detected at λEX 
360 nm and λEM 460 nm over 10 (for cathepsin L) or 20 min (for cathepsin B). Figure 5.1 
shows the inactivation of cathepsin B and L enzymes after exposure of cell lysates to LDL 
modified by HOSCN for 30 min and 24 h. In these experiments, any residual oxidant is 
removed by gel filtration prior to addition to the lysates to eliminate the contribution of the 
oxidants to alter enzyme activity. LDL modified by HOSCN (50 – 500 μM) for 30 min, prior 
to addition to the cell lysates (Fig 5.2A, B) showed significant decreases in cathepsin B and L 
enzyme activity. This effect was shown to be reflective of the dose of HOSCN used to 
modify LDL. Furthermore, LDL modified by HOSCN for 24 h (Fig 5.2C, D) also showed a 
decrease in cathepsin B and L enzyme activity after exposure of the cell lysates to this 
material. Similarly, inactivation occurred in an oxidant dose-dependent manner. 
Comparison of the effects of LDL pre-treated with HOSCN for 30 min and 24 h indicate that 
LDL pre-treated for 30 min showed a greater effect in inactivating Cys-dependent cathepsin 
enzymes, compared to the more extensively modified LDL, which had been pre-treated for 
24 h. 
Inactivation of Cys-dependent cathepsin enzymes was also observed with LDL modified by 
HOCl for 30 min and 24 h. Figure 5.3 shows the inactivation of cathepsin B and L enzymes 
after exposure of cell lysates to HOCl-modified LDL. The effects of the residual oxidants 
have been ruled out due to extensive gel filtration of the modified LDL to eliminate the 
contribution of any unreacted oxidants to alter enzyme function. Similar to HOSCN, there 
was a dose-dependent effect with higher concentrations of oxidants used to modify LDL, 
resulting in greater inactivation. Again, LDL pre-treated with HOCl for 30 min showed a 
higher extent of inactivation compared to LDL pre-treated for 24 h, before addition to the 
cell lysate. With LDL pre-treated for 24 h, significant loss in cathepsin B and L activity was 
only observed after treatment of J774A.1 cell lysates with LDL pre-treated with > 250 μM 
HOCl, compared to 50 μM with the 30 min pre-treatment. With cell lysates, HOCl-modified 
LDL had a more dramatic effect on cathepsin B and L activity compared to HOSCN-modified 
LDL. 
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Figure 5.2 – Inactivation of Cys-dependent cathepsin enzymes after exposure of J774A.1 
cell lysates to HOSCN-modified LDL. LDL (1 mg protein mL-1) was exposed to HOSCN (0 – 
500 μM) for 30 min (white) and 24 h (black) at 22 oC and 37 oC, respectively. Residual 
oxidants were removed from modified LDL samples using gel filtration.  Cell lysates (0.5 x 
106 cells mL-1) were exposed to HOSCN-modified LDL (0.1 mg protein mL-1) for 15 min at 22 
oC. The activity of (A) cathepsin B and (B) cathepsin L was determined by fluorescence after 
cleavage of the fluorescently-labelled substrates Z-Arg-Arg-AMC and Z-Phe-Arg-AMC, 
respectively, at λEX 360 nm and λEM 460 nm. The experiment was performed three times, 
each with a different LDL donor. Statistical analysis was performed using one-way ANOVA 
(Dunnett’s posthoc test). *, **, *** represent significant (p<0.05, 0.01, 0.001) difference 
compared to the incubation control (0 μM). #, ##, ### represent significant (p<0.05, 0.01, 
0.001) difference compared to lysates incubated in the absence of LDL.”a”, “aa”, “aaa” 
represent significant (p<0.05, 0.01, 0.001) difference comparing the effects of 30 min and 
24 h HOSCN-modified LDL by two-way ANOVA (Bonferroni’s posthoc test). 
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Figure 5.3 – Inactivation of Cys-dependent cathepsin enzymes after exposure of J774A.1 
cell lysates to HOCl-modified LDL. LDL (1 mg protein mL-1) was exposed to HOCl (0 – 500 
μM) for 30 min (white) and 24 h (black) at 22 oC and 37 oC, respectively. Residual oxidants 
were removed from modified LDL samples using gel filtration.  Cell lysates (0.5 x 106 cells 
mL-1) were exposed to HOCl-modified LDL (0.1 mg protein mL-1) for 15 min at 22 oC. The 
activity of (A) cathepsin B and (B) cathepsin L was determined by fluorescence after 
cleavage of the fluorescently-labelled substrates Z-Arg-Arg-AMC and Z-Phe-Arg-AMC, 
respectively, at λEX 360 nm and λEM 460 nm. The experiment was performed three times, 
each with a different LDL donor. Statistical analysis was performed using one-way ANOVA 
(Dunnett’s posthoc test). *, **, *** represent significant (p<0.05, 0.01, 0.001) difference 
compared to the incubation control (0 μM). #, ##, ### represent significant (p<0.05, 0.01, 
0.001) difference compared to lysates incubated in the absence of LDL treatment.”a”, “aa”, 
“aaa” represent significant (p<0.05, 0.01, 0.001) difference comparing the effects of 30 min 
and 24 h HOCl-modified LDL by two-way ANOVA (Bonferroni’s posthoc test). 
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The greater inactivation induced by LDL pre-treated with HOCl for 30 min compared to 24 h 
was attributed to the presence of chloramines, as suggested previously [67]. Chloramine 
formation was previously assessed in Section 3.3.2.3. In this case, high levels of LDL 
chloramines are generated after the initial 30 min exposure of LDL to HOCl, wheras after 24 
h incubation, all chloramines have further reacted and only minimal levels of these reactive 
species can be detected. Further studies were therefore performed to investigate the 
effects of LDL chloramines on cathepsin activity in cell lysates. Chloramines were removed 
by treatment of HOCl-modified LDL with Met (100 x molar excess compared to HOCl). The 
extent of LDL chloramines quenching was confirmed using the TNB assay (refer to Section 
3.3.2.3). Figure 5.4 shows the inactivation of cathepsin enzymes after exposure of J774A.1 
cell lysates to HOCl-modified LDL, treated with Met to quench the chloramines. There was 
a complete attenuation of the inactivation caused by HOCl-modified LDL on removal of the 
chloramines with Met. No significant decrease in cathepsin B and L activity was observed 
after Met addition, consistent with a role for chloramines in the inactivation of cathepsin B 
and L enzymes exposed to HOCl-modified LDL. 
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Figure 5.4 – Inactivation of Cys-dependent cathepsin enzymes after exposure of J774A.1 
cell lysates to HOCl-modified LDL in the absence of chloramines. LDL (1 mg protein mL-1) 
was exposed to HOCl (0 – 500 μM) for 30 min at 22 oC. LDL chloramines were quenched by 
adding 50 mM Met to each LDL sample. Residual oxidants were removed from modified LDL 
samples using gel filtration. Cell lysates (0.5 x 106 cells mL-1) were exposed to 0.1 mg mL-1 
HOCl-modified LDL (0.1 mg protein mL-1) for 15 min at 22 oC. The activity of cathepsin B 
(white) and cathepsin L (black) was determined by fluorescence after cleavage of the 
fluorescently-labelled substrates Z-Arg-Arg-AMC and Z-Phe-Arg-AMC, respectively, at λEX 
360 nm and λEM 460 nm. The experiment was performed three times, each with a different 
LDL donor. Statistical analysis was performed using one-way ANOVA (Dunnett’s posthoc 
test). No significant differences were observed in the inactivation of cathepsin B and L 
enzymes compared to the incubation control and cell lysates in the absence of LDL. 
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Comparing the reactivity of Cys-dependent cathepsin B and L enzymes to LDL modified by 
HOSCN or HOCl, it was shown that each type of modified LDL affected enzyme activity 
differently, which may be related to the different modifications induced by each oxidant 
(described in Chapter 3). LDL pre-treated with HOCl for 30 min was shown to reduce 
cathepsin B and L enzyme activity in cell lysates more extensively than LDL pre-treated with 
HOSCN (Figure 5.5). This is attributed to the generation of reactive chloramines that target 
Cys residues present within the active site in LDL treated with HOCl. In contrast, LDL pre-
treated with HOCl for 24 h was less effective than LDL pre-treated with HOSCN in reducing 
cathepsin B and L enzyme activity in cell lysates (Figure 5.6). This effect was more 
pronounced with cathepsin L, with no significant difference between the levels of cathepsin 
enzyme activity in lysates exposed to HOCl-modified LDL to that with incubation control. 
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Figure 5.5 – Comparison of Cys-dependent cathepsin enzyme activity after exposure of 
J774A.1 cell lysates to LDL pre-treated with HOSCN and HOCl for 30 min. LDL (1 mg protein 
mL-1) was exposed to 0 – 500 μM HOSCN (white) and HOCl (black) for 30 min at 22 oC, as 
described in the legends of Figure 5.2 and 5.3. The experiment was performed three times, 
each with a different LDL donor. Statistical analysis was performed using one-way ANOVA 
(Dunnett’s posthoc test). *, **, *** represent significant (p<0.05, 0.01, 0.001) difference 
compared to the incubation control (0 μM). #, ##, ### represent a significant (p<0.05, 0.01, 
0.001) difference compared to lysates incubated in the absence of LDL treatment. Two-way 
ANOVA (Bonferroni’s posthoc test) was performed to assess differences between LDL pre-
treated with HOSCN and HOCl at the same dose with “a”, “aa”, “aaa” representing a 
significant (p<0.05, 0.01, 0.001) difference between oxidants. 
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Figure 5.6 – Comparison of Cys-dependent cathepsin enzyme activity after exposure of 
J774A.1 cell lysates to LDL pre-treated with HOSCN and HOCl for 24 h. LDL (1 mg protein 
mL-1) was exposed to 0 – 500 μM HOSCN (white) and HOCl (black) for 24 h at 37 oC, as 
described in the legends of Figure 5.2 and 5.3. The experiment was performed three times, 
each with a different LDL donor. Statistical analysis was performed using one-way ANOVA 
(Dunnett’s posthoc test). *, **, *** represent significant (p<0.05, 0.01, 0.001) difference 
compared to the incubation control (0 μM). #, ##, ### represent a significant (p<0.05, 0.01, 
0.001) difference compared to lysates incubated in the absence of LDL treatment. Two-way 
ANOVA (Bonferroni’s posthoc test) was performed to assess differences between LDL pre-
treated with HOSCN and HOCl at the same dose with “a”, “aa”, “aaa” representing a 
significant (p<0.05, 0.01, 0.001) difference between oxidants. 
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Inactivation of cathepsin B and L enzymes was also observed after exposure of J774A.1 cell 
lysates to OCN- modified LDL. Figure 5.7 shows the loss of cathepsin B and L enzyme activity 
after exposure to OCN- modified LDL. There was a significant decrease in cathepsin B and L 
enzyme activity after exposure of cell lysates to LDL treated with increasing doses of OCN-. 
In this case, even at 500 μM OCN-, where low HCit formation was detected (Chapter 3, 
Section 3.3.2.5), a significant effect on cathepsin enzyme activity was observed. 
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Figure 5.7 – Inactivation of Cys-dependent cathepsin enzymes after exposure of J774A.1 
cell lysates to OCN- modified LDL. LDL (1 mg protein mL-1) was exposed to 0 – 5000 μM 
OCN- for 24 h at 37 oC. Residual OCN- was removed from modified LDL samples using gel 
filtration. Cell lysates (0.5 x 106 cells mL-1) were exposed to OCN--modified LDL (0.1 mg 
protein mL-1) for 15 min at 22 oC. The activity of (A) cathepsin B and (B) cathepsin L was 
determined by fluorescence after cleavage of the fluorescently-labelled substrates Z-Arg-
Arg-AMC and Z-Phe-Arg-AMC, respectively, at λEX 360 nm and λEM 460 nm. The experiment 
was performed three times, each with a different LDL donor. Statistical analysis was 
performed using one-way ANOVA (Dunnett’s posthoc test). **, *** represent a significant 
(p<0.01, 0.001) difference compared to the incubation control (0 μM). ### represents a 
significant (p<0.001) difference compared to lysates incubated in the absence of LDL 
treatment. 
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5.3.1.2 Intact Cells 
The lysate experiments were extended to intact cells, where the lysosomal enzyme activity 
may also be influenced by the cellular uptake of each modified LDL. LDL (1 mg protein mL-1) 
was pre-treated with 250 μM HOSCN, 250 μM HOCl or 2500 μM OCN- for either 30 min or 
24 h prior to addition to the cells in media. In this case, lysosomal enzyme activity was 
assessed after 4 and 24 h incubation of each modified LDL with the cells. Figure 5.8 shows 
the activity of cathepsin B and L enzymes after exposure of J774A.1 cells to LDL pre-treated 
with HOSCN or HOCl for 30 min. In general, there were no significant reductions in 
cathepsin B and L enzyme activity after exposure of cells for 4 or 24 h to HOSCN- or HOCl-
modified LDL, with the exception of a reduction in cathepsin B enzyme activity in cells 
treated with HOSCN-modified LDL for 24 h. This is quite different from the results obtained 
with the cell lysates. This may reflect quenching of chloramines and other reactive species 
by cell media components, which were not present in the cell lysate experiments, together 
with the presence of the cell membrane affecting uptake.  
Further studies were performed using LDL pre-treated with HOSCN, HOCl or OCN- for 24 h 
to demonstrate the effect of more extensively modified LDL on cathepsin B and L enzyme 
activity (Figure 5.9). There were no significant changes in cathepsin B and L enzyme activity 
caused by HOCl-modified LDL exposure to cells for 4 h (Fig 5.9 A). However, exposure of 
cells to HOSCN- and OCN--modified LDL demonstrated a significant loss in cathepsin B 
enzyme activity. After 24 h incubation, changes in enzyme activity after exposure of cells to 
LDL pre-treated with HOSCN-, HOCl- or OCN- for 24 h (Fig 5.9 B) resulted in an extensive 
reduction of cathepsin enzyme activity. In this case, HOSCN-modified LDL showed the 
greatest effect with approx. 50 – 60 % reduction in cathepsin B and L enzyme activity.  
Comparatively, HOCl- and OCN--modified LDL were able to reduce enzyme activity by 
approx. 20 %, which was also significant compared to the incubation control. 
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Figure 5.8 – Inactivation of Cys-dependent cathepsin enzymes after exposure of J774A.1 
cells to HOSCN- and HOCl-modified LDL. LDL (1 mg protein mL-1) was exposed to 250 μM 
HOSCN or HOCl for 30 min at 22 oC. Residual oxidants were removed from modified LDL 
samples using gel filtration.  J774A.1 cells (0.5 x 106 cells mL-1) were exposed to HOSCN- and 
HOCl-modified LDL (0.1 mg protein mL-1) in DMEM media containing 10 % LPDS for (A) 4 
and (B) 24 h at 37 oC. The activity of cathepsin B (white) and cathepsin L (black) was 
determined by fluorescence after cleavage of the fluorescently-labelled substrates Z-Arg-
Arg-AMC and Z-Phe-Arg-AMC, respectively, at λEX 360 nm and λEM 460 nm. The experiment 
was performed three times, each with a different LDL donor. Statistical analysis was 
performed using one-way ANOVA (Dunnett’s posthoc test). * represents a significant 
(p<0.05) difference compared to the incubation control (0 μM). No significant differences 
were observed compared to cells exposed to media in the absence of LDL. 
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Figure 5.9 – Inactivation of Cys-dependent cathepsin enzymes after exposure of J774A.1 
cells to HOSCN-, HOCl- or OCN--modified LDL. LDL (1 mg protein mL-1) was exposed to 250 
μM HOSCN, 250 μM HOCl, or 2500 μM OCN- for 24 h at 37 oC. Residual oxidants were 
removed from modified LDL samples using gel filtration.  J774A.1 cells (0.5 x 106 cells mL-1) 
were exposed to each modified LDL (0.1 mg protein mL-1) in DMEM media containing 10 % 
LPDS for (A) 4 and (B) 24 h at 37 oC. The activity of cathepsin B (white) and cathepsin L 
(black) was determined by fluorescence after cleavage of the fluorescently-labelled 
substrates Z-Arg-Arg-AMC and Z-Phe-Arg-AMC, respectively, at λEX 360 nm and λEM 460 nm. 
The experiment was performed three times, each with a different LDL donor. Statistical 
analysis was performed using one-way ANOVA (Dunnett’s posthoc test). ** represents a 
significant (p<0.01) difference compared to the incubation control (0 μM). ## represents a 
significant (p<0.01) difference compared to lysates incubated in the absence of LDL 
treatment. “a”, “aa”, “aaa” represent a significant (p<0.05, 0.01, 0.001) differences 
comparing the effects of HOSCN- and HOCl-modified LDL in reducing cathepsin enzyme 
activity.  
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5.3.2 Asp-dependent Cathepsins: Cathepsin D 
5.3.2.1 Cell Lysates 
Following assessment of the effects of LDL-derived species on the activities of Cys-
dependent cathepsin B and L, the Asp-dependent cathepsin D was also assessed after 
exposure of J774A.1 cell lysates to HOSCN, HOCl, and OCN- modified LDL. Figure 5.10A 
demonstrates the loss of Asp-dependent cathepsin enzyme activity after exposure of cell 
lysates to HOSCN-modified LDL. With the cathepsin D experiments, there was a discrepancy 
in the fluorescence values obtained in the incubation control LDL and no LDL control 
treatments. This is attributed to the interference due to the yellow-colour of the control 
LDL. Thus, in this case, the results obtained in the cell lysate experiments were expressed 
as activity mg-1 cell lysate protein, rather than as a percentage of the non-treated control. A 
significant loss of cathepsin D enzyme activity was observed on pre-treating LDL with 
HOSCN for 30 min (A) and 24 h (B). The loss of enzyme activity correlated with the extent of 
modification of LDL by HOSCN, with increased reduction observed on treating lysates with 
LDL exposed to a greater dose of HOSCN. Unlike with the Cys-dependent cathepsins B and 
L, the loss of Asp-dependent cathepsin D was more significantly reduced with LDL pre-
treated with HOSCN for 24 h, with significance observed after treatment of lysates with LDL 
exposed to 100 μM HOSCN. In contrast, LDL modified with HOSCN for 30 min only induced 
a significant reduction in cathepsin D activity in the lysates on treatment of LDL with higher 
doses (500 μM) of HOSCN. 
These studies were extended to HOCl-modified LDL to assess the effect of this modified LDL 
on the activity of the Asp-dependent cathepsin D enzyme in cell lysates.  Figure 5.10B 
demonstrates the loss of cathepsin D activity after exposure of cell lysates to HOCl-
modified LDL. There was no clear significant reduction in cathepsin enzyme activity 
detected, with the exception of LDL modified by HOCl for 30 min. These results may 
implicate a role of chloramines. Comparing the effects of HOSCN and HOCl-modified LDL on 
cathepsin D inactivation, it was demonstrated that there were no significant differences 
between the two types of modified LDL (Figure 5.11). 
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Figure 5.10 – Inactivation of cathepsin D on exposure of J774A.1 cell lysates to HOSCN- 
and HOCl-modified LDL. LDL (1 mg protein mL-1) was exposed to 0 – 500 μM (A) HOSCN  
and (B) HOCl for 30 min (white) and 24 h (black) at 22 oC and 37 oC, respectively. Residual 
oxidants were removed from modified LDL samples using gel filtration.  J774A.1 cells (0.5 x 
106 cells mL-1) were exposed to HOSCN- and HOCl-modified LDL (0.1 mg protein mL-1) for 15 
min at 22 oC. The activity of cathepsin D was determined by fluorescence after cleavage of 
the fluorescently-labelled substrate 7-methoxycoumarin-4-acetyl-Gly-Lys-Pro-Ile-Leu-Phe-
Phe-Arg-Leu-Lys(DNP)-D-Arg-amide at λEX 320 nm and λEM 410 nm. The experiment was 
performed three times, each with a different LDL donor. Statistical analysis was performed 
using one-way ANOVA (Dunnett’s posthoc test). *, ** represent a significant (p<0.05, 0.01) 
difference compared to the incubation control (0 μM). No significant differences were 
observed between the effects of 30 min and 24 h modified LDL on cathepsin D enzyme 
activity by two-way ANOVA (Bonferroni’s posthoc test). 
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Figure 5.11 – Comparison of the inactivation of cathepsin D on exposure of J774A.1 cell 
lysates to HOSCN- and HOCl-modified LDL for 30 min and 24 h. LDL (1 mg protein mL-1) 
was exposed to 0 – 500 μM HOSCN (white) and HOCl (black) for (A) 30 min and (B) 24 h at 
22 oC and 37 oC, respectively. Residual oxidants were removed from modified LDL samples 
using gel filtration.  J774A.1 cells (0.5 x 106 cells mL-1) were exposed to HOSCN- and HOCl-
modified LDL (0.1 mg protein mL-1) for 15 min at 22 oC. The activity of cathepsin D was 
determined by fluorescence after cleavage of the fluorescently-labelled substrate 7-
methoxycoumarin-4-acetyl-Gly-Lys-Pro-Ile-Leu-Phe-Phe-Arg-Leu-Lys(DNP)-D-Arg-amide at 
λEX 320 nm and λEM 410 nm. The experiment was performed three times, each with a 
different LDL donor. Statistical analysis was performed using one-way ANOVA (Dunnett’s 
posthoc test). *, ** represent a significant (p<0.05, 0.01) difference compared to the 
incubation control (0 μM). No significant differences were observed between the effects of 
HOSCN- and HOCl-modified LDL on cathepsin D enzyme activity by two-way 
ANOVA(Bonferroni’s posthoc test). 
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The loss of cathepsin D enzyme activity was also assessed after exposure of cell lysates to 
OCN--modified LDL (Figure 5.12). There was no significant reduction in cathepsin D enzyme 
activity observed after exposure of the cell lysates to LDL treated with high (2500 μM) OCN-
, where significant carbamylation and HCit formation was observed (Figure 3.15). Again, 
this behaviour is quite different to that seen with Cys-dependent cathepsin enzyme, which 
showed significant reductions in enzyme activity on treating lysates with OCN--modified 
LDL. 
 
 
 
Figure 5.12 – Inactivation of cathepsin D on exposure of J774A.1 cell lysates to OCN--
modified LDL. LDL (1 mg protein mL-1) was exposed to 0 – 2500 μM OCN- for 30 min (white) 
and 24 h (black) at 22 oC and 37 oC, respectively. Residual oxidants were removed from 
modified LDL samples using gel filtration.  J774A.1 cells (0.5 x 106 cells mL-1) were exposed 
to OCN--modified LDL (0.1 mg protein mL-1) for 15 min at 22 oC. The activity of cathepsin D 
was determined by fluorescence after cleavage of the fluorescently labelled substrate 7-
methoxycoumarin-4-acetyl-Gly-Lys-Pro-Ile-Leu-Phe-Phe-Arg-Leu-Lys(DNP)-D-Arg-amide at 
λEX 320 nm and λEM 410 nm. The experiment was performed three times, each with a 
different LDL donor. Statistical analysis was performed using one-way ANOVA (Dunnett’s 
posthoc test). *, ** represent a significant (p<0.05, 0.01) difference compared to the 
incubation control (0 μM). No significant differences were observed between the effects of 
30 min and 24 h modified LDL on cathepsin D enzyme activity by two-way ANOVA 
(Bonferroni’s posthoc test). 
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5.3.2.2 Intact Cells 
The activity of cathepsin D was also examined in an intact cell system using J774A.1 cells. 
Figure 5.13 demonstrates the loss of cathepsin D enzyme activity after exposure of the cells 
to different forms of modified LDL. LDL (1 mg protein mL-1) was modified for 30 min at 22 
oC with 250 μM HOSCN or HOCl. Cathepsin D enzyme was assessed after (A) 4 h and (B) 24 
h incubation of this modified LDL with J774A.1 cells. With the intact cell experiments, there 
are no interferences from the yellow-coloured LDL, which complicated the cell lysate 
experiments. Thus, in this case, the treatment in the absence of LDL (no LDL control) can be 
included and values were expressed relative to this. There were no significant losses in 
J774A.1 cathepsin D enzyme activity observed after exposure of the cells to either type of 
modified LDL for 4 or 24 h. 
This study was extended to examine the reactivity of cathepsin D in J774A.1 cells with more 
extensively modified LDL pre-treated with HOSCN, HOCl or OCN- for 24 h at 37 oC (Figure 
5.14). Similar to LDL-pre-treated with oxidants for 30 min, the effect of LDL pre-treated 
with HOCl for 24 h did not show any significant effect on cathepsin D enzyme activity. 
There was a significant reduction observed with HOSCN-modified LDL after 4 h incubation 
with the cells. However, there was no significant effect observed after exposure of J774A.1 
cells to LDL modified by HOSCN for 24 h. Cathepsin D appears to be less sensitive to 
modified-LDL induced inactivation compared to cathepsins B and L. 
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Figure 5.13 – Inactivation of cathepsin D on exposure of J774A.1 cells to HOSCN- and 
HOCl-modified LDL. LDL (1 mg protein mL-1) was exposed to 250 μM HOSCN or HOCl for 30 
min at 22 oC. Residual oxidants were removed from modified LDL samples using gel 
filtration.  J774A.1 cells (0.5 x 106 cells mL-1) were exposed to HOSCN- and HOCl-modified 
LDL (0.1 mg protein mL-1) in DMEM media containing 10 % LPDS for (A) 4 and (B) 24 h at 37 
oC. The activity of cathepsin D was determined by fluorescence after cleavage of the 
fluorescently-labelled substrate 7-methoxycoumarin-4-acetyl-Gly-Lys-Pro-Ile-Leu-Phe-Phe-
Arg-Leu-Lys(DNP)-D-Arg-amide at λEX 320 nm and λEM 410 nm. The experiment was 
performed three times, each with a different LDL donor. Statistical analysis was performed 
using one-way ANOVA (Dunnett’s posthoc test). No significant differences were observed 
between the effects of different modified LDL to the incubation control and cells treated in 
the absence of LDL. Furthermore, no significant differences were observed between the 
effects of HOSCN- and HOCl- modified LDL on the inactivation of cathepsin D activity. 
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Figure 5.14 – Inactivation of cathepsin D on exposure of J774A.1 cells to HOSCN-, HOCl-, 
and OCN--modified LDL. LDL (1 mg protein mL-1) was exposed to 250 μM HOSCN, 250 μM 
HOCl or 2500 μM OCN- for 24 h at 37 oC. Residual oxidants were removed from modified LDL 
samples using gel filtration.  J774A.1 cells (0.5 x 106 cells mL-1) were exposed to HOSCN- and 
HOCl-modified LDL (0.1 mg protein mL-1) in DMEM media containing 10 % LPDS for (A) 4 
and (B) 24 h at 37 oC. The activity of cathepsin D was determined by fluorescence after 
cleavage of the fluorescently-labelled substrate 7-methoxycoumarin-4-acetyl-Gly-Lys-Pro-
Ile-Leu-Phe-Phe-Arg-Leu-Lys(DNP)-D-Arg-amide at λEX 320 nm and λEM 410 nm. Statistical 
analysis was performed using one-way ANOVA (Dunnett’s posthoc test). * represents a 
significant (p<0.05) difference compared to the incubation control. # represents a significant 
(p<0.05) difference compared to cells incubated in the absence of LDL. No significant 
differences were observed between the effects of HOSCN- and HOCl- modified LDL on the 
inactivation of cathepsin D. 
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5.3.3 Lysosomal Acid Lipase 
5.3.3.1 Cell Lysates  
The ability of LDL modified by MPO-derived oxidants to modulate the activity of lysosomal 
acid lipase (LAL) was also assessed. Figure 5.15A demonstrates the inactivation of LAL by 
HOSCN-modified LDL. Cell lysates were exposed to HOSCN-LDL, which had a varying extent 
of modification induced by exposure to increasing concentrations of HOSCN. The detected 
values of the activity of LAL enzymes were corrected for cell lysate protein levels. 
Differences between the effects of 30 min and 24 h incubation of HOSCN with the LDL were 
also examined. Exposure of J774A.1 lysates to HOSCN-modified LDL led to a significant 
reduction in LAL activity. In this case, LDL pre-treated with HOSCN for 30 min or 24 h were 
shown to reduce LAL enzyme activity to a similar extent. Furthermore, the effects observed 
were also modulated by the extent of oxidation, with the LAL inactivation reflecting the 
dose of HOSCN used to modify LDL. 
The effect of HOCl-modified LDL on LAL enzyme activity in cell lysates was also assessed as 
shown in Figure 5.15B. Exposure of cell lysates to HOCl-modified LDL led to a significant 
reduction in LAL activity with a greater reduction in activity with higher HOCl. In this case, 
the exposure of LDL pre-treated with HOCl for 24 h to cell lysates resulted in a greater 
extent of LAL inactivation. This contrasts with the data obtained in the cathepsin B and L 
studies, where the LDL treated with the oxidant for 30 min was more potent. With LAL, no 
significant differences were observed in the extent of enzyme inactivation on comparing 
HOSCN- and HOCl-modified LDL (Figure 5.16). 
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Figure 5.15 – Inactivation of lysosomal acid lipase (LAL) enzyme after exposure of J774A.1 
cell lysates to HOSCN- and HOCl- modified LDL. LDL (1 mg protein mL-1) was exposed to 0 – 
500 μM (A) HOSCN and (B) HOCl for 30 min (white) and 24 h (black) at 22 oC and 37 oC, 
respectively. Residual oxidants were removed from modified LDL samples using gel 
filtration.  J774A.1 cell lysates (0.5 x 106 cells mL-1) were exposed to HOSCN- and HOCl-
modified LDL (0.1 mg protein mL-1) for 15 min at 22 oC. The activity of LAL was determined 
by fluorescence after cleavage of the fluorescently-labelled substrate 4-methylumbelliferyl 
oleate (4-MUO) at λEX 360 nm and λEM 460 nm. The experiment was performed three times, 
each with a different LDL donor. Statistical analysis was performed using one-way ANOVA 
(Dunnett’s posthoc test). *, ** represent a significant (p<0.05, 0.01) difference compared to 
the incubation control (0 μM). #, ## represent a significant (p<0.05, 0.01) difference 
compared to cell lysates without added LDL. Two-way ANOVA (Bonferroni’s posthoc test) 
was performed to examine differences between the effects of 30 min and 24 h modified LDL 
on lysosomal acid lipase activity; “a” represents a significant (p<0.05) difference comparing 
30 min to 24 h modified LDL.  
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Figure 5.16 – Comparison of lysosomal acid lipase (LAL) activity after exposure of J774A.1 
cells to HOSCN- and HOCl-modified LDL. LDL (1 mg protein mL-1) was exposed to 0 – 500 
μM HOSCN (white) and HOCl (black) for (A) 30 min and (B) 24 h at 22 oC and 37 oC, 
respectively. Residual oxidants were removed from modified LDL samples using gel 
filtration.  J774A.1 cell lysates (0.5 x 106 cells mL-1) were exposed to HOSCN- and HOCl-
modified LDL (0.1 mg protein mL-1) for 15 min at 22 oC. The activity of LAL was determined 
by fluorescence after cleavage of the fluorescently-labelled substrate 4-methylumbelliferyl 
oleate (4-MUO) at λEX 360 nm and λEM 460 nm. The experiment was performed three times, 
each with a different LDL donor. Statistical analysis was performed using one-way ANOVA 
(Dunnett’s posthoc test). *, ** represent a significant (p<0.05, 0.01) difference compared to 
the incubation control (0 μM). #, ## represent a significant (p<0.05, 0.01) difference 
compared to cell lysates without added LDL. No significant differences were observed 
comparing HOSCN- and HOCl-modified LDL by two-way ANOVA (Bonferroni’s posthoc test). 
175 
 
OCN--modified LDL was also assessed for its ability to alter LAL enzyme activity. Figure 5.17 
shows LAL enzyme activity after exposure of cell lysates to OCN- modified LDL. In this case, 
higher doses of OCN- were used to induce carbamylation, with concentrations ranging from 
500 – 2500 μM. There were no significant reductions in LAL activity detected after 
exposure of cell lysates to OCN- modified LDL compared to the incubation control LDL, 
though a loss in activity was apparent in comparison to lysates with no added LDL. 
 
 
 
Figure 5.17 – Inactivation of lysosomal acid lipase (LAL) activity after exposure of J774A.1 
cell lysates to OCN--modified LDL. LDL (1 mg protein mL-1) was exposed to 0 – 2500 μM 
OCN- for 24 h at 37 oC, respectively. Residual OCN- was removed from modified LDL samples 
using gel filtration.  J774A.1 cell lysates (0.5 x 106 cells mL-1) were exposed to OCN--modified 
LDL (0.1 mg protein mL-1) for 15 min at 22 oC. The activity of LAL was determined by 
fluorescence after cleavage of the fluorescently-labelled substrate 4-methylumbelliferyl 
oleate (4-MUO) at λEX 360 nm and λEM 460 nm. The experiment was performed three times, 
each with a different LDL donor. Statistical analysis was performed using one-way ANOVA 
(Dunnett’s posthoc test). No significant differences were observed comparing the effect of 
OCN- modified LDL to the incubation control (0 μM). #, ## represent a significant (p<0.05, 
0.01) difference compared to cell lysates without added LDL. 
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5.3.3.2 Intact Cells 
The effect of modified LDL on LAL enzyme activity was also examined in intact J774A.1 cells. 
Figure 5.18 shows the loss of LAL activity after exposure of the cells to LDL pre-treated with 
HOSCN, HOCl and OCN- for 30 min at 22 oC. LAL enzyme activity was examined after 4 and 
24 h of initial exposure of cells to the modified LDL. It was demonstrated that LDL modified 
for 30 min with HOSCN, HOCl or OCN- was not effective in reducing LAL enzyme activity 
significantly in J774A.1 cells on incubation for 4 and 24 h. 
This study was extended to a more extensively modified LDL, where LDL was pre-treated 
with oxidants for 24 h at 37 oC, as shown in Figure 5.19. LAL enzyme activity was examined 
after 4 and 24 h of exposure of cells to each modified LDL. In this case, exposure of cells to 
HOSCN-, HOCl-, and OCN- - modified LDL resulted in a reduction of LAL enzyme activity, 
which was significant after 24 h incubation. Comparatively, HOSCN-, HOCl- and OCN-- 
modified LDL contributed similarly to the reduction of LAL enzyme activity observed under 
these conditions. It is interesting, however, that although OCN- modified LDL did not 
contribute to the direct inhibition of LAL enzyme activity, there was a significant reduction 
observed when OCN- modified LDL was exposed to intact J774A.1 cells. This may suggest an 
indirect mechanism is responsible for the inhibition of LAL activity. 
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Figure 5.18 – Inactivation of lysosomal acid lipase (LAL) after exposure of J774A.1 cells to 
30 min HOSCN- and HOCl-modified LDL. LDL (1 mg protein mL-1) was exposed to 250 μM 
HOSCN, 250 μM HOCl, and 2500 μM OCN- for 30 min at 37 oC. Residual oxidants were 
removed from LDL by gel filtration.  J774A.1 cells (0.5 x 106 cells mL-1) were exposed to 
HOSCN- and HOCl-modified LDL (0.1 mg protein mL-1) in DMEM media containing 10 % LPDS 
for (A) 4 and (B) 24 h at 37 oC. The activity of LAL was determined by fluorescence after 
cleavage of the fluorescently-labelled substrate 4-methylumbelliferyl oleate at λEX 360 nm 
and λEM 460 nm. The experiment was performed three times, each with a different LDL 
donor. Statistical analysis was performed using one-way ANOVA (Dunnett’s posthoc test). 
No significant differences were observed on comparing the effect of modified LDL to the 
incubation control and cells incubated with no LDL. Furthermore, no significant differences 
were observed comparing the effect of HOSCN-, HOCl- and OCN--modified LDL. 
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Figure 5.19 – Inactivation of lysosomal acid lipase (LAL) after exposure of J774A.1 cells to 
24 h HOSCN, HOCl and OCN--modified LDL. LDL (1 mg protein mL-1) was exposed to 250 μM 
HOSCN, 250 μM HOCl and 2500 μM OCN- for 24 h at 37 oC. Residual oxidants were removed 
from modified LDL samples using gel filtration.  J774A.1 cells (0.5 x 106 cells mL-1) were 
exposed to HOSCN-, HOCl-, and OCN--modified LDL (0.1 mg protein mL-1) in DMEM media 
containing 10 % LPDS for (A) 4 and (B) 24 h at 37 oC. The activity of LAL was determined by 
fluorescence after cleavage of the fluorescently-labelled substrate 4-methylumbelliferyl 
oleate at λEX 360 nm and λEM 460 nm. The experiment was performed three times, each with 
a different LDL donor. Statistical analysis was performed using one-way ANOVA (Dunnett’s 
posthoc test). **, *** represent a significant (p<0.01, 0.001) difference compared to the 
incubation control. ##, ### represent a significant (p<0.01, 0.001) difference compared to 
cells treated in the absence of LDL. No significant difference was observed comparing the 
effect of HOSCN-, HOCl- and OCN--modified LDL on LAL enzyme activity. 
 
179 
 
5.3.4 Cys-dependent Cathepsins: Cathepsin B and L in Primary Human 
Monocyte Endothelial Cells 
Preliminary studies were performed with primary HMDM cells to assess the alteration of 
Cys-dependent cathepsins B and L enzyme activity, which was reduced in J774A.1 cells 
exposed to HOSCN-, HOCl, and OCN- modified LDL, particularly when LDL was pre-treated 
with the oxidant for 24 h at 37 oC. Given that studies in Chapter 4 showed that HMDM cells 
take longer to accumulate LDL compared to J774A.1 cells, in this case, cathepsin enzyme 
activity was assessed after incubation of HMDM with modified LDL for 24 h and 48 h at 37 
°C (Figure 5.20). Unlike J774A.1 cells, there were no significant reductions in Cys-dependent 
cathepsin activity observed. Although there were no significant changes in cathepsin 
enzyme activity, there was a trend towards an increase in activity in this case. Due to high 
variability, however, this preliminary result was not conclusive and further experiments are 
required to confirm these results. Sources of variability may be associated with the donors 
from which the primary HMDM cells were isolated from. Due to time constraints, no 
further HMDM experiments were performed to elucidate the effects of HOSCN-, HOCl- and 
OCN--modified LDL on cathepsin B and L activity in more detail. 
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Figure 5.20 – Inactivation of Cys-dependent cathepsins after exposure of HMDM cells 
with HOSCN-, HOCl- and OCN--modified LDL. LDL (1 mg protein mL-1) was exposed to 250 
μM HOSCN, 250 μM HOCl, and 2500 μM OCN- for 24 h at 37 oC. Residual oxidants were 
removed from modified LDL samples using gel filtration.  HMDM cells (0.5 x 106 cells mL-1) 
were exposed to HOSCN- and HOCl-modified LDL (0.1 mg protein mL-1) in RPMI media 
containing 10 % HS for (A) 24 and (B) 48 h at 37 oC. The activity of cathepsin B (white) and 
cathepsin L (black) was determined by fluorescence after cleavage of the fluorescently-
labelled substrates Z-Arg-Arg-AMC and Z-Phe-Arg-AMC, respectively, at λEX 360 nm and λEM 
460 nm. The experiment was performed three times, each with a different LDL donor 
Statistical analysis was performed using one-way ANOVA (Dunnett’s posthoc test). No 
significant differences were observed in the effect of modified LDL compared to the 
incubation control and cells treated in the absence of LDL. Furthermore, no significant 
differences were observed comparing the effects of HOSCN-, HOCl- and OCN--modified LDL.  
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5.4 Discussion 
The studies reported in this chapter examined the effect of LDL modified by MPO-derived 
oxidants on lysosomal enzyme function in macrophages. These data build on the studies 
reported in Chapter 4, which outlined the possible implications of MPO oxidant modified 
LDL on the accumulation of cholesterol and cholesteryl esters in macrophage cells. The 
uncontrolled cellular uptake of cholesterol and cholesteryl esters may be related to the 
dysfunction of macrophages in processing internalised LDL, which has been reported 
previously with other types of modified LDL [67, 70, 628]. This chapter assessed the ability 
of LDL modified by HOSCN, HOCl or OCN- to induce changes in lysosomal enzyme activity, 
focusing on the two main enzyme types present in the lysosomal compartment of 
macrophage cells, namely the cathepsin enzymes and LAL, which degrade proteins and 
hydrolyse cholesteryl esters, respectively [289, 290, 634]. Thus, inactivation of these 
enzymes may contribute to the accumulation of the LDL particle within macrophage cells 
and subsequent formation of foam cells [288, 289, 612, 634]. 
The present study demonstrated that HOSCN, HOCl and OCN- -modified LDL can alter 
lysosomal enzyme activity, both in cell lysates and intact cells Initial studies were 
performed by the exposure of cell lysates to modified LDL, which assessed the ability of 
modified LDL particles to interact directly with the enzymes under study. 
HOSCN-modified LDL was able to reduce Cys-dependent cathepsin enzyme activity in 
lysates significantly in a HOSCN dose-dependent manner. Inactivation of these enzymes 
was observed to be more pronounced after exposure to 30 min modified LDL. This may be 
associated with interactions of these enzymes with short-lived oxidation products formed 
on LDL, such as RS-SCN or RN-SCN species [92]. The nature of the reactive products formed 
on HOSCN-modified LDL was not examined further. Similarly, LDL exposed to HOCl for 30 
min had a significant effect on cathepsin B and L activity. This effect was observed to be 
greater than LDL modified by HOCl for 24 h. This difference may be related to formation of 
chloramines that decompose on prolonged incubation of LDL with HOCl, as quenching 
chloramines formed on LDL by the addition of Met, led to the prevention of enzyme 
inactivation. Chloramines are known for their reactive properties with a diverse range of 
targets. In particular, previous studies have highlighted the reactivity of chloramines with 
Cys residues and thiol-containing proteins [67, 631-633, 635]. In this case, cathepsin B and L 
enzymes are highly dependent upon the presence of Cys residues in their active site for 
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their catalytic activity [290]. Although both cathepsin B and L enzymes contain crucial Cys 
residues within their active site, it was demonstrated in the present study that cathepsin L 
is more sensitive to inactivation than cathepsin B. This observed difference could be 
attributed to the amount of these enzymes within the lysosomes. The absolute activity 
values of cathepsin L is 3-4-fold higher, which could be more susceptible to inactivation 
than cathepsin B. Carbamylation of LDL and HCit formation also resulted in alterations to 
enzyme activity when cell lysates were exposed to OCN- modified LDL. The mechanism for 
the interaction of carbamylated LDL on the cathepsin enzyme active sites is not certain. It 
may be associated with residual OCN- present, despite the extensive gel filtration, owing to 
the high concentrations OCN- employed. OCN- was shown to carbamylate Cys residues [66], 
which may result in the loss of cathepsin B and L activity. 
There is limited evidence showing the role of MPO-derived oxidant modified LDL on the 
inactivation of Cys-dependent cathepsin enzymes. It was previously shown that HOCl-
modified LDL is capable of reducing isolated cathepsin B enzyme activity [67], which agrees 
well with the data in the current study. Furthermore, it was postulated that Lys-derived 
chloramines were important in this effect [67]. Lys-derived chloramines have been shown 
to induce other effects in macrophages, including being implicated in the uptake of HOCl-
modified LDL [302]. Other studies that investigated the role of modified LDL on Cys-
dependent cathepsins were performed using Cu2+-modified LDL [70, 628]. It was previously 
demonstrated that Cu2+ can induce significant modifications to the LDL lipid moieties, 
which renders the LDL resistant to hydrolysis by lysosomal enzymes. Furthermore, it was 
shown that Cu2+-modified LDL can contribute to the inactivation of these enzymes and 
particularly cathepsin B [70, 628]. In this case, the reduction in cathepsin B enzyme activity 
was associated with the formation of reactive aldehydes that form after the decomposition 
of lipid hydroperoxides, such as 4-hydroxynonenal (4-HNE) [68, 70, 636-638]. In this case, 
4-HNE forms Michael adducts with the Cys 29 (mature A chain) and His 150 (a mature B 
chain) residues present within the active site of the enzyme. This effect of Cu2+-modified 
LDL may be important in the context of HOSCN-modified LDL. Similar to Cu2+-modified LDL, 
HOSCN-modified LDL was shown to induce lipid peroxidation, with evidence for lipid 
hydroperoxides, 9-HODE and F2-isoprostanes (refer to Chapter 3, Section 3.3.3.3). Thus, it is 
postulated that the formation of these lipid peroxidation products may contribute to the 
inhibition of enzyme activity in Cys-dependent cathepsins. However, the formation of 4-
HNE formed from lipid hydroperoxides generated by HOSCN was not quantified in the 
present study. 
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Assessment of the activity of Asp-dependent cathepsin D was also performed to further 
investigate the ability of modified LDL to inactivate cathepsin enzymes. Cathepsin D is 
reported to contribute to the degradation of LDL after uptake by macrophages, by 
facilitating the hydrolysis of apoB100 into peptides [627]. Asp- and Cys-dependent 
cathepsin enzymes have been reported to work together, with the Asp-dependent 
cathepsins being responsible for the hydrolysis of apoB100 into large peptides and the Cys-
dependent cathepsins being responsible for the further degradation of these large peptides 
into constituent amino acids [627]. The present study showed that although the direct 
exposure of cell lysates to modified LDL resulted in a significant reduction of cathepsin D 
activity, the effect was less marked than the loss of activity observed with the Cys-
dependent cathepsin B and L. Moreover, the loss in activity with cathepsin D was less 
dependent on the type of modified LDL, with similar effects observed with HOSCN, HOCl 
and OCN- modified LDL. The results obtained in the present study are in agreement with 
previous findings, where although HOCl-modified LDL has been shown to inhibit cathepsin 
B activity, no significant reduction in cathepsin D activity observed [67]. Analogous results 
are reported in studies using Cu2+-modified LDL, indicating that 4-HNE and lipid 
peroxidation events may not contribute to the inactivation of cathepsin D [70, 628]. The 
effect of HOSCN-modified LDL may be related to the decomposition of intermediate 
reactive species, which may help to explain the greater effect mediated by 30 min HOSCN-
modified LDL compared to the 24 h HOSCN-modified LDL. Again, the exact nature of 
species responsible on HOSCN-modified LDL was not further investigated. 
The role of modified LDL in potentially reducing LAL enzyme activity was also examined. 
Unlike cathepsin enzymes, LAL is responsible for the hydrolysis of cholesteryl esters into 
cholesterol, which can then be further utilised or removed from the cells [289]. In the case 
of macrophages, excess cholesterol can be removed via the reverse cholesterol transport 
pathway, mediated by HDL [287]. The impairment of the hydrolysis step by LAL can 
therefore contribute to the uncontrolled accumulation of lipids within macrophage cells 
and the formation of foam cells [289]. 
In the present study, evidence for the accumulation of lipids after exposure of 
macrophages to HOSCN-, HOCl-, and OCN- modified LDL was outlined in the previous 
chapter (Chapter 4). The exposure of cell lysates to HOSCN- and HOCl-modified LDL 
resulted in a significant inhibition of LAL activity. Unlike the reduction of cathepsin enzyme 
activity, LAL enzyme inactivation was shown to be greater when the cell lysates were 
184 
 
exposed to 24 h modified LDL, as opposed to 30 min modified LDL. This suggests that the 
mechanism behind LAL inactivation may be different to that responsible for cathepsin 
inactivation. This is consistent with the differences in the nature of the LAL active site, 
which contains serine residues at residues 99 and 153 [619]. In this case, carbamylated LDL 
was not shown to reduce LAL enzyme activity, even after modification of LDL with 2500 μM 
OCN- for 24 h. 
There is less information regarding the role of modified LDL in mediating LAL inactivation. 
One study showed evidence for a role of lipid peroxides in reducing the activity of acid and 
neutral cholesteryl esterases [620]. In this case, a correlation was found between the 
extent of inactivation and elevated levels of LDL lipid hydroperoxides [620]. Thus, it is 
postulated that LAL activity inactivation mediated by HOSCN-modified LDL (see Figure 3.19 
in Chapter 3) may be associated with the generation of lipid hydroperoxides. Although with 
HOCl- and OCN- modified LDL, there were no significant lipid peroxidation products 
observed under the conditions employed in this study, loss of LAL was apparent, indicating 
that other pathways may also contribute to the inactivation of these enzymes.  
To comprehensively assess the effects of HOSCN-, HOCl- and OCN- modified LDL on 
lysosomal enzyme function, the studies performed on cell lysates were extended to intact 
cell conditions to assess changes in both Cys- and Asp-dependent cathepsins and LAL 
enzyme in the presence of the cell membrane, which could limit accessibility of the 
lysosomal enzymes. 
The results obtained on exposure of intact cells to HOSCN-, HOCl- and OCN--modified LDL 
differed to those obtained in the cell lysate experiments. In this case, uptake of LDL and 
sub-cellular trafficking to the lysosomes is required to allow the interaction of the modified 
LDL with the lysosomal enzymes. Furthermore, interactions of reactive species present 
within LDL may also interact with components of the cell media used, whereas PBS was 
employed in the cell lysate experiments. LDL modified for 30 min with either HOSCN or 
HOCl did not lead to significant inactivation of Cys-dependent cathepsin enzymes after 
incubation for 4 - 24 h. On the other hand, LDL modified for 24 h resulted in the 
inactivation of these enzymes, with significant inactivation observed after 24 h exposure to 
J774A.1 cells. Moreover, in this case, HOSCN-modified LDL was more effective in reducing 
cathepsin enzyme inactivation compared to HOCl- and OCN--modified LDL. The difference 
demonstrated between 30 min and 24 h modified LDL is attributed to the extent of non-
reversible LDL modification induced by oxidants on extended incubation. Similarly, LDL 
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modified for 30 min did not elicit extensive lipid uptake in either J774A.1 or HMDM cells, 
consistent with limited exposure of lysosomal enzymes to modified LDL. With LDL modified 
for 24 h, there was more extensive uptake of modified LDL observed in both J774A.1 and 
HMDM cells, which was most pronounced with HOCl-modified LDL. Although lipid uptake 
studies have shown that the exposure of macrophages to HOCl-modified LDL resulted in 
the greater accumulation of cholesterol and cholesteryl esters, exposure of J774A.1 cells to 
HOSCN-modified LDL resulted in a greater reduction in cathepsin B and L activity compared 
to HOCl-modified LDL. This difference may be due to a limitation of the study, whereby the 
apoB100 protein uptake and turnover within these cells were not assessed, which opens up 
studies looking at the accumulation of apoB100 within macrophage cells. 
Although evidence for cathepsin B and L inactivation has been obtained, no loss in activity 
of cathepsin D was observed. This differed from the cell lysate experiments, which showed 
significant reductions in cathepsin D activity when J774A.1 cell lysates were exposed to 
HOSCN- and HOCl-modified LDL. These differences with HOSCN-modified LDL may be 
associated with the removal of crucial reactive intermediate radicals due to interactions 
with components of the cell media used, resulting in an underestimation of the effect 
mediated by HOSCN-modified LDL. In this case, much like HOCl- and Cu2+-modified LDL, 
HOSCN and OCN- modified LDL did not reduce cathepsin D enzyme activity. Although there 
was no correlation with the inactivation of cathepsin D enzyme mediated by HOSCN-, HOCl- 
and OCN—modified LDL, it has been previously postulated that inactivation of only one type 
of cathepsin enzyme may initiate the accumulation of lipids [67, 627]. 
Intact cell experiments were also performed to examine LAL enzyme activity in 
macrophages exposed to HOSCN-, HOCl- and OCN- -modified LDL. Exposure of intact 
J774A.1 cells to 30 min modified LDL led to no reductions in LAL activity with HOSCN- and 
HOCl-modified LDL. However, exposure of intact cells to 24 h modified LDL did lead to a 
significant reduction in LAL activity with HOSCN-, HOCl- and OCN--modified LDL, consistent 
with the Cys-dependent cathepsin results. The extent of the changes in LAL enzyme activity 
observed in the cell lysates and intact cells were different, where 24 h modification was 
required for significant inactivation of the LAL enzyme. This may be associated with 
increased recognition and uptake of the modified LDL by macrophages at this time point as 
has been demonstrated with HOCl-modified LDL (refer to Section 4.3.3), which leads to a 
greater exposure of the LAL enzyme to the modified LDL. Furthermore, the greater effect of 
186 
 
24 h modified LDL may also be attributed to the formation of crucial oxidation products, 
such has lipid hydroperoxides, which were shown to target cholesteryl esterases [620]. 
It is important to note that despite differences in the residues present within the active site 
of Cys-dependent cathepsin and LAL enzymes, similar reductions in activity was observed. 
It was previously observed that Ser residues are not easily prone to oxidation, compared to 
Cys-residues [56, 64, 66, 91]. This suggests that oxidation of LDL may generate reactive 
species that can target Ser residues. Another possibility for the loss of activity may be 
associated with the resulting unfolding of the protein due to modifications of other amino 
acid residues present within the LAL enzyme. However, further studies in protein 
sequencing and determining sites of modifications may need to be performed to 
comprehensively elucidate the mechanism behind the inactivation of the LAL enzyme. 
One previous study investigated the inactivation of cathepsin enzymes after exposure to 
Cu2+-modified LDL in mouse peritoneal macrophage (MPM) cells [70]. In this study, there 
was a reduction in Cys-dependent cathepsin enzyme activity after exposure of cells to Cu2+-
modified LDL [70]. Furthermore, no reduction in cathepsin D activity was observed when 
cells were exposed to Cu2+-modified LDL, which agrees with the findings observed in the 
present study. The changes in cathepsin activity were postulated to be associated with the 
formation of 4-HNE [636-638], which may be important, especially with HOSCN-modified 
LDL via the formation of lipid hydroperoxides. Thus, there was a greater reduction 
observed in Cys-dependent cathepsin enzyme activity compared to HOCl- and OCN- -
modified LDL. 
It is important to note that the preliminary studies with HMDM cells reported here showed 
a different pattern of reactivity compared to the J774A.1 cells. In this case, exposure of 
HOSCN, HOCl and OCN- modified LDL to HMDM did not significantly reduce cathepsin B and 
L activity. Although there was no significance detected, there was a trend towards an 
increase in activity in this case. The lack of significance may be reflective of the various 
donors from which the HMDM cells were isolated from. The significance of the possibility 
of increasing cathepsin B and L enzyme activity may be related to the role of cathepsin 
enzymes in the disruption of the lipid plaques. Multiples studies have shown that cathepsin 
enzymes are secreted by smooth muscle cells, endothelial cells, macrophages, and 
neonatal cardiomyocytes [639-642]. This may contribute to the notion that Cys-dependent 
cathepsins may be involved in the disruption of the extracellular matrix [643]. 
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The data reported in the present chapter partially reflect the outcomes of the lipid 
accumulation studies in Chapter 4. HOSCN- HOCl- and OCN- modified LDL were able to 
reduce Cys-dependent cathepsin and lysosomal acid lipase enzyme activity in both non-
intact and intact cell system, suggesting that direct inhibition is occurring. These data have 
biological significance with the outcome of poor protein and lipid degradation mediated by 
HOSCN-, HOCl- and OCN- -modified LDL, potentially leading to the accumulation of protein-
lipid crosslinked materials, known as ceriods, within cells. These accumulated particles have 
been demonstrated to be present within foam cells [644, 645]. However, the preliminary 
studies with HMDM provided different results that are inconsistent with the outcomes of 
the lipid accumulation studies reported in Chapter 4, which suggests that further studies 
should be carried out. Lysosomal enzyme inactivation has been suggested to be crucial in 
the development of atherosclerosis, which has been observed to be an initial event in the 
development of fatty streaks through the formation of foam cells [646]. Recently, it was 
reported that in tissues that contain fatty streaks, there was an alteration and structural 
changes in lysosomes, with the detection of lamellar bodies [646]. Lamellar bodies have 
been found in conditions that involve pathological lysosomal stress, which may reflect a 
reduced functional activity of the lysosomal enzymes [647, 648]. Thus, reduction in 
lysosomal enzyme activity mediated by HOSCN-, HOCl- and OCN--modified LDL 
demonstrated in this Chapter may make important contributions to the development of 
atherosclerosis, especially in smokers who display high plasma SCN-, contributing to the 
formation of HOSCN [327]. Furthermore, HOSCN contributes to the formation of OCN-, 
which may also contribute to lysosomal enzyme dysfunction. 
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Chapter 6: General Discussion and 
Future Directions 
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6.1 Overview 
The research described in this thesis was designed to elucidate the contribution of HOSCN 
to LDL modification and whether this mediates cellular dysfunction in a manner that may 
promote the development of atherosclerosis. Oxidative modification of LDL has been 
proposed as a key event in the initiation of atherosclerosis [259], which leads to the 
uncontrolled uptake of cholesterol and cholesteryl esters by macrophages [280, 335]. This 
triggers a cascade of pro-inflammatory events, which further exacerbate disease [219]. 
Understanding the agents responsible for modifying LDL in vivo and the resulting pathways 
of cell dysfunction is important for the development of new therapies for atherosclerosis. 
MPO is enriched in human atherosclerotic lesions and has been reported to modify LDL in 
vivo [11]. Furthermore, the level of MPO has been strongly associated with the 
development of atherosclerosis, both as a risk factor and a prognostic agent [209, 231]. The 
ability of MPO to modify LDL has been linked to the generation of HOCl [311, 415, 649, 
650]. There are many studies that show the important contribution of HOCl to LDL 
modification [102, 300, 302, 311, 415, 416, 649-651], however, the contribution of the 
other major MPO-derived oxidant HOSCN, has not been well studied previously. The 
biological importance of HOSCN formation by MPO is highlighted by tobacco smoking, 
which elevates plasma SCN- levels and hence the formation of this oxidant in smokers [326, 
327]. The reactivity of HOSCN and SCN--derived oxidants is known to differ from that of 
HOCl [652]. HOSCN specifically targets Cys residues within isolated proteins and in cells, 
which can result in cellular dysfunction [4, 65]. In addition, SCN--derived oxidants have 
been reported to induce lipid peroxidation after the exposure of LDL to the enzymatic 
MPO/H2O2/SCN
- system [82]. HOSCN can also decompose to OCN-, which may further 
contribute to the effects mediated by SCN--derived oxidants produced by MPO. Thus, OCN- 
promotes protein carbamylation, which is also linked to the development of cardiovascular 
disease [24]. 
The present study has shown that HOSCN, HOCl and OCN- each react with LDL in a distinct 
manner, which affects the way that the resulting modified LDL interacts with macrophages. 
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6.2 Characterisation of LDL Modification by HOSCN, HOCl 
and OCN- 
The modification of LDL induced by HOSCN was demonstrated to differ from that of HOCl. 
HOCl modifies apoB100 in a dose-dependent manner, resulting in the modification of 
susceptible amino acid residues (Cys, Met, Trp, Tyr and Lys), alteration of particle charge 
and changes in the protein structure with both fragmentation and aggregation observed. 
HOSCN, on the other hand, modified only Cys and Trp residues. This also caused changes in 
LDL charge, though to a lesser extent than HOCl. Decomposition of HOSCN resulted in the 
formation of OCN-, which at high concentrations (500 – 5000 μM), formed HCit [24]. 
However, the exposure of apoB100 to the enzymatic MPO/H2O2/Cl
-/SCN- system did not 
result in the detection of this product, consistent with the low yields of OCN- formed by the 
enzymatic system reported previously [24]. Modification of apoB100 induced by the 
enzymatic MPO/H2O2/Cl
-/SCN- system was dependent on the concentration of SCN-, with 
increases in SCN- inducing a greater extent of Cys oxidation and a corresponding reduction 
in HOCl-mediated modifications to Met, Trp and Lys residues. These effects reflect the shift 
of oxidant formation from HOCl to HOSCN, with increasing concentration of SCN-, in 
agreement with previous studies [653]. 
HOCl and HOSCN also contribute to lipid oxidation, with significant modifications of the 
polyunsaturated cholesteryl esters, linoleate and arachidonate seen in LDL exposed to 
these oxidants. Due to the absence of lipid peroxidation products detected in HOCl-
modified LDL under the conditions used in this study, it is postulated that modification of 
polyunsaturated cholesteryl esters by HOCl may be associated with the formation of 
chlorohydrins, rather than lipid hydroperoxides, 9-HODE or F2-isoprostanes, which were 
quantified in this study. This is consistent with a previous study showing that the exposure 
of LDL to HOCl at low molar excess can induce chlorohydrin formation, but not lipid 
peroxidation in LDL phospholipids [110]. In contrast, significant lipid peroxidation was 
detected in HOSCN-modified LDL under the conditions used in this study, as evidenced by 
the formation of lipid peroxidation products, including hydroperoxides, 9-HODE and F2-
isoprostanes. The mechanism behind HOSCN-mediated lipid peroxidation remains 
unknown and there is a lack of evidence for direct reaction of HOSCN with lipids [654]. 
Preliminary studies have shown that the enzymatic MPO/H2O2/SCN
- system is capable of 
inducing lipid peroxidation and this was postulated to be associated with the formation of 
thiocyanyl radicals (SCN·) derived from the peroxidase cycle, with SCN- acting as a 
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peroxidase substrate [82]. However, the reaction of SCN- with MPO is more favourable 
thermodynamically through the halogenation (two-electron reaction) cycle than the 
peroxidation (one-electron reaction) cycle [18, 655]. Another possibility would be the 
formation of radicals derived from protein modification induced by the enzymatic 
MPO/H2O2/SCN
- system [494]. However, in the current study, the lipid modification was 
observed in the absence of MPO using isolated HOSCN. 
Addition of BHT to LDL prior to oxidation by HOSCN showed full protection of LDL from lipid 
peroxidation, which highlights the contribution of reactive radicals. The initiating radicals 
may be derived from products formed from the oxidation of apoB100, as shown previously 
with HOCl, where intermediate apoB100 N-chloramines (RN-Cl) decompose via a radical 
pathway triggering lipid oxidation [102]. Although formation of the corresponding RN-SCN 
is reported to be unlikely at normal physiological pH [92], these products have been 
proposed to be formed after the exposure of poly-Lys to HOSCN [66]. Other products can 
also be formed after the reaction of proteins with HOSCN, including RS-SCN and RS-OH that 
may decompose further into reactive radicals [161]. However, it is not presently known 
whether RS-SCN can decompose to thiyl radicals (RS·), though this may be catalysed by the 
presence of transition metal ions, which is known to increase the rate of chloramine 
decomposition (e.g. [44]). The partial protection of LDL from lipid peroxidation after 
addition of DFO indicates that the presence of iron may influence the mechanism of lipid 
peroxidation on LDL by HOSCN. It was shown in the present study that there is a loss of the 
LPO Soret band during the enzymatic synthesis of HOSCN used in this study, which may 
reflect degradation of the heme group and the release of iron. Heme destruction and iron 
release from peroxidase enzymes has been previously demonstrated with HOCl [525]. 
However, further studies need to be performed to completely elucidate the mechanism of 
HOSCN-induced lipid peroxidation (see below). 
Further studies need to be performed to comprehensively characterise the modifications 
induced by HOSCN and OCN- to LDL. For example, site-specific Trp modification in apoB100 
induced by HOSCN could be analysed using LC-MS. Site specific analysis of modifications 
induced by HOCl has been recently reported [651]. This work could be extended to HOSCN 
and OCN- -modified LDL to assess changes in apoB100. This work can further the knowledge 
of the oxidative process and the site specific adducts formed after exposure of HOSCN to 
LDL. Furthermore, the analysis of apo100 modifications could be extended to the reaction 
of the enzymatic MPO/H2O2/Cl
-/SCN- system or stimulated neutrophils to LDL. This is 
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particularly relevant given that MPO may bind to LDL in vivo and hence influence the 
selectivity of oxidative modification [651]. 
Additional experiments could also further assess the effects of HOSCN and HOCl on lipid 
modification of LDL. Quantification of other lipid oxidation products (e.g. 7-ketocholesterol 
and 4-HNE) that may be formed after exposure of HOSCN to LDL may be of interest for 
further studies. In particular, 7-ketocholesterol and 4-HNE have been reported to be 
formed after the oxidation of LDL by Cu2+ ions [508, 636], and have been reported to be 
present in atherosclerotic lesions [508, 542, 581], which if also seen with HOSCN, may 
validate the contribution of this oxidant to disease development. Moreover, confirmation 
of chlorohydrin formation induced by HOCl [111, 536, 548] needs to be investigated, which 
may account for the loss of LDL cholesteryl esters found in this study. Finally, oxidation of 
isolated phospholipids present in LDL by HOSCN and HOCl may also provide another 
avenue for future work in the characterisation of lipid modification by these oxidants. 
Oxidation of phospholipids is a research area of growing importance, which is closely linked 
with the induction of pro-atherogenic effects (e.g. [359, 518, 577, 656]).  
Studies with antioxidants would also be a good avenue for future experimental work 
characterising the effects of HOSCN, HOCl and OCN- on LDL. There are many antioxidants 
that have been investigated in previous studies, which may prevent the modification of LDL 
in vivo. Antioxidants that eliminate reactive radicals, such as probucol, ascorbate, 
polyphenols and flavonoids, have been shown to inhibit the modification of LDL in vitro 
[456, 460, 464, 632, 657]. Thus, the ability of these antioxidants to inhibit LDL modification 
induced by HOSCN and HOCl would be of interest. Furthermore, MPO-inhibitors may also 
be another alternative therapeutic strategy that might protect LDL from oxidative 
modification by eliminating the production of MPO-derived oxidants [127, 479]. In 
particular, nitroxides and acetaminophen have been reported to inhibit the generation of 
HOCl [127, 479]. The ability of nitroxides and acetaminophen to inhibit LDL modification 
has not been investigated in vitro and may provide another area for future investigation. 
Selenium and selenium containing compounds have been shown to inhibit the oxidative 
damage to proteins and lipids induced by HOCl and HOSCN and hence may also be effective 
at preventing LDL modification by these oxidants oxidants [658, 659]. 
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6.3 Cellular Dysfunction Induced by HOSCN-, HOCl- and 
OCN--modified LDL 
Cellular dysfunction mediated by exposure of macrophages to HOCl-modified LDL has been 
extensively investigated in previous studies, with evidence for the uncontrolled 
accumulation of LDL-derived lipids [302] and cellular apoptosis [316, 317]. These 
mechanisms may contribute to the pathogenesis of atherosclerosis [302, 316, 317]. 
However, despite the extensive evidence for cellular dysfunction mediated by HOCl-
modified LDL, there are few studies examining the effects of HOSCN- and OCN--modified 
LDL on macrophage function. This is significant because HOSCN, HOCl and OCN- modify LDL 
in a distinct manner, which suggests each type of modified LDL may exert specific cellular 
effects. 
In the present study, no significant cellular toxicity was observed when macrophages were 
exposed to HOSCN-, HOCl- and OCN- -modified LDL for 24 h. Previous studies with THP-1 
and U937 cells have shown that HOCl-modified LDL can promote the onset of cellular 
toxicity in macrophages [316, 317]. However, the present study utilised a lower molar 
excess of HOCl (≤ 100-fold) to treat LDL prior to addition to the cells compared to previous 
studies, and hence the resulting modification of LDL was less extensive, particularly in 
respect to the oxidation of the lipid component. Thus, at high molar excess, HOCl can 
induce lipid peroxidation of LDL [102]. This effect was attributed to the formation of Lys-
derived chloramines, which initiated lipid peroxidation and the formation of reactive 
aldehydes [316, 317]. These lipid oxidation products were reported to be cytotoxic to 
macrophage cells [316, 317]. Hence, the absence of lipid peroxidation when LDL was 
exposed to the lower molar excess of HOCl in the present study may explain the lack of 
toxicity detected with macrophages after exposure to HOCl-modified LDL.  
In the case of HOSCN- and OCN--modified LDL, no significant influence on cellular toxicity 
was observed. Although HOSCN-modified LDL contains lipid peroxidation products, which 
have been reported to be cytotoxic [573, 582, 583], there was no evidence showing that 
HOSCN-modified LDL induced macrophage cell death. OCN--modified LDL is characterised 
by protein carbamylation and HCit formation [332, 571], but no reported effects on the 
lipid moiety of LDL. Previous studies have shown that exposure of cells to carbamylated LDL 
can promote toxicity of endothelial cells and macrophages [331, 600]. However, 
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carbamylation of LDL under the conditions used in this study was not extensive, which may 
explain the lack of toxicity found in this study. 
Exposure of macrophage cells to HOSCN-, HOCl- and OCN--modified LDL resulted in the 
cellular accumulation of cholesterol and cholesteryl esters. HOCl-modified LDL showed the 
greatest effect on the accumulation of cholesterol and cholesteryl esters, while HOSCN- 
and OCN--modified LDL resulted in a lower extent of lipid accumulation. This is believed to 
reflect the extent of modifications to the apoB100 protein, which serves as the main 
recognition site of scavenger receptors [313, 318, 605, 660]. The outcome of this study 
agrees with previous data showing that HOCl-modified LDL can promote the uncontrolled 
accumulation of cholesterol and cholesteryl esters in macrophages, potentially resulting in 
the formation of foam cells [302]. HOSCN- and OCN--modified LDL may also contribute to 
lipid uptake though to a lesser extent than HOCl. This effect was more obvious when LDL 
was exposed to the oxidants for 30 min, where HOSCN-modified LDL led to a greater 
accumulation of cholesterol and cholesteryl esters within macrophages than HOCl-modified 
LDL. This discrepancy between the effect of HOCl-modified for 30 min and 24 h could 
reflect the quenching of all chloramines present within HOCl-modified LDL when LDL was 
only exposed to HOCl for 30 min [302]. The fact that increasing SCN- concentrations can 
result in greater formation of HOSCN may indicate that the formation of HOSCN in place of 
HOCl could have a beneficial effect in vivo. Thus, reducing HOCl formation by elevating SCN- 
could possibly reduce foam cell formation. It has been reported that besides tobacco 
smoking, plasma SCN- is also elevated by a high intake of certain vegetables, including 
African yams and cassava [661, 662].  
However, these data do not support studies showing a correlation between plasma SCN- (in 
smokers) and early markers of atherosclerosis [326, 327], suggesting that smoking may 
induce foam cell formation that is independent of SCN-. Another possibility is that HOSCN 
may influence other pro-atherogenic effects that are independent of LDL modification. 
Recent reports have shown that HOSCN can directly interact and influence the cellular 
function of macrophages and endothelial cells [135, 136, 161]. This could represent 
another potential role for HOSCN in the pathogenesis of atherosclerosis. It has been 
previously demonstrated that HOSCN disrupt the redox balance of cells, targeting both 
thiol-derived enzymes and GSH [161]. Furthermore, it has also been demonstrated that 
HOSCN can promote the apoptosis of cells, including macrophages and endothelial cells 
[135, 136]. The pro-atherogenic effects of HOSCN may also involve compromising the anti-
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atherogenic mechanisms in vivo, such as the formation of dysfunctional HDL [93]. A recent 
report highlighted that HOSCN and OCN- can modify the HDL molecule and reduce the 
extent of cholesterol efflux from cholesterol-loaded macrophage cells [93]. 
The lipid uptake studies appear to conflict with the studies to examine lysosomal enzyme 
function. Lysosomal enzymes play a crucial role in the processing of the protein and lipid 
component of the LDL molecule after uptake by cells. Inactivation of these enzymes 
indicates that LDL may be poorly degraded within cells [67, 289]. The assessment of the 
activity of lysosomal enzyme in macrophages exposed to HOSCN-, HOCl- and OCN--
modified LDL resulted in the detection of inactivation of cathepsin enzymes and LAL. This 
effect was both observed in the exposure of modified LDL to cell lysates and intact 
macrophage cells. However, reduction of lysosomal enzymes were more effective after 
exposure of modified LDL to cell lysates compared to intact cells, which indicates that there 
is less accessibility for modified LDL to inactivate the activity off lysosomal enzymes when 
exposed to intact cells. In the case of exposing modified LDL to intact macrophage cells, 
HOSCN-modified LDL induced a greater effect on the activity of these enzymes compared 
to HOCl-modified LDL. The reasons behind the conflicting outcomes observed in the lipid 
uptake studies and studies to examine lysosomal enzyme function is not well understood 
and thus, further studies need to be performed to completely elucidate the contribution of 
HOSCN-, HOCl- and OCN--modified LDL on lysosomal enzyme function. For instance, 
accumulation of apoB100 and the formation of ceroid have not been investigated in the 
present study, which may serve as another avenue for future work. This may be biologically 
important since apoB100 accumulation and the formation of ceroid can influence cellular 
dysfunction by promoting cellular toxicity, which contributes to the exacerbation of 
atherosclerosis [515, 644, 663]. Additional future experimental work could involve 
monitoring the degradation and fate of the oxidised apoB100 after uptake of HOSCN-, 
HOCl- and OCN--modified LDL by macrophages. This is possible by use of radio-labelled LDL 
(125I-LDL)-modified by HOSCN, HOCl and OCN-. Similar work has been previously performed 
with Cu2+-modified LDL and glycated LDL, which highlighted the fate of apoB100 after 
uptake by macrophage cells [498, 626]. 
Further experiments to assess the inhibition of lysosomal enzyme function in macrophages 
need to be performed. Most of the data collected in the present study was obtained from 
the exposure of HOSCN-, HOCl- and OCN- -modified LDL to J774A.1 cells. Further 
experiments are required to assess these changes in HMDM cells, to supplement the 
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preliminary findings collected in the present study. These pilot studies were variable, which 
may be due (at least in part) to differences in the donors from which the monocyte-derived 
macrophages were isolated. Furthermore, data was only obtained at  two fixed time points 
(after 24 h and 48 h). Assessment of lysosomal enzyme activity after various incubation 
times and also varied molar ratios of oxidant:LDL could also be assessed. 
The present study has only assessed the activity of lysosomal enzymes when cells are 
exposed to HOSCN-, HOCl- and OCN- -modified LDL. To comprehensively assess the 
impairment of lysosomal function in these cells, further studies are required to examine 
other parameters associated with lysosomal function. For example, assessment of 
cathepsin protein expression needs to be performed using Western blotting to confirm 
whether the loss of activity arises from the modification of the proteins, change in 
expression, or alterations in lysosomal numbers. Thus, reduction of cathepsin enzyme 
activity may be related to reduced lysosome numbers. Lysosomal numbers can be assessed 
by measuring the Lysosomal Associated Membrane Protein-1 (LAMP-1) by Western Blotting 
or by use of lysosomal dyes with fluorescence imaging [572]. Furthermore, there are other 
cathepsin enzymes that were not assessed in the present study. In addition to Cys-
dependent cathepsin B and L, cathepsin S is another cathepsin enzyme that is expressed in 
macrophages, which may be important in the turnover of LDL apoB100 [288, 290]. 
There are other avenues for future work to elucidate the contribution of HOSCN-, HOCl- 
and OCN--modified LDL to cellular dysfunction. This includes the further assessment of 
cellular dysfunction in macrophages, endothelial cells and vascular smooth muscle cells. 
Further studies on macrophage cellular dysfunction could involve the assessment of 
scavenger receptor expression, as these receptors are responsible for the recognition of 
modified LDL [313, 664]. The expression of SR-AI, CD36 and SRBI are of particular interest in 
macrophage cells, as these receptors have been reported to be involved in the recognition 
and uptake of modified LDL [313, 664]. Although the scavenger receptors associated with 
the recognition of HOCl-modified LDL have been identified previously [313], the receptors 
involved in HOSCN- and OCN--modified LDL uptake have not been comprehensively 
investigated. 
The pro-inflammatory effects of HOSCN-, HOCl- and OCN- -modified LDL could also be 
investigated in macrophage cells. For example, it has been recently reported that 
macrophages can be polarised into M1 or M2 populations [665]. Macrophages that have an 
M1 phenotype are pro-inflammatory; while macrophages with the M2 phenotype are anti-
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inflammatory [665]. It has been reported that the M1 macrophages contribute to the 
pathogenesis of atherosclerosis by aggravating the inflammatory mechanisms associated 
with the development of the disease [665]. Thus, it would be interesting to see if and how 
the polarisation of macrophages by HOSCN-, HOCl- and OCN--modified LDL may contribute 
to altered and detrimental function of macrophages in atherosclerosis. This has been 
reported in studies with Cu2+-modified LDL [666]. Modified LDL can also influence the 
secretion of pro-inflammatory cytokines by macrophages. Previous studies have reported 
that both Cu2+- and HOCl-modified LDL can influence the secretion of TNF-α and IL-8, which 
play a crucial role in modulating the inflammatory process [321]. Furthermore, both Cu2+- 
and HOCl-modified LDL were also shown to modulate the expression of PPAR-γ and the 
MAP-kinase pathways [148, 321]. Thus, assessment of pro-inflammatory cytokine 
expression and modulation of signalling pathways would also be of interest with regard to 
macrophage cellular dysfunction in response to HOSCN- and OCN--modified LDL exposure.   
The cellular dysfunction induced by HOSCN- and OCN- -modified LDL could also be 
extended to other cells associated with atherosclerotic lesions, such as vascular smooth 
muscle and endothelial cells [667, 668]. Smooth muscle cells are known to migrate from 
the media into the intima after the onset of endothelial cell dysfunction, and contribute to 
lesion development [668]. These cells synthesise collagen, elastin, proteoglycans, growth 
factors and cytokines, which contribute to the development of atherosclerotic lesions into 
complex and advanced lesions [668]. Furthermore, vascular smooth muscle cell apoptosis is 
also apparent in the development of atherosclerotic lesions, which can cause thinning of 
the fibrous cap, a key step in the formation of rupture-prone clinically-relevant atheroma 
[669]. Thus, it may be important to assess the ability of modified LDL to induce dysfunction 
in vascular smooth muscle cells. These studies could include assessment of secretion of 
cytokines, growth factors and the modulation of signalling pathways, which are crucial for 
cell migration, proliferation and cell death. 
Endothelial cell dysfunction is believed to be crucial to the initiation of atherosclerosis 
[670]. Endothelial cells are known to contribute to the inflammatory mechanisms 
associated with atherosclerosis by the recruitment of macrophages and other inflammatory 
cells [670]. Recruitment of macrophages involves the expression of cell adhesion molecule 
by endothelial cells, including VCAM-1, ICAM-1 and E-selectin [437, 671, 672], and the 
secretion of MCP-1 [520, 673, 674]. Thus, the ability of HOSCN-, HOCl- and OCN--modified 
LDL to promote cell adhesion molecules and MCP-1 secretion is another potential area of 
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further investigation. Furthermore, damage to the endothelium has also been known to 
contribute to the development of atherosclerosis [670]. The ability of modified LDL to 
induce toxicity to endothelial cells has been investigated previously [354, 675, 676]. It has 
been shown that oxidised forms of LDL can promote cell death in endothelial cells [354, 
675, 676] by uptake of modified LDL, containing oxidised lipid fragments (e.g. 4-HNE) that 
can cause cell death [667]. Previous studies have shown that HOCl-induced modifications of 
fatty acids and phosphatidylcholines can induce perturbation of redox balance and cell 
death of endothelial cells [677, 678]. However, further studies in this area need to be 
performed to completely elucidate the contribution of HOCl-modified LDL to endothelial 
cell dysfunction.  Given the ability of HOSCN to promote LDL lipid oxidation, it may be of 
interest to investigate the ability of HOSCN-modified LDL to promote uptake and induce  
cytotoxic effects in endothelial cells. This could includes assessing the expression of 
scavenger receptors and cellular adhesion molecules, release of cytokines and activation of 
signalling pathways in endothelial cell after exposure to HOSCN-modified LDL. 
Antioxidant studies could also be performed to investigate the inhibition of cellular 
dysfunction mediated by HOSCN-, HOCl- and OCN- -modified LDL on macrophages, 
endothelial cells and vascular smooth muscle cells.  
6.4 Overall Conclusions 
The results presented in this thesis provide a greater understanding of the reactivity of 
HOSCN, HOCl and OCN- with the protein and lipid components of LDL at a range of 
concentrations expected to be present under physiological and pathological conditions. 
These modifications of LDL resulted in an altered function of macrophages, highlighted by 
the uptake of HOSCN, HOCl and OCN--modified LDL and the perturbation of lysosomal 
function. The reactivity of HOSCN was shown to be different to that of HOCl, which was 
partially reflected in the extent of uptake and accumulation of the modified LDL, though 
HOSCN-modified LDL was shown to induce more extensive impairment of lysosomal 
enzyme activity than HOCl-modified LDL within macrophage cells. These results indicate 
that SCN- may influence the type and extent of damage induced by MPO in vivo. Although 
this may have significance for smokers, who have higher plasma SCN-, the results in this 
study are perhaps more consistent with SCN- having a protective effect, preventing foam 
cell formation and modulating the extent of LDL modification induced by MPO. Indeed 
there is a growing body of evidence that supplementation with SCN- by dietary changes 
rather than smoking could be beneficial to human health (reviewed in [679]). Work is 
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needed to fully elucidate the role of MPO-derived SCN- oxidants, including HOSCN in health 
and disease. 
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